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Abstract 
This study investigated the hospital admission process in relation to two areas 
associated with known patient related risks, venous thromboembolism (VTE) risk 
assessment and medicines reconciliation in an English teaching hospital Acute 
Medical Unit (AMU). National guidance was available at the time of the study for 
both of these aspects of care. Government targets with associated financial 
penalties were set for VTE risk assessment in 2010, there were no similar targets for 
medicines reconciliation.   
NHS ethics approval was granted. A novel mixed methodology was used involving 
direct observations of the patient admissions process, interviews with staff and an 
audit of case notes. Data were collected over four one-week periods between 2009 
and 2011, 36 staff were observed admitting 71 patients, 44 staff were interviewed 
(25 VTE, 19 medicines reconciliation) and 930 sets of case notes were audited. 
The observations showed that at the start of the study guidance was rarely 
followed for both VTE risk assessment and medicines reconciliation. Staff were 
unaware of its existence and ignorant of the both the associated risks and the level 
of guideline compliance within the organisation. There were low levels of 
compliance with local and national VTE guidance until national financial sanctions 
were introduced when significant increases in the rates of both VTE risk assessment 
and appropriate prescribing of prophylaxis were seen, however inappropriate 
prescribing also rose. Observations showed poor medication history taking and 
prescribing practices, during the study the proportion of items with a prescribing 
error increased, however the interviews showed that staff did know how to 
establish an accurate medication history and were aware of the potential problems. 
A national financial sanction was associated with the effective implementation of 
VTE guidance however it remains to be seen whether standards can be maintained 
in a complex high pressure environment. Organisations must also be aware of the 
potential for unexpected adverse outcomes. Prescribing errors may be reduced if a 
mechanism can be found to ensure that theoretical knowledge is routinely 
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translated into practice, however greater pharmacy involvement before the 
admission prescription is written should also be considered. 
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Chapter 1 Introduction 
This study was carried out in a hospital in England; this chapter provides an 
overview of the development of hospital services, identification of the key risks to 
be investigated and concludes with the study aims and objectives. 
 National Health Service context 1.1
The National Health Service (NHS) in England and Wales was established in July 
1948, when the NHS Act 1946 came into effect, and is based on the principles that 
everyone is entitled to healthcare and that care is provided free of charge at the 
point of use of the service.1 Over the past 65 years it has grown into the largest 
employer in the UK with a budget of over £105 billion and employs 146,000 doctors 
and 370,000 nurses.2 In England there are 161 acute hospital Trusts which provided 
approximately 15,000 million individual episodes of care involving admission in 
2010/11.2 
 Acute Medical Units 1.2
Traditionally in the NHS emergency medical patients were admitted to hospital 
either from the Emergency Department (ED) or by direct referral from a General 
Practitioner (GP) to the ward under the care of the ‘on take’ physician.3 The ‘on 
take’ physician usually changed daily in accordance with a rota and the specified 
consultant was responsible for the management of all patients admitted during the 
allocated period. Historically physicians were generalists and were therefore 
experienced in the treatment of all general medical conditions but specialisation for 
doctors developed in the 1970s and wards then became specialty based (e.g. 
cardiology, respiratory etc.) rather than ‘general medicine’.3 As the medical 
physicians were ‘on take’ for all patients in accordance with a rota this resulted in 
many emergency medical patients being admitted to an inappropriate specialty 
ward, which led to a delay in them receiving expert treatment and often 
necessitated another ward transfer following admission. This was in contrast to 
patients who were less acutely unwell who were referred by their GP to an 
appropriate specialist according to their medical complaint and were admitted 
directly to an appropriate specialty ward.4 In the fifteen year period from 1997/98 
to 2012/13 annual emergency hospital admissions in England increased from 3.6 
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million to 5.3 million, a rise of 47%, although the population only increased by 10% 
in the same period.5 Over the same period, 1997/98 to 2012/13, the number of 
acute and general beds available in England decreased from 138,047 to 104,888, a 
reduction of over 24%.6 The resulting increased pressure on hospital beds led to 
emergency medical patients being admitted to any available medical bed and in 
extreme circumstances to surgical beds. This presented operational difficulties for 
the medical teams as they were then responsible for the management of patients 
on many wards, compromising the care which they were able to provide. 
Acute Medical Units have been developed over the past fifteen years in response to 
increasing numbers of medical admissions and concerns regarding the quality of 
care.7, 8 In 2004 the Royal College of Physicians (RCP) recommended that all Trusts 
admitting acutely unwell medical patients should have a dedicated area for 
managing these patients and that to avoid confusion this area should be called an 
‘Acute Medical Unit’ or ‘AMU’,9 however this term is still not used universally 
throughout the NHS. This allows acutely unwell patients to be seen rapidly by a 
consultant specialising in acute medicine and if hospital admission is necessary, 
patients are transferred directly to the appropriate specialty ward enabling more 
efficient, disease specific care. Recent studies have shown that hospital re-
organisation and the introduction of AMUs reduces the length of stay without 
affecting readmission rates,10-12 and also reduces mortality.11 
 Royal Liverpool University Hospital 1.3
This study is set in the Royal Liverpool University Hospital (RLUH), which is one of 
the largest and busiest acute hospitals in the North West of England and focuses on 
acute and complex care.13 It has over 800 beds and provides services for all acute 
medical specialties. The ED sees over 88,000 patients annually14 and over 12,000 
medical patients each year are admitted via the AMU. The AMU at RLUH was 
established in 19994 and was one of the first in England. Over the years it has grown 
from an initial 20 beds to 37 beds and consultant staffing had increased from two to 
seven (5.3 whole time equivalents) at the time the study took place. Consultant 
availability was also extended on weekdays ensuring AMU consultant presence 
from 8am until 8pm Monday to Friday and for four hours each day at weekends. 
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Consultants with additional expertise in diabetes / endocrinology, rheumatology, 
pharmacology and gerontology were recruited to provide expert care to these 
patient groups and also to provide expert advice to fellow doctors in complex cases. 
The average length of stay is approximately 18 hours and about one third of 
patients seen are discharged home from AMU (2009/10 to 2012/13 data). 
The AMU medical staffing at the time of the study comprised seven AMU 
consultants (4 full time, 3 part time), two daily ‘post-take’ consultant physicians, 
eight AMU based doctors (2 senior, specialist registrars, 6 junior), and five ‘hot 
block’ doctors (2 senior, 3 junior). The ‘hot block’ is a period of time when medical 
staff are released from their current medical rota and spend a few days taking 
responsibility for the new patients being referred to AMU. ‘Hot block’ periods run 
from 9am to 10pm Monday to Thursday inclusive and 9am to 10pm Friday to 
Sunday inclusive, a separate team operates overnight. One of the two specialist 
registrars from the ‘hot block’ team usually remains in ED seeing new medical 
patients, the remaining four doctors are responsible for seeing new patients on 
AMU.  
At the time of the study two ward rounds on weekdays (one morning and one 
afternoon) and one ward round on Saturday and Sunday were led by the ‘post take’ 
consultant who was on call or on ‘take’ and as such responsible for providing advice 
to junior staff regarding any difficult clinical situations and if necessary reviewing 
complex patients. As the periods of medical ‘take’ ran 5pm to 9am and 9am to 5pm, 
this resulted in two different visiting consultants leading ward rounds on AMU each 
weekday. These consultants were drawn from a pool of around 20 consultant 
physicians who had a variety of expertise and each of whom led the AMU ward 
round once or twice a month. Another simultaneous ward round was carried out 
each morning by an AMU consultant to ensure that all patients had been reviewed 
by lunchtime. 
 Hospital admission process via AMU 1.4
On arrival at AMU patients are booked into the hospital by an AMU receptionist 
who records the necessary personal details and are then triaged by an experienced 
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nurse using a Modified Early Warning System (MEWS) score. MEWS scores used on 
admission have been shown to reliably identify those patients most in need of 
medical attention and also most susceptible to a sudden deterioration.15-17 Nurse 
triage was originally used in EDs but its use has been expanded to AMUs where 
improvements in patient flow and more rapid clinical decision making by medical 
staff have been demonstrated as a result.18 
Following nurse triage patients are seen by a doctor or a suitably trained nurse 
clinician. All doctors are trained to carry out an effective consultation with a patient 
as medical students, in accordance with the requirements of the General Medical 
Council (GMC).19 There are many different consultation models, however the 
method routinely taught in UK medical schools and generally used is the ‘hospital 
clerking model’ otherwise known as ‘the inductive method’.20, 21 This model 
involves a consultation with the patient about the current medical problem taking 
into account any relevant past medical or surgical history, a physical examination, 
ordering and interpreting the results of investigations with the aim of making a 
diagnosis, developing a management plan and writing the admission prescription. 
Home circumstances are noted to facilitate the discharge process, alternative care 
arrangements may be required if patients are unable to manage at home. After this 
consultation has taken place in the AMU, patients together with their management 
plans are reviewed by a consultant on one of the twice daily ward rounds in 
accordance with RCP guidance.22 The consultant will make a decision to admit the 
patient to a specialty ward, keep them on AMU for a short period of further 
observation or discharge them. 
 Other hospital AMUs 1.5
AMUs vary in their layout, number and type of beds, staffing and operational 
procedures. A recent national audit involving 38 AMUs showed that on average 
they had 43 beds and a further 17 short stay beds.23 To help identify some of the 
differences visits were made to two AMUs in the North West of England in 2011. A 
large district general hospital had a 32 bed AMU of which 16 beds were allocated to 
GP referrals. In this unit there were 2 consultant ward rounds daily and a there was 
a designated senior house officer (SHO – 2 to 4 years post qualification) to clerk GP 
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admissions. Another large acute teaching hospital AMU had 56 beds, 28 allocated 
to ED admissions, 20 short stay (patients expected to stay less than 24 hours) and 
10 GP admission chairs / trolleys. This AMU operated two simultaneous ward 
rounds one to review the short stay patients and the other to see the remaining 
patients. The average length of stay was not known by the staff working in either of 
these units but pharmacy staff from both indicated that a significant proportion of 
patients stayed 48 hours. 
 Mechanisms for improving patient safety 1.6
Healthcare is becoming increasingly complex as with the development of new 
technologies and new medicines it is possible to treat more patients and medical 
conditions than previously. However this increase in complexity is associated with 
an increased risk of a medical error to patients.24 This was highlighted by the 
Department of Health (DH) in 2000 in the report ‘An Organisation with a Memory’25 
which estimated that adverse healthcare events which cause harm to patients 
occur in 10% of hospital admissions and cost the NHS at least £2 billion a year in 
extended hospital stays. Subsequent DH documents provided a framework to guide 
changes necessary to improve patient safety.26, 27 Adverse events are rarely the 
result of a single factor, more often there are a number of circumstances which 
together precipitate the error, usually the error is detected and prevented as a 
result of checks in the system. However on rare occasions all the checks in the 
system simultaneously fail as in Reason’s Swiss cheese model of system accidents28 
and a major error occurs. In industries such as nuclear power and aviation, 
engineered safety devices may be used to minimise errors, however in healthcare it 
is frequently the personal skills and experience of the staff which are responsible 
for protecting the patient from harm.29  
1.6.1 NHS guidance 
Each year the DH introduces new guidance, in response to identified risks or 
developments in treatment, which must be integrated into an already complex 
system. The Labour government elected in 1997 focused on quality in the NHS and 
established the National Institute for Clinical Excellence (NICE – now renamed 
National Institute for Health and Care Excellence) to improve the standards of 
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clinical care, reduce unacceptable variations in practice and ensure best use of 
resources.30 Since its inception in 1999, NICE has published 181 clinical guidelines 
and 49 quality standards with many more in development,31 all of which require 
implementation throughout the NHS. In addition the National Patient Safety Agency 
(NPSA), which was established by the DH in 2001 (and whose functions were 
transferred to the NHS Commissioning Board Special Health Authority in 2012 
following reorganisation of NHS services) to identify patient safety issues and 
design solutions,32, 33 has issued 72 alerts, all of which require implementation 
across the NHS in England and Wales.  
This study investigates the implementation of two recent guidance documents 
which affect almost all adult patients on admission to hospital, risk assessment for 
venous thromboembolism (VTE)34 and medicines reconciliation35 in an NHS acute 
Trust. The DH VTE risk assessment tool states that all patients should be risk 
assessed for VTE on admission to hospital, the medicines reconciliation patient 
safety guidance states that medicines reconciliation should be carried out for all 
adult patients on admission to hospital, preferably within 24 hours of arrival. 
1.6.2 NHS targets 
The first targets for NHS acute Trusts were introduced following the election of the 
Labour government in 1997 and were set out in the NHS plan of 2000.36 Initial 
targets were generally around waiting times but these have been developed over 
the years to be more outcome focused and they now form part of the NHS 
outcomes framework.37 The original VTE target set in 2010 was that 90% of patients 
should have had a VTE risk assessment on admission to hospital and was increased 
to 95% in 2013/14 to maintain momentum as most Trusts were achieving 90%. It is 
now one of four national Commissioning for Quality and Innovation (CQUIN) goals 
for NHS acute service providers, failure to achieve the target results in a financial 
penalty. There are no similar targets for medicines reconciliation, the Royal 
Pharmaceutical Society (RPS) hospital pharmacy standards38 state that medicines 
reconciliation should ideally be carried out within 24 hours of admission, in line 
with the NICE/NPSA alert,35 however this is guidance for service development not a 
mandatory target. 
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 VTE risk assessment practices at RLUH 1.7
A venous thromboembolism (VTE) is a clot which occurs in the body, venous 
thromboemboli usually occur in the deep veins of the leg,39 a thrombosis in this 
location is therefore known as a deep vein thrombosis or DVT. If a DVT breaks free 
from the leg vein it is transported by the circulation to the lungs where it becomes 
trapped in the small vessels and is then known as pulmonary embolism or PE.40  
A Health Select Committee inquiry in 2004 estimated that PE is responsible for 
approximately 25,000 deaths in English hospitals each year and is the immediate 
cause of death in 10% of patients who die in hospital.41, 42 A number of factors 
increase the risk of patients admitted to hospital developing a VTE, therefore 
prophylaxis is generally advocated. The recommended prophylactic medication is 
daily injections of Low Molecular Weight Heparin (LMWH) or fondaparinux, which is 
an inhibitor of the clotting factor Xa. 43 
In 2004 an initial audit at the study hospital showed that prescribing of VTE 
prophylaxis for medical patients with identifiable risk factors was poor, only 18% of 
patients at risk were prescribed prophylactic LMWH. A protocol was developed for 
the risk assessment of medical patients in 2005 but subsequent audits showed poor 
compliance with the protocol and that many medical patients at risk of VTE were 
not receiving prophylactic treatment.  
 Medicines reconciliation practices at RLUH 1.8
An accurate and comprehensive current medication history is essential for safe and 
appropriate management of all patients on admission to hospital.35 The information 
documented should comprise all medication currently being taken by the patient 
together with doses and frequencies and include any medication recently started 
by the GP, Over the Counter (OTC) medicines and herbal remedies.35, 44 Medicines 
reconciliation on admission to hospital, as defined by NICE, is the process of 
collecting information to prepare the patient’s current medication history, verifying 
this list against the current hospital medication chart, identifying any discrepancies 
and taking appropriate action.35 Errors in medicines reconciliation have an adverse 
impact on clinical care and may also have a financial impact.45  
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At RLUH the admitting doctor is responsible for taking a medication history and 
writing the initial prescription following admission to hospital as part of the clerking 
process. Pharmacists visit AMU seven days a week, according to a rota, and 
complete the medicines reconciliation process with as many patients as time allows. 
In addition to the resources available to the medical staff pharmacists are able to 
access EMIS web, which is the computer system used by the majority of GPs in 
Liverpool, enabling them to print a list of patients current medication. 
Discrepancies identified may be corrected by a pharmacist prescriber, immediately 
drawn to the attention of the medical staff or documented in the case notes for 
review at a later time depending on the likely clinical impact. Pharmacists aim to 
identify and correct medication errors as early as possible in the patients stay to 
minimise adverse events and facilitate best possible care. However resources do 
not allow a constant pharmacist presence on AMU on weekdays and are restricted 
further in times of staffing shortages. Fewer pharmacists are available at weekends 
which limits the number of patients who can be seen and difficulties often arise as 
primary care services (GPs, anticoagulant clinics, drug addiction services) are not 
generally available at weekends if information is required. 
In 2004 a study carried out at the RLUH showed that 39% of medicines identified by 
pharmacists by interviewing the patient shortly after admission were not prescribed 
on the hospital medication chart46 and subsequent audits have shown that this 
situation has not changed in recent years. 
 Purpose of study 1.9
It is recognised that hospital admission is associated with a significant risk to 
patients and there was ample evidence from the local audits cited above that 
neither VTE risk assessment nor medicines reconciliation were being carried out in 
accordance with national guidance at the start of the study. Over the years 
preceding the study various initiatives had been tried in order to improve VTE risk 
assessment with limited effect including, education for junior doctors, development 
of an in house risk assessment tool and pre-printing medication charts with the 
appropriate prophylactic medication as an aide memoir so that only a date and 
signature were required to complete the prescription. Since 2005 pharmacists have 
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provided education sessions to medical students from Liverpool University but 
errors in prescribing for patients on admission remain a daily occurrence. 
Evidence suggests that these problems are not unique to Liverpool but are seen 
both nationally and internationally.47-52 Published studies of both VTE risk 
assessment and medicines reconciliation have generally focused on identifying and 
assessing the size of the problem. No published studies were located which have 
attempted to investigate and understand the root of the problem in order to 
suggest appropriate solutions. 
There is thus considerable value in investigating how best to successfully integrate a 
novel process into hospital admission procedures. VTE risk assessment was one of 
the first NICE quality standards to be introduced in 2010; eventually these will 
number around 150 covering many aspects of patient care. It is therefore vital that 
NHS Trusts have systems in place to implement the necessary changes efficiently 
and effectively particularly in the current economic climate. Failure to implement 
evidence based guidance effectively has major implications for the NHS in terms of 
patient safety and financial governance. If barriers can be identified and overcome, 
this project may have benefits not just for RLUH but for the wider NHS. 
 Study aim 1.10
To explore the hospital admission process at RLUH for acute medical patients in 
relation to VTE risk assessment and accuracy of medication history documented in 
order to identify barriers to good practice and make recommendations to improve 
patient safety. 
 Study objectives 1.11
1.11.1 VTE risk assessment 
i. To explore and map the processes involved in VTE risk assessment and 
management. 
ii. To assess the frequency with which VTE prophylaxis is prescribed 
appropriately for medical patients at risk of VTE and the relevant clinical 
outcomes in these patients. 
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iii. To compare the perceived and actual activities of healthcare professionals 
in the assessment and management of medical patients with respect to 
VTE.  
iv. To identify perceived barriers to and facilitators for the implementation of 
VTE guidance. 
v. To assess the impact of the introduction of government targets for VTE 
risk assessment. 
vi. To make recommendations which may help to increase the proportion of 
patients who are VTE risk assessed and have VTE prophylaxis prescribed if 
indicated. 
1.11.2 Medicines reconciliation 
i. To explore and map the processes involved in taking a medication history 
and prescribing on admission to hospital. 
ii. To assess the frequency with which errors occur in prescriptions written 
on admission to hospital and their potential adverse clinical impact. 
iii. To compare the perceived and actual activities of healthcare professionals 
in the assessment and management of medical patients with respect to 
medicines reconciliation and prescribing. 
iv. To identify perceived barriers and facilitators to accurate prescribing on 
admission to hospital. 
v. To identify any changes in prescribing error rates over time. 
vi. To make recommendations which may help to increase the numbers of 
patients who have an accurate prescription written on admission to 
hospital. 
 Summary 1.12
This chapter has provided the background to the study setting including the 
evolution of the NHS, the introduction of AMUs into hospitals and NHS targets. The 
key risks to be investigated, VTE risk assessment and medicines reconciliation have 
been introduced and are discussed in more detail in the next chapter. 
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Chapter 2 Study Background 
This chapter provides the background to the two key risks on admission to hospital 
which are to be explored, VTE risk assessment and medicines reconciliation and 
also reviews the difficulties associated with guideline implementation. 
 Literature search strategy 2.1
2.1.1 VTE literature 
The literature for VTE was searched to identify current knowledge regarding the 
incidence of DVT and PE in medical patients, the potential long term consequences, 
the effectiveness of prophylaxis with LMWH, national and international guidelines 
for risk assessment and the proportion of patients both VTE risk assessed and 
prescribed prophylaxis. Both national and international literature was searched as 
death from VTE was likely to be a global health risk. MEDLINE was searched from 
01.01.50 to 08.01.14, only publications in English were included. Initial search terms 
were ‘venous thromboembolism medical patients’, ‘venous thromboembolism risk 
assessment’, and ‘venous thromboembolism pathophysiology’. Web of Science was 
also searched using the terms “venous thromboembolism risk assessment” but 
returned few additional relevant papers. Due to the significant growth in the 
published literature on this topic during the course of the study search criteria were 
later narrowed to include ‘venous thromboembolism risk assessment admission’, 
‘venous thromboembolism risk assessment observation’, ‘venous 
thromboembolism risk assessment medical patients’, ‘strategies to improve 
prophylaxis for venous thromboembolism’, and ‘venous thromboembolism 
guideline implementation’. National guidelines for England and Wales were 
identified using the NICE website, http://www.nice.org.uk, using search terms 
‘venous thromboembolism’. The search engine Google was used to search the UK 
grey literature for audits of VTE risk assessment carried out in NHS hospitals which 
had not been formally published; search terms used were ‘audit  venous 
thromboembolism medical NHS trust’. 
2.1.2 Medicines reconciliation literature 
For medicines reconciliation the literature was searched to identify national and 
international guidelines, the accuracy of prescriptions written on admission to 
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hospital and the potential causes of prescribing errors. Both national and 
international literature was search as it was assumed that prescribing errors were 
likely to be a risk worldwide. MEDLINE was searched from 01.01.50 to 08.01.14, 
only publications in English were included. Search terms were ‘medicines 
reconciliation’, ‘medication history pharmacist’, ‘medication history taking 
accuracy’, ‘drug history taking accuracy’, ‘prescribing error admission’, ‘medical 
admissions unit prescribing’, ‘prescribing training admission’ and ‘prescribing error 
prevalence’. Google scholar was also searched for articles relating to training for 
doctors in medicines reconciliation, search terms used were ‘medicines 
reconciliation training doctor’ but no useful papers were identified. The Student 
BMJ was searched for papers about the hospital clerking process using the search 
term ‘clerking’. National guidelines for England and Wales were again identified 
using the NICE website http://www.nice.org.uk.   
2.1.3 Guideline literature 
As the study was investigating the implementation of guidelines for both VTE and 
medicines reconciliation the literature was searched separately to identify potential 
facilitators and barriers and to guideline implementation and any studies which had 
used direct observation to investigate guideline implementation. MEDLINE was 
searched from 01.01.77 to 19.12.13, only publications in English were included. 
Search terms for guideline implementation were ‘guideline implementation 
observation’, ‘clinical guidelines adherence barrier’, ‘incentives healthcare guideline 
implementation’, and ‘opinion leader guideline’.   
Citations identified in the electronic databases were initially screened to identify 
potentially relevant papers, abstracts of these papers were then screened and 
those which were not relevant to the study were excluded. Full copies of papers 
were obtained for the remaining relevant articles. Key authors were identified from 
the principal papers located and MEDLINE was searched separately to identify 
further relevant papers by these authors. Further articles were also identified from 
the references lists of significant papers. 
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 Venous thromboembolism 2.2
2.2.1 Definitions 
A venous thromboembolism is a clot which occurs in the body in response to three 
principal factors, damage to a blood vessel, a reduction in the rate of blood flow 
and changes in the ability of the blood to clot, these three factors are generally 
known as Virchow’s triad.39 Venous thromboemboli usually occur in the deep veins 
in the calf of the leg,39 a thrombosis in this location is therefore known as a deep 
vein thrombosis or DVT. If a DVT breaks free, is transported by the circulation 
through the heart and lodges in the pulmonary arteries this is known as pulmonary 
embolism or PE.40 
2.2.2 Historical background 
VTE was first described in detail in England 1676 in a patient who developed  
swelling and pain in one leg following childbirth, its association with debilitating 
medical illnesses was noted in 1810 and its association with surgery recognised in 
1866.53 During the 20th century, accumulating evidence of risk factors for VTE, 
especially those associated with surgery, led to the first consensus statement for 
preventing VTE and PE which was published in America in 198654 and 
recommended prophylaxis with unfractionated heparin for both medical and 
surgical patients. The THRIFT consensus group published similar recommendations 
in the UK in 1992.55 
For surgical patients the adverse effects of trauma due to surgery and venous stasis 
due to immobility during and following surgery have been recognised for over a 
century.53 National guidance for reducing the risk of VTE in patients undergoing 
surgery was published in England in 200756 and as a result prescribing of VTE 
prophylaxis for surgical patients is currently accepted as routine clinical practice 
throughout the UK. In contrast the situation for medical patients is more complex, 
less evidence is available, national guidance for England was published in 2010,43 
some years after that for surgical patients, and implementation for medical patients 
has taken longer. 
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2.2.3 Risks associated with VTE 
A House of Commons Health Select Committee inquiry in 2004 estimated that PE is 
responsible for approximately 25,000 deaths in English hospitals each year and is 
the immediate cause of death in 10% of patients who die in hospital.41, 42 A review 
of post mortems carried out in a London hospital between 1991 and 2000 showed 
that death from PE is more likely to occur in medical patients than surgical 
patients.57 Studies have also shown that a DVT may break free and lead to a PE 
without any clinical symptoms,58, 59 approximately 50% of patients with proven DVT 
have a high probability of PE on ventilation-perfusion lung scanning.60 
2.2.4 Long term consequences of VTE 
There are a number of long term consequences associated with VTE and therefore 
it is preferable to provide appropriate prophylaxis to minimise the number of 
patients developing a DVT or PE. Of patients with a DVT 30%-50% will develop post-
thrombotic syndrome which in some cases causes severe leg pain, oedema and 
chronic leg ulcers.61, 62 Between 2% and 4% of patients with a PE will develop 
chronic thromboembolic pulmonary hypertension which causes severe shortness of 
breath and may lead to death as a result of right ventricular failure.61, 62 It has been 
shown that approximately 30% of PEs prove fatal within 7 days of diagnosis.63  
2.2.5 VTE risk assessment tools 
The process of risk assessing patients for VTE initially involves identifying any 
predisposing factors. The first American consensus statement of 1986 included a list 
of known VTE risk factors for medical patients but noted that the combined impact 
of multiple risk factors was unknown,54 the most recent version of these guidelines 
(8th edition) was published in 2008.64 Many hospitals used the consensus 
statements to develop ‘in house’ risk assessment models or tools,65 which generally 
consisted of a list of risk factors, and were refined when the criteria used in large 
studies such as MEDENOX66 and PREVENT,67 which assessed the efficacy of LMWH 
for VTE prophylaxis in medical patients, and ENDORSE68 which investigated the 
proportion of at-risk medical patients who received prophylaxis, were published. 
Some studies have suggested the use of weighted scoring systems,69, 70 these are 
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more complicated to use than simple lists of risk factors but may enable tailored 
prophylaxis in certain groups of high risk patients such as those with cancer.71 
2.2.6 VTE risk factors and pharmacological prophylaxis 
Medical patients acutely admitted to hospital may be at risk of VTE due to a 
number of factors including immobility, increasing age, and co-morbidities in 
addition to their presenting medical condition. The link between the inflammatory 
process and increased VTE risk was first proposed in 197472 and it is now recognised 
that many acute medical conditions which have an inflammatory component such 
as respiratory disease, inflammatory bowel disease, acute arthritis and acute 
infection are all associated with an increased risk of VTE.73 Common VTE risk factors 
are shown in Figure 2-1. 
Figure 2-1:  Common VTE risk factors 
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During the 1980s and 1990s increasing evidence became available regarding the 
many risk factors for VTE which are associated with medical conditions culminating 
with the publication of the MEDENOX study in 1999.74 This large multinational 
study showed that the incidence of VTE in general medical patients aged over 40 
• Age > 60 years 
• Acute or chronic lung disease 
• Chronic heart failure 
• Acute infectious disease (e.g. pneumonia) 
• Acute or chronic inflammatory disease 
• Active cancer or myeloproliferative disorder 
• Diabetic hyperosmotic hyperglycaemic state 
• Personal or family history of DVTa or PEb 
• Expected to be immobile for 3 days or more 
• Hormone therapy containing oestrogen (HRTc or OCPd) 
• Lower limb paralysis (excluding acute stroke) 
• Obesity: BMI > 30 
• Known thrombophilia 
• Varicose veins with phlebitis 
• Pregnant or ≤ 6 weeks post-partum 
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Hormone replacement therapy, 
d
Oral 
contraceptive pill 
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years is almost 15% and that VTE was effectively prevented in 63% of cases by the 
use of a LMWH, in the MEDENOX study enoxaparin was the product used. In 2003 
the PRINCE study from Germany showed that in medical patients with heart failure 
or severe respiratory disease enoxaparin is at least as effective as unfractionated 
heparin75 and in 2005 the PREVENT study demonstrated the efficacy of a standard 
dose of the LMWH dalteparin for the prevention of VTE in acutely ill medical 
patients.67 
Many medical patients have multiple risk factors, thus not surprisingly it has been 
shown that the proportion of patients who develop VTE increases as the number of 
risk factors increases,76 over 80% of medical patients admitted to hospital have at 
least one risk factor.74, 77 The risk of DVT in hospitalised medical patients if no 
thromboprophylaxis is given was shown to be approximately 20% in a meta-analysis 
of 17 randomised clinical trials.78 Prophylaxis with the LMWH enoxaparin or 
dalteparin reduces the number of hospital-acquired VTEs in medical patients by up 
to 60%.66, 67, 74 No studies have been published to support the use of tinzaparin, the 
third LMWH available in the UK, for VTE prophylaxis in medical patients and it is not 
currently licensed for this indication. Fondaparinux, an inhibitor for the clotting 
factor Xa, has also been shown to be effective in medical patients79 reducing the 
incidence of VTE by almost 50%. Fondaparinux is recommended as an option for 
VTE prophylaxis in medical patients by both NICE43 in the UK and the American 
College of Chest Physicians64 however in practice it is usually reserved for patients 
with a heparin allergy due to its increased cost, around twice that of LMWH.80 
2.2.7 Risks associated with LMWH 
As LMWHs are anticoagulants there was concern that their widespread use for VTE 
prophylaxis would be associated with an increased incidence of haemorrhage. 
However the large multinational studies such as MEDINOX74 and PREVENT67 
showed a prevalence of major bleeding events of 1.7% and 0.43% respectively in 
patients receiving LMWH, which was not significantly different to the incidence in 
patients treated with placebo. A meta-analysis published in 2007 showed that 598 
patients would have to be treated with LMWH prophylaxis for every case of major 
bleeding.81 The IMPROVE study showed that as expected medical patients with 
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known bleeding, active gastrointestinal ulceration or a low platelet count (<50 x 109) 
were most likely to develop bleeding within 14 days of hospital admission when 
treated with prophylactic LMWH,82 1.2% developed a major bleed and 2.1% a less 
severe but clinically relevant bleed. Patients must be assessed for bleeding risk in 
accordance with NICE guidelines and LMWH should only be prescribed if the risk of 
VTE outweighs the individual risk of bleeding.43 Common bleeding risks are shown 
in Figure 2-2. 
Figure 2-2:  Common bleeding risks 
 
 
 
 
 
 
 
 
 
 
 
2.2.8 Cost effectiveness of VTE prophylaxis 
A large study from America showed that treatment of patients with a VTE is 
associated with significant costs and that management of a second  DVT costs 21% 
more than the initial event.83 Another American study showed that appropriate VTE 
prophylaxis, for medical and surgical patients, is associated with a decreased length 
of hospital stay and the overall cost of care was significantly lower for patients who 
received appropriate prophylaxis with LMWH.84 An Australian study also showed 
significant savings,85 however no UK cost-effectiveness studies were located in the 
literature. This may be because healthcare costs have traditionally been carried out 
at individual patient level in the USA and Australia as required by private medical 
insurance companies, however in the UK the NHS has traditionally been funded 
according to block contracts, hence the mechanisms for accurately costing 
healthcare services to individual patient level are not well developed. 
• Active bleeding 
• Taking warfarin or other anticoagulant or antiplatelet therapy 
• Haemophilia or other known bleeding disorder 
• Acute stroke in past month (haemorrhagic or ischaemic) 
• Blood pressure > 200 systolic or 120 diastolic 
• Hypersensitivity to heparin 
• History of Heparin Induced Thrombocytopenia (HIT) 
• Lumbar puncture / spinal / epidural in previous 4 hours or indicated now 
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2.2.9 Prescribing of VTE prophylaxis 
In the 21st century there has been increasing international awareness of VTE risks as 
shown by studies assessing current prophylactic prescribing practice which have 
been published in Europe,86, 87 Brazil,88 the United States89, 90 and Canada.91 
However the ENDORSE study, which was conducted in 32 countries worldwide in 
2008, showed that prescribing rates of recommended VTE prophylaxis in medical 
patients varied between countries from 3% to 70%.68 In the UK uptake was slow, a 
2004 audit from Oxford showed that only 25% medical patients, for whom 
prophylaxis was indicated, received it,92 a 2009 paper from Leeds showed an 
improvement to 56% following interventions93 and a 2010 paper from Nuneaton 
showed 48% of medical patients received appropriate prophylaxis.94 A more recent 
audit, published in 2013, showed that in some centres 98% of patients are now 
appropriately prescribed prophylaxis.95 
2.2.10 National guidance in England and Wales 
In 2007 an independent expert working group, commissioned by DH, recommended 
a mandatory VTE risk assessment of every hospitalised patient on admission96 and 
in autumn 2008 the DH introduced a screening tool for VTE which was 
recommended for use by all acute NHS trusts.34 In early 2010 NICE published 
guidance on reducing the risk of VTE in patients admitted to hospital43 which 
reiterates the need for all patients to be VTE risk assessed on admission. In March 
2010 the DH announced that data collection relating to VTE risk assessment would 
be mandatory from June 2010 and this subsequently formed part of the DH CQUIN 
financial framework for 2010/11 for England.97 In December 2010 the DH 
announced that the incidence of hospital acquired VTE was to be included in the 
new NHS Outcomes framework for England for 2011/12 in the domain of treating 
and caring for people in a safe environment and protecting them from avoidable 
harm.98 The published national data show that it took 18 months for the national 
target of 90% of patients to be risk assessed on admission to hospital to be 
achieved by acute NHS trusts.99 The national VTE risk assessment initiative has been 
effective as there has been a significant reduction in both deaths directly attributed 
to VTE and VTE related deaths in patients admitted to NHS hospitals in England for 
a period of less than four days since national targets were introduced.100  
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 Medicines reconciliation 2.3
2.3.1 Definitions 
Medication errors have been defined by the NPSA as “incidents in which there has 
been an error in the process of prescribing, dispensing, preparing, administering, 
monitoring, or providing medicine advice, regardless of whether any harm 
occurred”.101 This is a broad definition which is generally accepted for use in the 
NHS. 
Prescribing errors constitute one type of medication error and have been defined as 
occurring: “when, as a result of a prescribing decision or prescription writing process, 
there is an unintentional significant (1) reduction in the probability of treatment 
being timely and effective or (2) increase in the risk of harm when compared with 
generally accepted practice”.102 
A medication history should comprise a list of all medication currently being taken 
by the patient together with doses and frequencies and include any medication 
recently started by the GP, Over the Counter (OTC) medicines and herbal 
remedies.35, 44 Medicines reconciliation on admission to hospital, as defined by NICE, 
is the process of collecting information to prepare the patient’s current medication 
history, verifying this list against the current hospital medication chart, identifying 
any discrepancies and taking appropriate action.35 The World Health Organisation 
(WHO) has defined unintentional medication discrepancies as those “in which the 
prescriber unintentionally changed, added or omitted a medication the patient was 
taking prior to admission”.103 
2.3.2 Medication history taking process 
Guidance suggests that at least two sources should be used when obtaining a 
medication history and where possible the patient should be involved.44, 104-106 
Suitable sources suggested in the literature include: the patient’s own medicines, 
discussion with the patient or carer, GP repeat prescription order form, computer 
printout from GP clinical records system, case notes, community pharmacy, and 
medication administration records (MAR) from care homes.44, 103, 106 The WHO has 
stated that a “best possible medication history” involves the use of more than one 
source and should include a patient interview where practical.103  
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2.3.3 Risks associated with medication 
Medication errors are recognised as an important cause of morbidity and mortality 
and in 2000 the DH report “An Organisation with a memory”25 noted that in general 
medical practice 25% of litigation claims related to medication errors. It 
recommended that action should be taken to reduce the number of errors 
associated with prescribed medicines by 40% over the next five years. The 
implementation guidance published in 2001 “Building a safer NHS for patients: 
implementing an organisation with a memory”26 noted that some hospital 
pharmacists were already working to improve the quality of the medication history 
recorded when patients are admitted to hospital. The follow up report “Building a 
safer NHS: improving medication safety” was published in 2004107 and noted the 
problems which arise with medication when patients transfer between care 
settings. These risks have also been recognised by the World Health Organisation 
(WHO) and international guidance has been published.103, 108 
2.3.4 Quality of medication histories 
Several studies in the literature show that medication histories taken by doctors 
during the hospital admission process are frequently inaccurate,47-50 the proportion 
of histories with an error ranging from  23%49 to 62%48 of cases. A large study 
carried out in acute trusts in the North West of England in 2009 found that 
prescribing errors were most often made at the time of admission to hospital with 
13.4% of prescriptions containing an error of which 1.74% were classified as being 
potentially lethal.109 However none of these studies investigated the actual process 
of obtaining a medication history, data were collected retrospectively by reviewing 
medication charts.  
Pharmacists have been shown to document medication histories more accurately 
than medical staff.46, 47, 110 A recent American study which collected data from a 
computerised medicines reconciliation template found that pharmacists 
documented more prescribing changes on admission to hospital than doctors and 
also that pharmacists were more likely to document additional information such as 
indications for medicines and the rationale for changes made.111 
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2.3.5 Causes of prescribing errors 
The causes of prescribing errors are multifactorial but common themes include lack 
of time / workload pressures, poor communication and lack of knowledge and / or 
training.112, 113 A study carried out in North West England which interviewed 30 
junior doctors also found that these three factors were involved when errors 
occurred.109 Results from a Scottish study in which 40 junior doctors from eight 
hospitals (four teaching, four district general) were interviewed provided more 
insight into the effect of time pressure. Doctors in this study felt that they had little 
time for checking, whether this involved checking sources during medicines 
reconciliation, checking reference sources such as the BNF or checking tasks which 
they had carried out.114 Access to necessary information outside of normal working 
hours also caused difficulties as, although electronic systems were sometimes 
available, junior medical staff on call often did not have a password.114 
2.3.6 Incidence and potential impact of prescribing errors on admission 
to hospital 
A systematic review of 63 published studies from countries worldwide found that 
50% of patients admitted to hospital experience a prescribing error115 and 
prescribing errors were found to affect approximately 15% of newly written 
medication orders in London.112 An error in the medication history has been 
identified as the source of approximately 80% of the prescribing errors made on 
admission to hospital.116 However the incidence of errors reported in the literature 
is variable due to the different ways in which results are expressed.117  A systematic 
review of 24 studies found that prescribing error rates ranged from 4.2% to 82% of 
prescription charts reviewed.118 Topical preparations such as eye drops seem to be 
most often omitted from admission prescriptions,119 a check list highlighting 
common medicines which are not taken orally and those which are taken or used 
less frequently than once a day has been shown to be effective in reducing the 
number of medicines omitted from the prescription written on admission to 
hospital.120 
A recent large study carried out in eight hospitals in Scotland showed that 60% of 
prescribing errors reached the patient,113 although less than 1% resulted in harm or 
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required additional monitoring. Few studies have attempted to assess the impact of 
prescribing errors identified during medicines reconciliation and a variety of 
methods have been used. A Welsh study using an adapted version of a tool 
developed by the NPSA121 classified 20% of errors as ‘major’ or ‘moderate’,48 other 
studies using consensus panels to estimate impact have reported 32.9% of errors 
could potentially cause moderate discomfort or clinical deterioration122 and a study 
from London concluded that 26% were potentially serious.123 A Dutch study, using a 
scheme developed by the Netherlands Association of Hospital Pharmacists, found 
that preventable harm was caused by about 2% of prescribing errors,50 and a 
French study using two pharmacists and a doctor to assess the impact of errors 
found that 6.4% had the potential to cause temporary patient harm, 20.8% may 
have resulted in a greater need for patient monitoring but the majority (72.8%) 
were unlikely to be harmful.124 Overall all of the above studies concluded that the 
majority of prescribing errors identified during medicines reconciliation following 
admission to hospital were unlikely to cause serious harm despite the different 
methods used to assess the likely impact. 
2.3.7 Problems associated with medicines reconciliation. 
Medicines reconciliation on admission to hospital is problematic as patients are 
often too unwell to provide any substantial information and the patient’s own 
medication is often forgotten in the rush to get to hospital. Lists of medication from 
GP surgeries may be inaccurate125 and between 10% and 50% of patients may not 
take their medicines as prescribed.126, 127 
2.3.8 Time required for medicines reconciliation 
The costing template published by NICE/NPSA to support the implementation of 
the medicines reconciliation alert in 2007 suggests that 15 minutes is required to 
carry out medicines reconciliation for the ‘average’ emergency admission but 
acknowledges that complex patients are likely to require longer.104 A UK study 
showed that the median time taken for medicines reconciliation in acute medical 
admissions was 15 minutes, interquartile range 10 to 20 minutes,126 and a study 
from the USA found that the mean time required to complete both medicines 
reconciliation and make any necessary interventions was 21.2 minutes.116 A French 
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study found that the time taken by pharmacists to determine the best possible 
medication history in accordance with the WHO definition103 was 36 minutes.124 
2.3.9 Cost effectiveness of medicines reconciliation 
A systematic review has shown that medicines reconciliation by pharmacists is a 
cost effective method of reducing prescribing errors on admission to hospital.45 A 
study from Sheffield showed that pharmacist-led medicines reconciliation was most 
likely to be cost effective, when compared with pharmacy technicians or nurses 
using a standard medication history form and lists of medication faxed by GPs, and 
that savings made from preventable adverse drug reactions may be significant.128 
2.3.10 National guidance in England and Wales 
National guidance for medicines reconciliation was introduced in England and 
Wales in late 2008 when NICE and the NPSA jointly published patient safety 
guidance.35 Acute NHS Trusts were advised to ensure that policies were in place for 
medicines reconciliation and the guidance also stated that pharmacists should be 
involved in medicines reconciliation as soon as possible following the admission of 
patients to hospital. The RPS professional standards for hospital pharmacy services 
indicate that ideally pharmacy staff should carry out medicines reconciliation within 
24 hours of admission.38 Although most Trusts have carried out local audits and 
there has been at least one benchmarking study carried out in the south east of 
England129 there have been no formal national audits and, in contrast to VTE, no 
national targets for medicines reconciliation have been introduced. 
 Implementation of guidelines 2.4
2.4.1 Guideline implementation rates 
There is a significant gap in clinical practice between recognised best practice in line 
with available evidence and care actually received by patients. An American study 
found that patients received only 54.9% of the steps recommended in their care 
pathways.130 A study from the Netherlands showed that even when knowledge of 
guidelines is good and there is wide acceptance of their benefits, implementation 
by GPs only occurred in 67% of relevant clinical situations.131 
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2.4.2 Potential barriers to guideline implementation 
A systematic literature review of 256 articles in 2007132 investigated the barriers to 
integrating guidelines, evidence and research into clinical practice. This study 
identified seven categories of barriers: cognitive/behavioural, attitudinal, 
professional, guideline/evidence, patient, support/resource, and system/process. 
An earlier review identified physician related barriers including lack of awareness, 
lack of motivation and lack of agreement with the guideline or lack of belief that the 
intervention will lead to the desired outcome.133 A recent investigation into the 
uptake of evidence from systematic reviews identified similar barriers including lack 
of awareness, lack of trust in the results and lack of motivation.134 
2.4.3 Potential strategies to improve guideline implementation 
A review of guideline dissemination and implementation strategies from 1966 – 
1998 showed an overall failure to adhere to guidelines and concluded that 
implementation strategies such as education, audit and feedback and reminders 
have a limited effect improving uptake by 4 – 34%.135 A later study from Australia 
also showed a modest increase in uptake of guidance following the use of various 
implementation strategies. The most useful strategies were identified as being 
grand rounds, peer review sessions and informal discussions, reminder cards and 
information packs were deemed less useful.136 However in another study personal 
timely reminders were effective in increasing the number of staff who wore gloves 
when inserting an intravenous cannula or taking a blood sample.137 
The layout and content of guidelines may also affect uptake, a study in 2011 
developed a framework consisting of 22 elements which, if included in guidelines, 
should improve the level of implementation.138 These include usability, evidence of 
validity, tools for implementation and advice for monitoring. Thus modification of 
some existing guidelines in line with this framework may result in greater 
implementation rates. 
Adoption of a guideline often starts with a small number of enthusiasts, it is then 
adopted by those who are respected in local networks including local opinion 
leaders and then spreads to the majority.139 However identification of current 
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opinion leaders is not easy as it has been shown that these individuals change in a 
period of less than two years.140 
Complex interventions such as VTE risk assessment and medicines reconciliation, 
which have a number of different components and require clinical judgement may 
present particular difficulties in implementation,141 organisational factors are 
thought to be particularly important.142 The successful integration of this guidance 
into the complex process required for unplanned admissions is likely to prove 
especially challenging. Therefore the study investigated the integration of these 
two interventions into the hospital admissions process and explored the various 
factors impacting on their implementation. 
 Summary 2.5
This chapter has provided the background and rationale for both VTE risk 
assessment and medicines reconciliation to be carried out for all patients on 
admission to hospital. The difficulties associated with the implementation of clinical 
guidelines have also been reviewed. The methods used in the study to explore the 
implementation of both VTE and medicines reconciliation guidance are discussed in 
the next chapter. 
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Chapter 3 Methods 
This chapter discusses the research design, the methodology chosen for the study, 
the design of the research instruments, the conduct of the study and the data 
management and analysis.  
 Research design 3.1
The study was originally designed as a change management project focusing on VTE 
risk assessment involving an initial series of data collection periods, analysis of the 
data, design and implementation of interventions and a further series of data 
collection periods to identify any changes in practice. However due to political 
pressure the study Trust began introducing measures to improve VTE risk 
assessment starting with the appointment of a thrombosis nurse in February 2010. 
Since the original change management project was no longer viable and 
information regarding medication had been collected as part of the VTE project it 
was decided to change the study focus and investigate the implementation of two 
different pieces of guidance, VTE risk assessment and medicines reconciliation, on 
admission to hospital. Government pressure was being applied to improve the 
implementation of the VTE guidance, but not the medicines reconciliation guidance, 
so the effect of national targets on guideline implantation was felt to be worthy of 
investigation. As three large data sets had already been collected prior to VTE data 
collection becoming mandatory in June 2010 it was decided to have a final data 
collection period 12 months after government intervention commenced in order to 
detect any changes over time. 
Pharmacy and medicine are healthcare disciplines which are rooted in science and 
hence an overall scientific approach was taken to the study. Scientific methods 
involve the systematic study of the area of interest including outcomes and aim to 
minimise the effects of external factors on the data collected and therefore usually 
involve quantitative methodologies. The principal philosophy on which quantitative 
scientific methods are based is positivism which assumes that phenomena are 
measurable.143 However, not all aspects of healthcare are measurable, especially 
the opinions of individuals as in this study. Quantitative methods would provide the 
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outcomes in terms of how many patients received VTE prophylaxis or how many 
had an error in their prescription however it was important to try to understand the 
reasons behind the poor compliance with guidance. A pragmatic approach was 
therefore taken to developing the methodology,144, 145 in order to find out how 
errors were occurring it was necessary to observe the admission clerking process 
and to understand why there was a problem it was necessary to speak to the 
individuals involved which required the inclusion of a qualitative approach. Mixed 
methods which include both qualitative and quantitative components enable a 
wider range of data to be collected and facilitate triangulation in which findings 
from one methodology may be supported or confirmed by findings from another 
methodology potentially strengthening the results.143, 146   
As the problems in implementing both VTE risk assessment and medicines 
reconciliation guidance were likely to be multifaceted, a methodology was required 
which would enable information to be gathered not only about the processes 
involved but also the opinions of relevant staff and patient outcomes. A mixed 
methods approach was therefore chosen comprising direct observation of the 
admission process, interviews with healthcare staff and a retrospective review of 
case notes. Observations were chosen to obtain ‘real life’ data about what actually 
happens when a patient is admitted to hospital and interviews to gather 
information about the knowledge and opinions of staff to support and inform the 
findings of the observations. The case note review established what was 
documented in relation to VTE risk assessment and prescribing of medicines and 
enabled outcomes to be identified. The data collected were mainly quantitative 
from the case note reviews, the observations and the structured interviews. A small 
amount of qualitative data was gathered from the observations and from the 
limited number of open questions in the interviews, although this did not provide 
the rich data normally associated with qualitative studies the methodology still falls 
within the definition of mixed methods.145 
In order to avoid the focus of the study becoming known observations were carried 
out first for each data collection period, interviews were scheduled and case notes 
reviewed once observations were complete.  Interviews were completed as soon as 
28 
 
possible as medical staff rotate frequently, often to different hospitals, which may 
have compromised the completeness of the data had they been delayed. The case 
note review continued throughout the study, including weeks when observations 
were conducted, the rate of data collection being dependent on the rate of 
discharge of the patients and the availability of the notes.  
 Selection of methodology 3.2
Various methods have been used to study how best to implement clinical guidelines 
and evidence has accumulated demonstrating the efficacy of many different 
methods. Several studies in healthcare have used a single methodology to 
investigate barriers to guideline implementation. For example semi structured 
interviews alone have been used to explore the use of antibiotics for the treatment 
of pneumonia147 and the treatment of hypertension,148 questionnaires alone have 
been used to investigate the implementation of guidelines relating to intravenous 
catheter insertion149 hypertension150 and maternity care.151 
Non-participant observation has been used previously in healthcare research to 
investigate the interaction between healthcare professionals and patients, for 
example the assessment of nutrition,152 and various aspects of direct nursing 
care.153-156 The consultation skills of medical students and specialist registrars 
working in general practice have been assessed using direct observation.157, 158 In 
relation to medication observation has been used to assess nurses’ prescribing 
consultations,159 explore various aspects of the supply of over the counter 
medicines from community pharmacies160, 161 and investigate the recently 
introduces Medicines Use Review (MUR) service.162 During the hospital admission 
process direct observation been used to assess how data relating to children’s 
allergies is ascertained and documented.163 However no published studies were 
found in the literature to date which used non-participant observation for the 
investigation of any other aspects of the hospital admission process or for the 
purpose of managing guideline implementation. Given the potential need for 
changes to practice in order to implement both VTE and medicines reconciliation 
guidelines, observation of current practices is essential in order to understand what 
needs to change and the likely barriers to these changes.  
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Participant observation was considered but rejected as it was not possible for the 
researcher to collect the necessary detailed data while continuing to function as a 
consultant pharmacist. The literature highlights the possible conflicts between the 
various roles required of a participant observer in a healthcare study and the 
difficulties in satisfying the demands of both employee and researcher roles 
simultaneously.164 In the present study there would have been a constant conflict 
between her pharmacist role and researcher role, the practicalities of observing 
medical staff in such an unpredictable and busy setting necessitated her presence 
to do research without any additional commitments or distractions.  
The use of video as an alternative to direct observation was briefly considered as it 
has been used in healthcare research for example to assess the nursing care of 
cancer patients,165 to assess the performance of anaesthesiologists166 and to 
improve multidisciplinary team working in the discharge process.167 However this 
approach posed additional ethical problems, was likely to prove technically difficult 
in such a fast moving complex clinical environment and may have deterred both 
staff and patient participation. 
A systematic literature review in 2007132 investigated the barriers to integrating 
guidelines, evidence and research into clinical practice. Of the 178 studies identified 
44 were mixed method studies and only six involved the use of more than two 
methods of assessment. The authors note that mixed methods studies may yield 
more reliable results. It was therefore decided that, in order to obtain as much 
information as possible about current practices in relation to both VTE and 
medicines reconciliation, the study should have a mixed methodology including 
observations, interviews and a review of case notes, the latter also facilitating the 
determination of outcomes. This methodology was presented and discussed at the 
PhD forum held at the Health Services Research and Pharmacy Practice (HSRPP) 
Conference in March 2009 in order to seek the opinions of experienced researchers 
(Appendix 1). The proposal was well received; the problems associated with the 
researcher being a member of the AMU team in the study hospital were discussed. 
However a large, high turnover AMU was needed in order to enable sufficient data 
to be collected within the time available, other local units did not have sufficient 
30 
 
patient numbers. In addition recent audit data demonstrating the need for this 
research was available in the study hospital. 
 Study risk assessment 3.3
A risk assessment was carried out and documented as required by RLBUHT 
(Appendix 2). As the project was to be carried out in the investigator’s normal 
working environment and there were no alterations to the usual policies and 
procedures, it was not anticipated that participation in the study would incur any 
additional risks to any of the individuals involved (including patients); it was 
therefore scored as ‘low’. 
 Research instruments 3.4
The admission process data collection form (Appendix 3), the structured interview 
schedules (Appendix 4, VTE, Appendix 5, Medicines reconciliation) and the case 
note data collection form (Appendix 6), were designed by the investigator based on 
her NHS experience and the requirements of the study. They were reviewed by the 
supervisory team, which included both experienced health services researchers and 
a senior clinician working on the AMU, and amended in line with comments 
received. The admission process data collection form was designed as a booklet 
with very limited information documented on the front page to minimise the 
possibility of data entries being seen by staff and revealing the study focus. Once 
ethical approval was granted, the admission process data collection form was 
piloted in the Emergency Department (ED) at RLUH, which is a similar clinical 
setting to AMU, no further amendments were required. The case note data 
collection form was not piloted as the researcher was experienced in carrying out 
audits of case notes. The interview schedules were not piloted, the researcher’s 
extensive clinical experience enabled suitable questions to be devised and as any 
doctor in the Trust may have been allocated to work on AMU during the course of 
the study this may have reduced the pool of staff available to participate and may 
also have resulted in the focus of the study becoming known. The information 
sheets for healthcare staff (Appendix 7) and patients (Appendix 8) and the consent 
form for staff (Appendix 9) were designed by the investigator in line with templates 
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provided by Liverpool John Moores University (LJMU). They were reviewed by the 
supervisory team and amended in line with comments received. 
 Confidentiality 3.5
Patient confidentiality was maintained by the allocation of a unique study number 
to each patient for use throughout the study, to facilitate matching of data from 
observations and the case note audit. Each patient was allocated a unique study 
number in the format A1, A2, A3 and B1, B2, B3 etc. where A is the first data 
collection period and number 1 is the first patient in that period. A single master list 
cross referencing the unique study numbers to the patients’ hospital numbers and 
names was held by the investigator.  
Healthcare staff confidentiality was maintained in a similar way by use of a unique 
study number for each staff member throughout the study, to facilitate matching of 
data from observations and interviews. Each member of staff was allocated a 
unique study number in the format G1, G2, G3 and H1, H2, H3 etc. where G is the 
first data collection period and number 1 is the first member of staff recruited in 
that period. A single master list cross referencing the unique study numbers to staff 
names and contact numbers (bleep and/or telephone) was held by the investigator. 
When not in use during the study period these reference lists were stored in a 
locked filing drawer within the Pharmacy department accessible only to the 
researcher. The pseudoanonymised study data were stored separately in a locked 
filing cabinet within the Pharmacy department. Access to the Pharmacy department 
is restricted to Pharmacy staff and those visiting senior pharmacy staff by 
appointment; the department is secure at all times. The reference lists remained on 
Trust premises at all times. Case notes were reviewed within the Trust and 
remained on Trust premises at all times. Pseudoanonymised data collection forms 
were taken to LJMU in batches for entry into SPSS databases and analysis. At LJMU 
they were securely stored in a locked filing cabinet in a locked office. 
The study number cross reference lists containing staff or patient details were 
destroyed by shredding three months after the completion of the study. The 
original pseudo anonymised data collection forms will be retained for a period of 5 
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years from the end of the study in accordance with Records Management: NHS 
Code of Practice part 2.168 This will allow further analysis by the original or other 
research teams subject to consent, and will support monitoring by regulatory and 
other authorities. At the end of this period these data will be destroyed in 
accordance with the prevailing Trust procedures for confidential waste. 
 Sample size 3.6
3.6.1 Observations and interviews 
Staff were purposively selected from those available on the AMU rotas to ensure 
that all grades were represented and that a similar number of staff participated in 
both the VTE and medicines reconciliation interviews. As many staff as possible 
were included from those working on AMU during the study periods to maximise 
the range of views collected and also so that the outcomes identified from the case 
note audit could be related to the staff observed and interviewed. 
3.6.2 Case notes 
A power calculation was performed based on previous VTE audit data and 
estimated potential improvement in the frequency of VTE risk assessment, 
following implementation of guidelines. The purpose was to determine whether the 
number of case notes available from patients admitted to AMU during a one week 
period, approximately 200 to 250, would provide sufficient statistical power to 
enable meaningful analysis.  Following government intervention to improve VTE 
risk assessment the study design was changed to include a medicines reconciliation 
arm and the same case note samples were used for both arms, there were no audit 
data available regarding the frequency with which medicines reconciliation was 
performed to inform this part of the work. 
The power calculations were carried out using the power and sample size routine in 
Minitab version 15 using the following criteria: 
 Number of case notes = 200 
 Baseline number of documented VTE risk assessments = 5% 
 Minimum anticipated final number of documented  risk assessments = 20% 
Statistical power calculated = 99% 
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Assuming 20% of patients have a contraindication to treatment: 
 Number of patients who require LMWH treatment = 160 
 Baseline number of patients treated with LMWH = 30% 
If number of patients treated rises to 45%, statistical power = 79% 
If number of patients treated rises to 50%, statistical power = 96% 
As the AMU admits approximately 250 patients each week it was decided that 
following up all patients admitted during a series of one week periods should 
provide a sufficiently large sample to provide suitable power for the statistical 
analysis of the VTE arm of the study.  
 Data collection periods 3.7
The study periods were spread over time, originally the study was designed as an 
interrupted time series so the first three data sets were at 12 week intervals. 
Following the changes necessitated by government intervention in VTE prophylaxis 
it was agreed that a final data collection period after an interval of 12 months 
should provide sufficient data regarding the effect of national targets and would 
also enable comparison of data from the same time of year. The spread of data 
collection periods helped overcome bias resulting from seasonal variations in 
healthcare workload, cardiac admissions have been shown to increase over the 
Christmas / New Year period,169 thunderstorms increase acute asthma attacks170 
and heat waves are associated with increased mortality.171 It also helped minimise 
bias due to experience of staff and allowed for comparison between the same 
period in two successive years. Foundation year 1 (F1) and 2 (F2) doctors (first and 
second year post registration) rotate every four months and specialist trainees (ST, 
3 to 8 years post registration) rotate every six months. No data were collected 
within the two weeks following the rota changes in August, December, February or 
April, weeks including bank holidays were also avoided as different medical rotas 
operate to those on normal working days. The data collection periods were 
therefore selected to avoid observing medical staff who were new to AMU as this 
may cause undue pressure on the individuals and may also have had an adverse 
impact on the results if they had had insufficient time to become familiar with the 
usual working practices in the AMU and were not following normal procedures.  
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Data were collected during four one-week study periods: November 2009 (1), 
January 2010 (2), April 2010 (3) and April 2011 (4). Study periods were selected to 
enable the participation of as many medical staff as possible (one week involves 
two visiting staff rotations) within the constraints of the AMU rotas and to identify 
any changes in practice over time. Direct observation of a sample of admissions and 
case note review and was carried out for all four study periods. All staff observed in 
periods 1, 2 and 3 participated in a structured interview regarding VTE risk 
assessment, these interviews took place before government VTE initiatives were 
introduced. In order to apply the same methodology to the medicines reconciliation 
arm of the study as that for the VTE arm interviews regarding medicines 
reconciliation were required, therefore staff observed during period 4 together 
with further purposively selected staff participated in medicines reconciliation 
interviews. 
 Recruitment of study participants (hospital staff) 3.8
Staff were purposively selected from rotas, some were working full time on AMU 
others were working a ‘hot block’ in which a group of doctors who are usually 
based on other wards in the Trust take responsibility for clerking the admissions to 
AMU for a period of three or four days at a time (9am -10pm). Staff were selected 
to ensure that all grades usually working on AMU were represented, they could 
chose to participate in either the observations and / or one interview (covering VTE 
or medicines reconciliation). The researcher personally approached staff and 
explained that she was undertaking a research project based on hospital 
admissions, no further details were given, a study information leaflet was provided 
(Appendix 7). Staff who agreed to participate were asked to complete a consent 
form (Appendix 9) which was retained by the researcher, they were free to 
withdraw at any time without the need to provide a reason.  
 Selection of patient episodes 3.9
3.9.1 Observations 
On arrival at the AMU, patients are initially triaged by an AMU nurse who will 
record a set of basic observations including temperature, blood pressure, and pulse. 
They are then seen by a doctor or nurse clinician who is responsible for taking a 
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history (including medication), assessing the patient, making a provisional 
diagnosis, documenting a management plan, ordering initial investigations and 
writing the admission prescription. This process is known as clerking. Acutely unwell 
patients are clerked as a priority and may be seen by a senior doctor prior to initial 
clerking, the remaining patients are clerked in order of arrival. The medical and 
nursing staff responsible for clerking simply select the next patient due to be seen. 
Hence patients whose admissions were observed were included by virtue of the 
member of staff who clerked them agreeing to participate in the study. A brief 
explanation of the study was provided for all patients whose admission was 
observed, or their carers, an information leaflet was provided (Appendix 8) and it 
was made clear that they could ask the researcher to leave at any time during the 
consultation. Observations were carried out on weekdays only, few patients are 
admitted to AMU from GPs at weekends as GP surgeries are closed and a primary 
care on call service has to be contacted. 
3.9.2 Selection of case notes 
All patients admitted during the study week (7 days, Saturday to Friday) were 
included in the case note audit. Patients were identified daily during the study 
weeks using the AMU admissions register which is kept by the AMU reception staff. 
 Ethical issues 3.10
A number of ethical issues were considered in the design of the study. If the staff 
involved had been aware of the specific areas of interest to the researcher then it is 
likely that they would have modified their behaviour such that the data collected 
would not reliably reflect current practice, the Hawthorne effect.172 A recent study 
showed that hand hygiene compliance was significantly improved when staff were 
aware that it was being monitored.173 Studies have also proposed that 
improvement in doctors assessment of their patients pain score174 and reduction in 
inappropriate antibiotic prescribing175 were due to the Hawthorne effect. For this 
reason participants were advised that the researcher was interested in the medical 
admissions process in general, all the necessary study documents simply stated 
‘Medical admissions study’. Any other staff who expressed an interest in the study 
both on AMU and those encountered elsewhere in the hospital during the data 
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collection including nurses, doctors, pharmacists, receptionists, medical secretaries, 
healthcare assistants, cleaners, physiotherapists, occupational therapists and 
electrocardiogram (ECG) technicians, were also told that the study was about 
medical admissions in general. The focus of the study (VTE or medicines 
reconciliation) was shared with participants at the start of the interviews and the 
need to withhold the specific details during the observations explained. The need 
for the purpose of the research to remain covert was discussed at the National 
Research Ethics Service (NRES) meeting and approved. 
The researcher was a Consultant Pharmacist with considerable NHS experience who 
was therefore able to make a clinical judgement regarding actions or omissions 
observed during the clerking process and their potential to have an adverse impact 
on patient care. If such situations were encountered, she shared her concerns with 
the member of healthcare staff involved in a location remote from the patient and, 
if necessary, with an appropriate senior member of the AMU team as is her usual 
practice. 
It was recognised that circumstances may arise in which the researcher felt that it 
would be unethical for her to remain as an observer particularly if she felt that she 
was having an adverse impact on either the member of healthcare staff being 
observed or the patient. In these situations it was agreed that she would withdraw. 
The study was approved by the National Research Ethics Service ((Liverpool Central 
REC Ref 09/H1005/67), LJMU Ethics Committee (approval no 09/PBS/015); Research 
Governance approval was granted by RLUBHT (study no 3862). 
During the course of the study annual reports were provided to NRES and a final 
report was provided once data collection was complete in accordance with NRES 
regulations, copies were sent to the RLUBHT Research Governance Manager. 
 Observations 3.11
Staff gave informed consent for observations, patients or their carers could exclude 
the researcher at any time. During observations, data relating to both VTE risk 
assessment and medication were recorded on a standard form (Appendix 3) with 
additional field notes.  
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General details including the route of referral, reason for admission, and the time 
taken to complete the admission clerking were noted. For the VTE part of the study 
questions asked and patient responses relating to VTE were recorded and also 
whether or not a VTE risk assessment form was available and whether or not it was 
completed. Outcomes in terms of prescription of LMWH or thromboembolism 
deterrent (TED) stockings were also documented. For medicines reconciliation 
questions asked and patient responses were also noted, sources of information 
available and used for medication histories and outcomes in terms of prescribing 
were documented. Field notes included details of interruptions, problems 
encountered in the process and requests for pharmacist assistance.  
For the purposes of the study interruptions were considered to be those made by 
either people or pagers which caused cessation of the activity in which the member 
of staff was involved. Situations in which a member of staff self-interrupted the task 
e.g. because they forgot to take the correct equipment with them when taking a 
blood sample, were not included. Distractions such as other staff entering the room, 
extraneous conversations or telephones ringing were not included. 
All data, including some field notes, were entered into an SPSS database for analysis 
and all observations were later transcribed as case studies using a standard 
template (Appendix 10). Some data were categorised to facilitate analysis as 
detailed below (see section 3.14.3, page 42). 
During observations the researcher positioned herself in such a way as to minimise 
her impact on the staff / patient interaction, in most cases this was achieved by 
standing behind the patient and so out of their line of view. She had only social 
interaction (non-work related conversation) with staff, any questions directed to 
her relating to medication were answered as succinctly as possible, to avoid issues 
relevant to the study being discussed and minimise the impact on the data 
collected, all such incidents were recorded. If the researcher felt that the 
interaction impacted significantly on either VTE risk assessment or medicines 
reconciliation then these cases were excluded from the analysis. Questions from 
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other members of the healthcare team who were not involved in the study were 
answered in the usual way. 
  Interviews 3.12
Interviews with all staff took place as soon as practical following the associated 
observation periods at a mutually convenient time. Interviews had to be scheduled 
to fit in with the unpredictable nature of a hospital working day and were often 
both arranged and cancelled at very short notice. It was therefore impossible to 
book a room for an interview and the most suitable location available at the time 
was used. As these were often public areas of the hospital such as coffee bars or 
reception areas it was not appropriate to record interviews due to the risk of other 
unrelated conversations being accidentally recorded. In view of this restriction, 
structured interview schedules with a limited number of open questions were used, 
to which additional comments could be added as required. Two similar structured 
questionnaires were used to ascertain staff knowledge, training experiences, 
perceptions and practices on admission relating to either VTE risk assessment 
(Appendix 4) or medicines reconciliation (Appendix 5). In periods 1, 2 and 3 the 
focus was VTE and in period 4 it was medicines reconciliation. At the start of each 
interview the need for covert observations was explained to participants and staff 
were asked to keep the subject discussed confidential to avoid any impact on the 
data. 
3.12.1 VTE risk assessment interviews 
Basic demographic details of the staff member, including age and stage of training 
were recorded. A flash card (Appendix 11, answers Appendix 12) which listed 
causes of death in order of prevalence in the UK was used to establish awareness of 
the number of deaths caused by VTE. Staff were asked to spontaneously list VTE 
risk factors which they looked for in their patients and were also asked to list any 
circumstances in which they would withhold prophylactic treatment with LMWH. 
Questions were also asked to ascertain awareness of any local or national policies 
available at the time of the interview. Further questions elicited opinions regarding 
responsibilities for completing a VTE risk assessment and prescribing prophylaxis if 
indicated. Final questions asked for suggestions to improve the rate of VTE risk 
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assessment and increase the number of patients prescribed prophylaxis (Appendix 
4). A list of common VTE risk factors was provided and participants were asked to 
rate them according to importance on a scale of 1 to 5, a similar exercise was 
carried out for bleeding risks (Appendix 13). 
3.12.2 Medicines reconciliation interviews 
Basic demographic details of the staff member including age and stage of training 
were recorded. Staff were asked to estimate how many prescription charts written 
on admission would contain an error in order to gauge their awareness of the 
problem. Questions were asked regarding the availability of local or national 
policies pertaining to medicines reconciliation at the time of the interview. 
Participants were asked to list the sources which they commonly used to document 
a medication history and whether more than one source would be used. If the 
member of staff indicated that on occasion more than one source was used this 
was explored in more detail to ascertain the rationale for this action. Staff were also 
asked how frequently they would discuss the admission prescription with the 
patient and to provide examples of situations when this would not occur. Any 
problems which had been encountered in obtaining information about patients’ 
medication on admission to hospital were documented. Checking of prescriptions 
was also explored; staff were asked who they considered should check 
prescriptions and the timeframe in which this should occur. Finally they were asked 
to make suggestions as to how the number of prescribing errors could be reduced 
(Appendix 5). A list of common sources for medication histories was provided and 
participants were asked to rate them on a scale of 1 to 5 according to their 
usefulness (Appendix 14). 
 Case note review 3.13
Case notes for all patients admitted during each of the four study periods were 
reviewed retrospectively, following discharge or death and data were recorded on a 
standard form (Appendix 6). Patients who had been discharged were identified on a 
daily basis, using the pharmacy computer system, for approximately six weeks 
following each of the data collection periods. As far as possible the researcher 
visited the appropriate wards to review the case notes before they were returned 
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to the Trust case note library. This overcame difficulties in data collection and 
resulted in more complete data for these patients, since old medication charts were 
often located in filing trays on the ward and it is likely that on occasion notes were 
returned to the medical records library before all associated documents had been 
filed. Frequently considerable time was spent looking through boxes, shelves and 
piles of notes to locate those required. Case notes ran to several volumes on 
numerous occasions and were not always filed in chronological order. Many 
patients had frequent admissions so perseverance was needed to locate all the 
relevant documentation relating to a specific episode of care, it is possible that this 
contributed to some of the missing data. Case notes which had been returned to 
the library before the researcher reached the ward were retrieved at a later date 
with the assistance of the AMU medical secretaries. 
For VTE data collected included all VTE risks and bleeding risks documented on the 
VTE risk assessment form, if available, and also all VTE risk and bleeding risks which 
could be identified from the case notes. Outcomes in terms of whether LMWH was 
prescribed and whether the patient developed a DVT or PE, or bleeding were 
recorded, case notes for all patients who died during admission were followed up 
to ascertain the cause of death. For medicines reconciliation data included whether 
medicines reconciliation of the admission prescription was completed by a 
pharmacist, any discrepancies identified, the medicines involved and the time taken 
to rectify the discrepancies. Data collected were entered into an SPSS database for 
analysis. 
3.13.1 Review for VTE risk assessment 
For VTE risk assessment the purpose of case note review was to establish the 
frequency of both VTE risk assessment and prescribing of prophylactic LMWH and 
to identify evidence of VTE risk factors and bleeding risks in order to assess the 
appropriateness of prescribing. Any DVTs, PEs, deaths or episodes of bleeding 
during hospitalisation were also recorded to assess both the effectiveness and any 
adverse outcomes associated with LMWH prophylaxis.  
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For initial screening purposes inappropriate prescribing of LMWH was defined as 
“prescribing for patients with at least one known bleeding risk” and was 
subsequently assessed by an expert panel of four AMU consultant physicians. Each 
consultant independently reviewed a case summary for each patient with at least 
one bleeding risk who was prescribed LMWH. The case summary template 
(Appendix 15) included the presenting complaint, both VTE risk factors and 
bleeding risks and relevant results of investigations. Each consultant was asked to 
indicate that LMWH was either appropriate or inappropriate. The results were 
collated and if there was consensus i.e. all four consultants agreed, the decision 
was accepted. Where there was initial disagreement the cases were debated in a 
meeting, at which all four consultants were present, until consensus was reached. 
3.13.2 Review for medicines reconciliation 
For medicines reconciliation the purpose of case note review was to establish 
whether a prescription was written on admission to hospital, whether medicines 
reconciliation was carried out by a pharmacist and if so the accuracy of the original 
prescription. If the original prescription was inaccurate, the medication errors were 
noted and the time from prescribing to these being rectified was recorded. If there 
was no documented medicines reconciliation by a pharmacist, the case notes were 
excluded from this part of the analysis. At the time of the study all prescriptions 
were hand written on paper charts. 
For the purposes of the study, prescribing errors were defined as one of the 
following: unintentional omission of medication, unintentional prescribing of 
additional medication, prescribing of incorrect medicine devices (for inhalers, 
insulin etc.) and changes in doses for which no justification could be identified. 
Minor discrepancies such as errors in timing of doses, missing frequencies, and 
prescribing by generic name when the brand is required, or vice versa, were not 
included within the definition of prescribing errors, as it was not possible to reliably 
identify these retrospectively, and were not recorded. Errors of omission were 
subsequently classified as red (significant or catastrophic, long term patient 
impact), amber (significant, short term patient impact) or green (negligible patient 
impact) in accordance with the United Kingdom Medicines Information (UKMI) tool 
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for assessing harm from omitted or delayed medicines.176 This tool has clearly 
defined categories, requiring minimal interpretation, hence coding was carried out 
by only one researcher. The remaining errors were classified using an adapted 
version of the NPSA risk assessment tool121 as used in a Welsh study in 200748 
which has been simplified to include only the number of patients affected, the 
consequences to the patient in terms of injury or death, the potential impact on the 
organisation and the potential for litigation. It has also been modified to provide 
timeframes for the resolution of injuries. 
 Data management and analysis 3.14
3.14.1 Data entry 
Two SPSS databases were created, the first for the case note data and the second 
for the observation and interview data, qualitative data including quotes was 
included in the observation/interview database. Data were entered by the 
researcher and once it was complete all columns were checked for both 
unexpected and missing values.  
3.14.2  Statistical methods 
Descriptive analysis was carried out using SPSS version 17. Statistical tests were 
carried out using SPSS and Minitab V.16, a p value of <0.05 was used to define a 
significant difference. A Student t-test was used to detect differences estimates of 
the proportion of prescribing errors between junior and senior doctors. Chi-square 
tests were used to detect differences in dependent variables such as proportion of 
VTE risk assessments or medicines reconciliations carried out between study 
periods. Mann-Whitney tests were used to identify any differences in actual VTE 
knowledge between staff with below average or average perceived knowledge and 
those with good perceived knowledge and also to highlight any differences in the 
number of questions about medicines asked by junior and senior doctors. Where 
case notes and/or prescription charts were missing these cases were excluded from 
the relevant analyses.  
3.14.3 Data categorisation 
Some data were categorised to enable quantitative analysis. Doctors were split into 
two groups “junior” which included foundation years 1 and 2 and “senior” which 
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included all other grades in order to generate two groups of a similar size. The 
reasons for patient admission were initially categorised according to the principal 
signs and /or symptoms where possible e.g. seizure, where there were several signs 
and /or symptoms they were categorised according to medical specialty e.g. cardiac 
see Table 3-1. 
Table 3-1:  Reason for admission - categories 
Signs / Symptoms Medical specialties 
Infection Gastroenterology 
Pain Neurology 
Vomiting / diarrhoea Social 
Possible VTE Rheumatology 
Alcohol related Endocrine 
Falls Mental health 
Abnormal biochemistry Renal 
Cancer Cardiac 
Overdose   
Stroke / Transient Ischaemic Attack  
Falls  
Adverse drug reaction  
Respiratory disease exacerbation  
GI Bleed  
Collapse  
Seizure  
Confusion  
 
For the VTE analysis patients categorised as follows in order to ascertain whether 
patients were treated appropriately or inappropriately: 
 VTE risk factors only 
 Bleeding risk factors only 
 Both VTE risks and bleeding risks 
 Neither VTE risks nor bleeding risks 
 
Prescribing errors were categorised according to the type of error: 
 Medication unintentionally omitted 
 Medication unintentionally restarted 
 Incorrect medication prescribed 
 Incorrect medicine device prescribed (for inhalers, insulin etc.) 
 Incorrect dose prescribed 
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3.14.4 Data analysis 
The data from the observations were transcribed as case studies using a series of 
standard headings in a template to facilitate analysis (Appendix 10), where there 
had been a significant number of interruptions a timeline detailing the progress of 
the clerking was included. Outcome data relating to both VTE and medicines 
reconciliation from the case note review were added where this information was 
available (Appendix 10). Key words or phrases were identified both from the case 
study transcripts and from the observation/interview SPSS database. Some 
observation data were analysed quantitatively including duration of clerking, 
number of questions asked regarding VTE and medication and proportion of 
medication charts written. Activities which were observed during the clerking 
process but which were unrelated to VTE or medicines reconciliation were reported 
as background information. 
The data from the interviews were analysed mainly quantitatively (using SPSS and 
Minitab V 16) but responses to open questions such as reasons for poor compliance 
with guidance and suggestions for improvement were analysed qualitatively. The 
data was read to identify key words and/or phrases from the SPSS database; these 
were then sorted into themes. 
The case note data were analysed quantitatively using the SPSS database and 
Minitab V 16. 
All data were considered to be of equal importance. The VTE datasets were 
analysed first as due to the rapidly changing national situation any conference 
presentations or publications needed to be timely. Observation and interview VTE 
data were analysed separately and then combined in order to compare observed 
practices with staff views about those practices, case note data which provided 
evidence of outcomes were analysed last. The process was repeated for the 
medicines reconciliation data, observation and interview data were analysed 
separately first, then combined during and case note data were analysed last. 
Finally the VTE data and medicines reconciliation datasets were compared to 
identify any common themes or differences. This has been described as a 
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convergent parallel type of mixed methods research in which the research 
components remain independent during data collection and analysis and are 
combined during interpretation.145, 177 
 Summary 3.15
This chapter has detailed and justified the methodology used in the study, the 
results are presented in the following three chapters, chapter 4 details those for the 
AMU admission process, chapter 5 those for VTE risk assessment and chapter 6 
those for medicines reconciliation. 
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Chapter 4 Results and Discussion AMU Admission Process 
 Introduction and overall sample characteristics 4.1
During the four study periods a total of 71 patient admissions involving 36 staff 
were observed and 930 sets of case notes were reviewed. Although the study 
focused on VTE and medicines reconciliation some interesting additional 
observations relating to the admissions process itself were made which are 
reported in this chapter. The demographic details of the patients included in the 
study are shown in Table 4-1. 
Table 4-1:  Demographic details of patients included in case note reviews and 
observations   
Characteristic Case note review Observations 
Number of case 
notes retrieved 
930 71 
Relevant admission 
notes available 
876 67 
Sex - male (% ) 381 / 876 (43.5%) 28 / 67 (39%) 
Age range (mean) 
 
16 -98 (64) years 16 – 98 (68) years 
Average length of 
stay (median) 
1 – 182 (5.5) days 1 – 47 (5.0) days 
Most frequent 
presenting 
complaint 
(descending order 
of occurrence) 
 
 
Infection (285; 32.5%) 
Pain (72; 8.2%) 
Cardiac cause (60; 6.8%) 
Shortness of breath (54; 6.2% 
Abnormal biochemistry* (51; 
5.5%) 
Possible VTE‡ (46; 5.3%) 
Infection (15; 22%) 
Pain (8; 12%) 
Abnormal biochemistry* (8; 
12%) 
Possible VTE‡ (7; 10%) 
Shortness of breath (5; 7%) 
Vomiting or diarrhoea (5; 7%) 
 
*Results outside of the normal range for haemoglobin, glucose, thyroid hormones, sodium, 
potassium, magnesium, or calcium 
‡
Venous thromboembolism 
4.1.1 Details of staff observed included in the study 
A total of 44 staff were included in the study, 36 were both observed and 
interviewed, eight participated in a single interview relating to either VTE or 
medicines reconciliation. Eighteen were based on AMU at the time of the study, 23 
were part of the ‘hot block’ team and three were on call. The level of practice for all 
staff is shown in Figure 4-1, numbers of staff and patient admissions observed in 
each study period are shown in Table 4-2, page 49. 
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Figure 4-1: Level of practice of study participants (healthcare staff) 
 
* Venous thromboembolism ‡ Medicines reconciliation 
 Observations 4.2
4.2.1 Admission time for observed patients 
Observations took place on weekdays only, the majority of patients observed were 
admitted between 10am and 6pm (Figure 4-2) which is to be expected as most 
(66/71; 93%) were referred by their GP and therefore arrived during the late 
morning and afternoon following a GP consultation during normal surgery hours. Of 
the remaining patients two were referred by their Community Matron, one by a 
Walk in Centre, one by the Emergency Department (ED) and one by another 
hospital. 
 
 
 
 
 
0 2 4 6 8 10 12
Nurse clinician
Foundation Year 1
Foundation Year 2
Specialist Trainee  Year 1
Specialist Trainee  Year 2
Specialist Trainee Year 3
Specialist Trainee Year 4
Specialist Trainee Year 5
Specialist Trainee Yesr 6
Specialist Registrar
Consultant
Number of Staff 
VTE* interview only (1)
Med Rec‡ interview only (7) 
Observed & Interview -VTE
(24) or Med Rec (12)
48 
 
Figure 4-2:  Time of day of admission for observed patients 
 
4.2.2 Waiting time and duration of clerking 
The waiting time to be first seen by a doctor or nurse clinician (from time of 
booking in by reception staff), duration of clerking and the total time taken for 
documentation of the initial management plan for each study period are shown in 
Table 4-2. Eighteen (18/71; 25%) patients were clerked by the most junior doctors, 
grade Foundation year 1 (F1), who have less than 12 months post qualification 
experience. For seven patients (7/71; 10%) the time from arrival at hospital to 
documentation of a clinical management plan took longer than the Society for 
Acute Medicine (SAM) four hour target, an F1 doctor was responsible for clerking 
two of these seven patients. All seven of these patients arrived on a weekday 
between 12.30 and 16:00. In total 48 (48/71; 68%) patients were clerked by an 
experienced nurse clinician or a doctor grade foundation year 2 (F2) or above 
within four hours of arrival at AMU. The overall median duration of clerking was 75 
minutes (Interquartile range; IQR 40 minutes), there was no significant difference in 
duration between the four study periods (Kruskal-Wallis test P=0.202). The overall 
median waiting time was 67 minutes (IQR 67) and increased significantly in periods 
3 and 4 (Kruskal-Wallis test P=0.011). Figure 4-3 shows the median duration of 
clerking by staff grade, when senior doctors (grade Specialist Trainee year 1; ST1 
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and above) were compared with junior doctors (grade F1/2) senior doctors were 
significantly quicker at clerking patients (Mann-Whitney U test P<0.001). 
Table 4-2: Waiting time, duration of clerking and time to documentation of 
management plan for newly admitted patients 
 Period 1 
(Nov 
2009) 
Period 2 
(Jan 
2010) 
Period 3 
(Apr 
2010) 
Period 4 
(Apr 
2011) 
Total 
Total number of staff observed 8 7 9 12 36 
Number of senior doctors 
observed (grade ST1‡ and above) 
3 5 3 6 17 
Number of patient admissions 
observed 
16 21 14 20 71 
Number of patients clerked by 
senior doctor (grade ST1 and 
above) 
7 14 8 9 38 
Median waiting time to be seen by 
doctor/nurse clinician minutes 
(IQR*) 
44 (40) 67 (63) 101(89) 79 (50) 67(67) 
Median duration of clerking –
minutes (IQR*) 
62 (55) 70 (38) 80 (29) 82 (51) 75 (40) 
Median time to documentation of 
management plan -clerking + 
waiting time – minutes (IQR*) 
124 (62) 136 (86) 183 (96) 160 (93) 141 (88) 
*interquartile range  
‡
Specialist trainee doctor – 2 years post qualification 
 
Figure 4-3:   Median time taken to complete the medical clerking process 
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Of the 71 patients admitted; 27 (38%) had a VTE risk assessment completed and 
documented as part of the admission process. However, there was no significant 
difference in the duration of clerking between those patients who did (27 patients, 
mean duration 81 minutes) and those who did not (44 patients, mean duration 71 
minutes) have a VTE risk assessment completed (Mann-Whitney U test P=0.143). 
4.2.3 Interruptions 
During the four study periods a total of 66 interruptions were observed during 36 of 
the 71 admissions (51%), of these 19 (53%) were interrupted more than once. 
Eighteen (18/35; 51%) doctors were interrupted during at least one patient clerking, 
however the nurse was not interrupted at all whilst clerking any of the three 
patient admissions observed. There was no difference in the number of junior 
doctors interrupted (17/30; 57%) when compared with senior doctors (19/38; 50%), 
chi-square test P=0.584. Interruptions generally occurred when the doctor was 
based in the office either reviewing or writing medical notes, the patients’ privacy 
was respected when they were being examined or interviewed at the bedside. The 
number of interruptions per patient admission observed is shown in Figure 4-4, the 
most common types of interruption are shown in Table 4-3.   
Figure 4-4: Number of interruptions per patient admission observed 
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Table 4-3: Types of interruption observed during the medical clerking process 
Type of 
interruption 
Junior doctor 
interrupted – 
number of instances 
Senior doctor 
interrupted – 
number of instances 
Total number 
of instances 
observed 
General advice 
and assistance 
6 18 24 
Input to another 
patient 
17 4 21 
Input to patient 
clerked by this 
doctor 
8 5 13 
Other 4 4 8 
Total 35 31 66 
 
Interruptions from nursing staff included a request to review an inflamed venflon 
site, to speak to a patient’s family regarding a ‘Do not attempt resuscitation’ order, 
to write a medication chart for a patient clerked earlier, to insert a cannula for a 
patient prescribed intravenous (IV) antibiotics and to write a letter needed by a 
patient who was going home. Nine doctors were paged during the clerking process 
however it proved impossible to ascertain the reason for paging in most cases as 
only the observed doctor’s conversation could be heard so analysis of these calls 
was not possible. One F1 doctor was interrupted seven times whilst clerking a 
patient, the duration of this clerking was 120 minutes; details of the interruptions 
are shown in Figure 4-5. Senior doctors were more often interrupted for general 
advice and assistance whereas junior doctors were more often asked to input to 
another patient. During the interviews one ST1 doctor commented that “nurses 
often ask the wrong doctor” which leads to unnecessary interruptions. In nine of 
the 25 clerkings which were interrupted, patients (9/25; 36%) experienced a 
prescribing error on admission compared with eight (8/21; 38%) for patients whose 
clerking was not interrupted. It was not possible to assess the impact of the 
interruptions in detail due to the complexity of the environment, however there 
was no impact on prescribing error rates (chi –square test P=0.883). 
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Figure 4-5: Case study illustrating interruptions during the medical clerking 
process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.4 Delays 
Thirty one of the 71 admissions (44%) were subject to a delay, 14 (45%) of these 
delays involved either an X-ray or an ECG; Figure 4-6. In five cases the patient was in 
radiology when the doctor needed to speak to them, on nine occasions the arrival 
of an ECG technician requiring immediate access to the patient interrupted the 
admission process. Problems with medical equipment / Trust documentation 
availability or operation resulted in a delay in six cases:   
 Blood gas analyser out of order   
 No ‘pods’ (plastic canisters) to send samples to laboratory via air tube system  
  Ophthalmoscope could not be located when it was needed 
  Hospital trolley could not be lowered sufficiently to examine a patient 
 Tourniquet was not available so doctor improvised with a disposable glove 
 No blank medication charts available for admission prescription to be written 
Patient clerked by F1* doctor 
Admitted at 14.12 on a Friday 
18.29: Clerking commenced 
18.29: Asked for incontinence pad by relative of another patient – provided 
from ward store 
19.45: Asked by nurse to prescribe co-codamol for another patient who is in 
pain – prescribed 
19.48: Asked by nurse to review ECG for another patient – asked F2 doctor to 
do this as in the process of writing medication chart 
20.00: Asked by nurse to take this patient’s blood samples so they can move 
this patient back to the foyer as there are no free cubicles to clerk 
patients 
20.18:  Bleeped by Heart Emergency Centre (HEC) 
20.25:  Nurse came from HEC with query about IV fluid (Digami) regimen 
20.30:  Asked to prescribe PRN nebuliser for a different patient who is short of 
breath 
20.30: Clerking complete 
*Foundation year doctor – first year post qualification 
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On four occasions the ward / office space or computer availability were insufficient 
to enable efficient working: 
 Doctor unable to find anywhere suitable to review a patient’s case notes 
 No bed or trolley available to examine a patient 
 No computer terminal  available to review blood test results or X-Rays  
 Only available computer had been locked by the previous user 
 
A system problem, in which a difficulty was encountered as a result of a failure in 
the usual process, accounted for a further five delays:  
 No referral letter provided by one GP  
 Clerking doctor did not have a password for the electronic X-Ray system 
  Two telephone calls required to the radiology department to order urgent scan 
 Consultant responsible for leading post take ward round could not be located 
 Delay in contacting the medical microbiology department regarding appropriate 
antibiotics 
 
Other delays were noted in three cases, a Healthcare assistant (HCA) was 
attempting to take a blood sample from a patient when the doctor went to clerk, 
clarification of the sequence of events was needed from a relative who could not be 
located, and the doctor had to go to the radiology department to discuss another 
patient.  
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Figure 4-6:  Factors contributing to delays in the hospital admission processes 
 
4.2.4.1 Taking blood samples 
Routine blood samples on admission to AMU are usually taken by a suitably trained 
HCA or a nurse prior to the patient being clerked so that the results are available to 
inform the patient management plan once clerking is complete. However if these 
staff are unavailable or are unsuccessful in obtaining a sample then this task falls to 
the doctor clerking the patient. In 22/71 (31%) of the admissions observed the 
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The pharmacist researcher was asked for advice by the clerking doctor on thirteen 
occasions; these requests included the appropriate medicine, the appropriate dose 
and identification of medication. Details of these requests are shown in Figure 6-6, 
page 123. Use of the pharmacist researcher in this way may have slightly reduced 
the overall clerking time for these patients.  
4.2.6 General observations derived from field notes   
4.2.6.1 Operational issues 
There appeared to be no formal induction to AMU working practices for new 
doctors, it was unclear who was in charge of the ‘hot block’ clerking team and there 
was little evidence of teamwork, principally because the four medical staff on the 
rota often did not know each other. Doctors appeared unsure which patient to see 
next and were often unable to interpret the various indicators used by nursing staff 
on the whiteboard to chart the patient’s progress through the unit. Frequently the 
doctors themselves were unclear who was more senior in the ‘hot block’ clerking 
team and who to ask for advice, this wasn’t always grade dependent as the F1 who 
had just completed a cardiology rotation may know more about dosing warfarin 
than the F2 who although qualified for longer hasn’t yet worked in cardiology. 
Where the doctors had worked together before there was much more of a team 
spirit, they were aware of each other’s previous experience and the workload was 
handled more efficiently. 
Nursing staff frequently complained that there were ‘no doctors’ available as there 
were regular problems with all the doctors going for lunch / break at the same time. 
It seemed to depend on the personal skills of the most senior doctor available as to 
whether or not breaks were organised, the role did not appear to be explicit. The 
3pm post take ward round created problems, sometimes the consultant was late; 
on one occasion the ST1 doctor spent considerable time trying to find the 
appropriate consultant to review the patients. All three AMU based ‘hot block’ 
doctors (the fourth doctor is usually busy in ED) generally went on the post take 
round which could take two hours and often resulted in no patients being clerked 
from 3pm to 5pm thus generating a backlog. Once again the nursing staff were 
aware of the problem but seemed powerless to change the situation. 
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Junior doctors often lacked the relevant background knowledge of the Trust 
relating to specialties. They did not know the ward or consultant specialties and so 
were unable to access relevant advice efficiently; this information did not appear to 
be readily available either in AMU or on the Trust intranet. 
4.2.6.2 Medical hierarchy 
The continuing existence of the medical hierarchy resulted in delays and difficulties 
in junior doctors seeking senior advice. The most junior doctors were clearly in awe 
of the seniors especially consultants and were reluctant to admit their ignorance. 
One junior doctor who had to clerk a very complex patient was clearly out of her 
depth but unwilling to seek help from the consultant on duty for fear of reprisal. To 
ensure appropriate management of this patient the pharmacist researcher sought 
assistance from the consultant. 
 Case note review 4.3
4.3.1 Presenting complaint 
Patients presented with a wide range of medical complaints (Table 4-1, page 46), 
however, the proportion of patients with cardiac symptoms is relatively low as in 
the study hospital these patients are usually admitted directly to the Heart 
Emergency Centre (HEC). When the HEC is full then cardiac patients are admitted 
via AMU following discussion with, and acceptance by, either an AMU consultant or 
the medical registrar. 
4.3.2 Admission route, time and day of the week 
The majority of patients were admitted via the ED (56.0%) or directly from their GP 
(38.6%), the remaining patients were referred by out-patient clinics (1.9%), other 
hospitals (1.5%) walk in centres (1.4%), or specialist community nurses (0.6%).  
Similar numbers of patients were admitted to AMU on weekdays, Monday to Friday 
and fewer on Saturdays and Sundays as GP surgeries are closed at weekends and 
patients then have to access a primary care on call service or attend the ED prior to 
hospital admission, Figure 4-7 and Figure 4-8. Overall 81.6% of patients were 
admitted on a weekday and 18.4% at a weekend. 
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The daily admission patterns seen in the study generally matched those for all 
patients admitted to the Trust between 2009 and 2011, Figure 4-9. 
Figure 4-7:  Number of study patients admitted to hospital by day of the week 
 
 
Figure 4-8:  Route of admission by day of the week – study data 
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Figure 4-9:  Route of admission by day of the week – Trust data 2009 – 2011 
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Figure 4-10:  Admission time and route of admission– study data 
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Figure 4-11:  Admission time and route of admission– Trust data 2009 - 2011 
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4.3.3 Length of stay 
The median length of stay was 5.5 days (mean 9.9 days; interquartile range 10 days), 
a quarter of patients (235/930; 25.3%) were discharged within 48 hours and a 
further quarter (220/930; 23.7%) within 5 days. However a significant minority 
(154/930; 16.6%) stayed in hospital for longer than 15 days, the reasons for these 
prolonged admissions were outside of the scope of the study and were not 
investigated (Figure 4-12).  
Figure 4-12:  Length of stay of study patients 
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from a surgical ward (25/930; 2.7%) and six patients (6/930; 0.6%) were discharged 
from a high dependency unit (HDU), Figure 4-13. 
Figure 4-13:  Discharge ward for study patients 
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The results show that a greater number of female patients (56.5%) were admitted 
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4.4.2 Admission route and time of day 
Just over half (56%) of patients were admitted via the ED and 38.6% were referred 
by their GP. These proportions match the 2013 audit data from 38 AMUs which 
reported 56% and 38% respectively.23 Admissions from GP surgeries tended to 
follow the usual opening hours of GP surgeries with admissions starting to arrive 
from 10am, remaining steady throughout the day until 6pm and then declining 
overnight. Few patients were admitted from GPs between 10pm and 10am which 
would require a referral from a GP urgent care service rather than the patients 
usual GP. 
Overall admissions to AMU rose rapidly throughout the morning from 8am until 
lunchtime, remained at a high level throughout the afternoon and then declined 
after 6pm, this pattern mirrors the admission pattern recently reported in an AMU 
in Nottingham180 and also the Trust data for all patients admitted between 2009 
and 2011. A smaller study from Plymouth reported a similar pattern with a slight 
shift to later in the day the busy period being from 9am to 8pm,181 this  shift may be 
due to either differences in local working patterns such as GP opening hours or the 
smaller numbers involved. 
Maximum numbers of medical admissions were seen on Mondays and Fridays with 
slightly lower numbers on other week days, smaller numbers of patients were 
admitted on Saturdays and Sundays. This is in line with data published by the 
National Audit Office in 20135 which shows the same trend for emergency 
admissions for the past five years. 
4.4.3 Waiting time and duration of clerking 
The waiting time for patients to be first seen increased significantly in periods 3 and 
4, April 2010 and April 2011. However no particular reason could be reliably 
identified for this finding, the total number of admissions was similar for each 
period, the number of staff available to clerk was the same and there was no 
significant difference in the duration of clerking. During the course of the study the 
number of beds in the study hospital was reduced in preparation for the building of 
a new hospital due to open in 2017. This has resulted in an increased pressure on 
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beds and in the later study periods there may have been a delay in clerking as there 
were sometimes no beds free in AMU for patients to be examined. 
The SAM quality standards for acute medical units state that a full clinical 
assessment should be undertaken and a clinical management plan initiated and 
documented by a competent decision maker (grade F2, ST1-3 or nurse practitioner) 
within four hours of the patients arrival on AMU.182 The four hour targets were 
originally introduced in the NHS Plan in 2000 and stated that by 2004 no patient 
should wait more than four hours in an ED.36 They have proved successful in 
ensuring that patients are assessed more rapidly183 hence a similar target has been 
adopted for AMUs.182 The results show that 10% of patients whose admissions 
were observed had not been clerked by a doctor or nurse within four hours of 
arrival and that all of these patients arrived between 12.30pm and 4pm on a 
weekday. The delay was therefore most likely to result from fewer staff being 
available to clerk over lunchtime, as mandatory education sessions are usually held 
between 12.30pm and 2pm, and the reduced number of doctors available between 
3pm and 5pm due to attendance on the post take ward round. A recent study from 
Nottingham180 showed the impact of breaks and ward rounds on the number of 
doctors available to clerk in AMU and used analysis of patient arrival time to 
redesign rotas to reduce patient waiting times. Further analysis showed that 68% of 
patients in the present study were seen by a competent decision maker within this 
four hour timeframe which exceeds the proportion of 48% reported in recent 
survey of 30 UK AMUs184 however improvement is desirable as all patients should 
be seen within four hours. 
Delays in the present study were also prolonged by equipment failure in four cases 
and lack of availability of the necessary facilities in an additional four cases. 
However it is not possible to assess the overall impact of these factors on the 
service due to the small numbers involved. Provision of hand held computers for all 
clinical staff may be an option in the future but currently it is not possible to run 
hospital systems such as those used for reporting blood tests results and X-Rays on 
devices such as iPads due to differences in the software. 
64 
 
The mean time spent waiting to be seen was 76 minutes which is less than the 112 
minutes reported by researchers from an AMU in Plymouth who carried out a 
similar study in 2010.181 However it is not possible to comment on the reasons for 
this difference as the Plymouth study gives no details regarding staffing levels. 
The mean time taken for the medical clerking process was 75 minutes, this is very 
similar to the time of 76.7 minutes reported in the Nottingham AMU study,180 no 
further comparative studies were identified in the literature. However the original 
Royal College of Physicians guidance for establishing AMUs9 states that junior 
medical staff should be allowed one hour to clerk each new patient including 
carrying out interventional procedures, gathering results and writing a medication 
chart, and it is known anecdotally that some AMUs have a local target of one hour 
to clerk a patient. The Nottingham researchers180 redesigned their rotas as a result 
of their findings and now allow 80 minutes to clerk a patient.  
Senior doctors were found to be significantly quicker at clerking patients than junior 
doctors. It was thought that this may have been partly due to the ‘see and treat’ 
system which operates when the AMU is busy when patients identified by nursing 
staff as those unlikely to require admission are seen by  a consultant with the aim of 
making a rapid diagnosis, providing treatment if necessary and discharging the 
patient within a few hours. However in the study observations only one patient was 
‘see and treat’ and so this is unlikely to account for the difference in clerking times. 
4.4.4 Length of stay 
It proved impossible to compare the average length of stay to national data using 
Hospital Episode Statistics (HES) as HES data include all hospital admissions and the 
present study collected data for emergency medical admissions only. The results of 
the present study show that 49% of patients were discharged within 5 days of 
admission which is fewer than in a study carried out in Ipswich in 2005 which 
reported 57.9% of patients discharged within 5 days when an AMU consultant was 
present.10 However the Ipswich study provides no information regarding the 
patient presenting complaints, in the study hospital patients presenting with 
cardiac complaints are triaged to the HEC rather than AMU which may explain the 
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difference. A 2010 study which was carried out in 91 AMUs in England reported a 
mean length of stay of 8.5 ± 1.3 days185 which is slightly less than the 9.9 days found 
in the present study . However the latter study used hospital episode statistics data 
which records length of stay in minutes whereas in the present study length of stay 
was rounded up to the next whole day as the time of discharge was not readily 
available at the time of data collection.  
National reports in 2010/11 ranked Liverpool, the location of the study hospital, as 
the most socially deprived local authority area in England.186, 187 Majeed et al 
showed that social deprivation is associated with increased hospital admission 
rates188 and other studies have shown that social deprivation is associated with 
increased hospital admissions due to respiratory tract infections,189 increased 
emergency admissions in older people190, 191 and increased length of stay for 
patients with chronic obstructive pulmonary disease (COPD).192 The 2013 health 
profile for Liverpool193 shows not only a higher death rate for Liverpool residents 
but also a greater proportion of emergency hospital admissions when compared to 
the national average. This may indicate that fewer Liverpool patients seek early 
appropriate care in the community resulting in them being more unwell on 
admission to hospital which may explain the longer length of stay. 
4.4.5 Discharge from AMU 
The results show that 27% of patients in the study were discharged directly from 
AMU which is fewer than the 40% reported in the recent national survey of 
AMUs,184 the difference is likely to be due to differing operational policies between 
units. Some Trusts may include ambulatory patients in their admission and 
discharge data, the study hospital includes only those who require hospital 
admission and excludes patients who are reviewed by the medical staff and 
discharged within a few hours without having been allocated a hospital bed. In 
addition the patients seen in the study hospital AMU may have been more unwell 
as discussed above. The duration of the initial care provided to medical patients on 
an AMU in the UK, prior to discharge or transfer to another ward, can vary from 12 
to 72 hours11, 22, 179 as short stay beds may be part of AMU in some hospitals but 
located elsewhere in others. The length of stay in the study hospital AMU has been 
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shown to be 15 to 21 hours4 and varies across 19 Trusts in the North West of 
England from 12 to 72 hours.194  
4.4.6 Interruptions 
The results showed that senior doctors were more often interrupted for advice and 
junior doctors to resolve issues with patients whom they had not clerked, this may 
be indicative of nursing staff having greater respect for senior doctors. 
Interruptions to clinical tasks are of concern as doctors may delay or fail to 
complete the task which may compromise patient safety195 and frequent 
interruptions may be associated with an increase in doctors’ workload.196 In the 
present study an interruption occurred during half of the observed patient 
admissions and therefore presents a considerable risk of error. Although an 
exhaustive literature search did not return any studies which evaluated the impact 
of interruptions during clerking due to the complexity of the healthcare 
environment197 there is evidence that errors occur when nurses are interrupted 
during the medication administration process.198 The types of interruption 
observed in the present study are broadly similar to those reported by Weigl et 
al.196 with the majority of interruptions being made by nursing or medical 
colleagues either in person or via a pager. However it is difficult to compare the 
results of the present study with those in the literature as the definition used for an 
interruption is not always clear. There may be opportunity to schedule 
investigations differently in the study hospital in order to maximise use of staff time 
and minimise delays and risk to patients. Further work to determine practices in 
other Trusts regarding the interruption of clinical staff would be of benefit.  
4.4.7 Recent operational changes 
Since the data collection took place a number of changes have been made in the 
study hospital AMU, partly due to an interim report of the study findings provided 
to the Divisional Medical Director in October 2010. Grade F1 doctors now wear 
purple tunics and trousers making it easier for nursing staff to identify the correct 
grade of staff and minimising unnecessary interruptions. A whiteboard has also 
been introduced to show which consultants are on duty and the junior doctors 
allocated to them together with pager numbers again enabling staff to identify the 
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most appropriate individual to consult. The AMU has employed additional AMU 
consultants so there are no longer ‘post take’ ward rounds with visiting consultants 
from elsewhere in the Trust and junior rotas have been adjusted in order to better 
match the peaks of demand. All morning ward rounds are carried out by dedicated 
AMU consultants to improve continuity and newly admitted patients are reviewed 
throughout the day when the results of their investigations are available rather 
than having to wait for a formal ward round. As there is no afternoon ward round 
junior doctors are now available to clerk patients throughout the afternoon helping 
to minimise waiting times. There is also agreement that at least one doctor does 
not attend the lunchtime education sessions but remains on AMU to clerk new 
patients. 
Two additional consultation rooms have been created, making a total of four; these 
are used for AMU clinic sessions on week day mornings but are free in the 
afternoons as additional areas for clerking patients to help relieve the afternoon 
bottlenecks. 
The medical hierarchy in which doctors are reluctant to challenge the opinions of 
others199 continues to exist, a Scottish study found that senior doctors felt that this 
was now confined to surgical specialties but junior doctors felt that it was a 
problem in all specialties.200 In the present study it was noted that juniors were 
reluctant to speak to seniors on occasion. The presence of regular AMU consultants 
on ‘the shop floor’ should enable staff to interact informally on a day to day basis 
and thus make it easier for juniors to approach seniors when they require 
assistance. 
 Summary 4.5
The results relating to the admission process as a whole have been presented and 
discussed in this chapter, those pertaining to VTE risk assessment are discussed in 
the next chapter and the results for the medicines reconciliation arm are discussed 
in chapter 6. 
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Chapter 5 Results and Discussion: Venous Thromboembolism 
Risk Assessment and Prophylaxis 
This chapter presents the results for the VTE risk assessment arm of the study and 
discusses them in the context of the current published literature. 
 Overview 5.1
During the four data collection periods a total of 71 patient admissions, involving 36 
staff, were observed and 930 sets of case notes were retrieved, the distribution 
over the four periods is shown in Table 5-1. Data from the 71 patient admissions 
were transcribed as case studies to facilitate analysis (Appendix 16). Interviews 
were carried out with a total of 25 staff including all 24 staff observed in periods 1, 
2 and 3 and an additional member of staff who also volunteered to be observed but 
for whom no observations were conducted due to logistics. Staff were purposively 
selected to ensure that participants were representative of the range of grades of 
staff working on AMU during the course of the study. Similar numbers of 
admissions observed and case notes reviewed were included in all four periods. 
Table 5-1:  Subject numbers in each study period - venous thromboembolism data 
 Period 1 
(Nov 
2009) 
Period 2 
(Jan 2010) 
Period 3 
(Apr 
2010) 
Period 4 
(Apr 
2011) 
Total 
Number of patient 
admissions observed 
16 21 14 20 71 
Number of staff 
observed 
8 7 9 12 36 
Number of staff 
interviewed 
9 7 9 0 25 
Number of staff both 
observed and 
interviewed 
8 7 9 0 24 
Number of patients 
admitted during study 
period 
265 255 239 256 1015 
Number of case notes 
retrieved 
243 / 265 
(91.7%) 
232 / 255 
(91.0%) 
221 / 239 
(92.4%) 
234 / 256 
(91.4%) 
930 / 1015 
(91.6%) 
Number of patients with 
documentation 
available* 
207 / 243 
(85.2%) 
202 / 232 
(87.1%) 
190 / 221 
(86.0%) 
211 / 234 
(90.1%) 
810 / 930 
(87.1%) 
*No significant difference between study periods chi-square P=0.391 
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 Context 5.2
During the course of the study the DH continued to issue guidance34, 43, 98, 201-204 to 
ensure that all patients were VTE risk assessed on admission to hospital and were 
prescribed appropriate prophylaxis. As a result there were numerous local and 
national initiatives to try to improve practice in this area. Local initiatives were 
introduced to increase staff awareness and facilitate the implementation of 
national guidance and included both education and provision of risk assessment 
tools. A thrombosis nurse was recruited to provide ward based training for nursing 
staff and education sessions were provided for medical staff at two of the weekly 
Grand rounds. Paper risk assessment forms were initially based on the available 
literature and those used by other local hospitals. These were modified during the 
course of the study in line with comments received from staff and to comply with 
the revised DH risk assessment tool introduced in March 2010.201 They were printed 
on green paper to make them highly visible and easily distinguished from the 
copious number of forms that must also be completed for each patient as part of 
the admission process. An electronic risk assessment tool was introduced in April 
2010 but proved very cumbersome, it was later simplified (new version 10/05/10) 
to electronic confirmation that VTE risk assessment had been completed and 
whether or not the assessment had taken place within 24 hours of admission 
(Figure 5-1). 
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Figure 5-1:  Local and national initiatives relating to venous thromboembolism 
(VTE) prophylaxis 
 
 
 
1. Nov 2009– All Party Parliamentary Thrombosis Group - Audit of acute trusts (National) 
2. 24th Nov 2009 – Trust Risk Assessment (RA) forms placed with medication charts on AMU 
(Local) 
3. 27th Jan 2010 – NICE  guidance – national press & TV coverage (National) 
4. 15th Feb 2010 – Thrombosis nurse employed (Local) 
5. 26th Feb 2010 – VTE Grand round (1) – launch of Trust VTE policy (Local) 
6. March 2010 – DH RA tool (version 2) (National) 
7. 21st March 2010 – DH letter - Collecting of VTE RA data to be mandatory (National) 
8. 1st April 2010 – electronic VTE RA (Local) 
9. 15th April 2010 – VTE reminder posters on AMU (Local) 
10. 27th April 2010 – Trust RA form version 4 (in line with DH / NICE guidance) (Local) 
11. 10th May 2010 – electronic VTE RA – version 2 – simplified (Local) 
12. 21st May 2010 – NICE guidance notes re VTE RA data collection (National) 
13. 1st June 2010 – VTE data collection mandatory (National) 
14. June 2010 NICE VTE quality standard (National) 
15. 6th September 2010 – Trust VTE risk assessor of the week scheme (Local) 
16. 22nd October 2010 – VTE Grand Round (2) (Local) 
17. 26th October 2010 – VTE training – Pharmacists (Local) 
18. 20th December 2010 – VTE RA in NHS outcomes framework 2011/12 (National) 
19. 2nd February 2011 – How to guide for VTE risk assessment (National) 
71 
 
 Observations 5.3
A total of 36 staff were observed during the four study periods 35 doctors (four 
consultant/specialist registrar, four specialist trainee year 4/5, nine specialist 
trainee year 1/2/3 and 18 foundation year1/2) and one advanced nurse practitioner.  
The average age of the patients involved in the observed admissions was 68 years, 
39% were male and the most common reasons for admission were infection, pain, 
abnormal biochemistry, shortness of breath and vomiting or diarrhoea, details are 
shown in Table 5-2. 
Table 5-2:  Demographic details of patients included in case note reviews and 
observations (Reproduced here from Chapter 4, page 46 for ease of reference) 
Characteristic Case note review Observations 
Number of case 
notes retrieved 
930 71 
Relevant admission 
notes available 
876 67 
Sex - male (% ) 381 / 876 (43.5%) 28 / 67 (39%) 
Age range (mean) 
 
16 -98 (64) years 16 – 98 (68) years 
Average length of 
stay (median) 
1 – 182 (5.5) days 1 – 47 (5.0) days 
Most frequent 
presenting 
complaint 
(descending order 
of occurrence) 
 
 
Infection (285; 32.5%) 
Pain (72; 8.2%) 
Cardiac cause (60; 6.8%) 
Shortness of breath (54; 6.2% 
Abnormal biochemistry* (51; 
5.5%) 
Possible VTE‡ (46; 5.3%) 
Infection (15; 22%) 
Pain (8; 12%) 
Abnormal biochemistry* (8; 
12%) 
Possible VTE‡ (7; 10%) 
Shortness of breath (5; 7%) 
Vomiting or diarrhoea (5; 7%) 
 
*Results outside of the normal range for haemoglobin, glucose, thyroid hormones, sodium,    
potassium, magnesium, or calcium 
‡
Venous thromboembolism 
5.3.1 Questions asked about VTE 
Over the first three study periods, only eight of the 51 patients (16%) observed 
were asked questions relating to VTE, three of whom had presented with symptoms 
suggestive of VTE, whereas in period 4, six out of the 20 observed (30%) were asked 
VTE related questions, only one of whom presented with symptoms suggestive of 
VTE. Questions asked are shown in Table 5-3. Of the remaining 57 patients who 
were not asked VTE related questions four (4/57; 7%) presented with symptoms 
suggestive of VTE. 
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Table 5-3:  Questions which patients were asked relating to venous 
thromboembolism (VTE) during observations 
Question Asked Proportion of total number 
of patients 
Proportion of those with 
possible VTE 
Have you ever had a clot? 13/71 (18%) 8/13 
Has anyone in your family 
ever had a clot? 
5/71 (7%) 4/5 
Are you taking warfarin? 2/71 (3%) 2/2 
Have you taken warfarin in 
the past? 
2/71 (3%) 2/2 
Have you had any recent 
surgery? 
1/71 (1%) 0/1 
Do you have varicose veins? 1/71 (1%) 1/1 
 
As the number of patients seen by each of the more senior grades of staff was small 
the doctors were divided into two groups to enable analysis. A total of 14 patients 
were asked VRE related questions, junior doctors comprising grades F1 and F2 (18 
staff) asked 8/30 patients whom they clerked and senior doctors grade ST1 and 
above (17 staff) asked 6/38 patients, the nurse was excluded from this part of the 
analysis. When the two groups were compared there was no significant difference 
between them in terms of the proportion of patients who were asked questions 
relating to VTE, chi-square test P=0.271. The three patients clerked by the nurse 
were not asked any VTE related questions.  
5.3.2 VTE risk assessments 
The numbers of observations, numbers of risk assessments performed and the 
numbers of patients for whom appropriate VTE prophylaxis was prescribed are 
shown in Table 5-4, for each study period. No risk assessment forms were 
completed in period 1, and while this increased in periods 2 and 3, a greater change 
was noted between periods 3 and 4. Placement of risk assessment forms with 
medication charts prior to period 2 resulted in only seven of 21 being completed, 
five being actively removed and nine being ignored. An electronic risk assessment 
form implemented prior to period 3 was not routinely used by staff, with only four 
of the 14 admissions assessed using this process.  
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Table 5-4:  Frequency of venous thromboembolism (VTE) risk assessment and 
appropriate / inappropriate prescribing of low molecular weight heparin (LMWH) 
during observations 
Study period November 2009 
(1) 
January 2010 
(2) 
April 2010 
(3) 
April 2011 
(4) 
Number of admissions 
observed 
16 21 14 20 
VTE risk assessment 
form completed 
Confidence Interval 
0/16 (0%) 
(0%-17%) 
7/21 (33%) 
(15%-60%) 
4/14 (29%) 
(8%-58%) 
15/20 (75%) 
(51%-91%) 
LMWH prescribed 
appropriately 
(including therapeutic  
& prophylactic doses  
initiated anytime 
during stay) 
Confidence Interval 
9/16 (56%) 
 
(30%-80%) 
12/21 (57%) 
 
(34%-78%) 
7/14 (50%) 
 
(23%-77%) 
12/20 (60%) 
 
(36%-81%) 
LMWH prescribed 
inappropriately 
Confidence Interval 
0/16 (0%) 
(0%-17%) 
2/21 (10%) 
(1%-30%) 
0/14 (0%) 
(0%-19%) 
1/20 (5%) 
(0%-25%) 
 
5.3.3 Prescribing of LMWH 
A summary of VTE risks, bleeding risks and treatment with LMWH for the 71 
admissions observed is shown in Figure 5-2, page 75. Only 19 of 32 patients for 
whom VTE prophylaxis with LMWH was indicated were prescribed this treatment 
by the admitting doctor. In addition three patients who had bleeding risks were 
prescribed LMWH potentially putting them at increased risk of haemorrhage. When 
these three cases were formally reviewed by the AMU consultant consensus group 
the decision was that the benefits of VTE prophylaxis did not outweigh the risks for 
any of these three patients (Appendix 17, Appendix 18 and Appendix 19). 
Of the 14 patients with both VTE and bleeding risks for whom LMWH was not 
prescribed six had a completed VTE risk assessment form in the case notes. 
However the rationale for a decision regarding VTE prophylaxis was very rarely 
documented and therefore it is not known whether a clinical decision was made 
not to prescribe LMWH was made for any of these patients.  
5.3.3.1 Dose of LMWH 
The Trust formulary choice of LMWH for VTE prophylaxis in the study hospital is 
dalteparin, the licensed dose for prophylaxis in medical patients is 5,000 units 
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daily.205 Two patients were prescribed a lower dose of 2,500 units daily which is 
recommended in the Trust policy for patients with an estimated glomerular 
filtration rate (eGFR) <30ml/min.206 (A normal eGFR is above 90ml/min; an eGFR of 
<30ml/min indicates severe renal impairment). One patient had been transferred 
from another hospital and was already prescribed this dose so the prescription was 
continued; no rationale for the dose reduction was identified for the other patient. 
Both patients had an eGFR >30ml/min one being 75ml/min and the 
other >90ml/min. 
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Figure 5-2:   Overview of VTE risks and prescription of LMWH on admission for observed patients 
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 Interviews 5.4
All 24 healthcare staff observed during periods 1, 2 and 3 were interviewed, three 
consultant/specialist registrar, two specialist trainee year 4/5, six specialist trainee 
year 1/2, 12 foundation and one advanced nurse practitioner. An additional F1 
doctor who volunteered to participate in the study was also interviewed, it was not 
possible to observe this doctor for logistical reasons (Figure 5-3). 
Figure 5-3:  Demographics of staff participating in venous thromboembolism 
observations and interviews 
 
5.4.1 VTE training 
Of the 25 staff interviewed 14 (56%) reported having undergone VTE training, four 
doctors received undergraduate training and nine as postgraduates, five at the 
study hospital and four at another hospital. In the majority of cases (12/14; 86%) 
the duration was less than one hour, in one case it was one to two hours and in one 
case longer than two hours. Most staff (8/14; 57%) had been trained within the 
preceding 12 months but for six (6/14; 43%) training had been longer ago. Training 
had been received in a variety of formats both formal and informal including: at 
Trust induction, Grand rounds, from a VTE nurse, audit presentation, talk given by a 
medical representative, F1 teaching session, university lecture. Two staff indicated 
that they had “just picked it up on the job”. Only the nurse appeared to have had in 
depth training as she had attended a ‘Hot topic’ session about VTE at a SAM 
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conference. There was no correlation between staff receiving training and whether 
or not VTE risk assessment was completed (chi- square test, P=0·106).  
5.4.2 VTE knowledge 
Self-rated knowledge of VTE risk assessment was ‘good’ in nine cases (9/25; 36%), 
‘average’ in fourteen (14/25; 56%) and ‘below average’ in two (2/25; 8%). The 
number of spontaneously listed VTE risk factors ranged from three to eight out of a 
possible 18, the most commonly cited in descending order were: 
 Immobile for > 3 days (25 staff) 
 Personal or family history of VTE (20 staff) 
 Active cancer (16 staff) 
 Age over 60 years (14 staff) 
 Recent surgery (13 staff) 
 
The number of spontaneously listed bleeding risks ranged from 1 to 3 out of a 
possible 12, the most commonly cited in descending order were: 
 Actively bleeding (20 staff) 
 Taking warfarin or another anticoagulant (10 staff) 
 Haemophilia or other known bleeding disorder (9 staff) 
 Acute stroke - in the last month (8 staff) 
 Platelet count <100 (7 staff) 
 
In order to assess actual knowledge, ability to spontaneously list VTE risk factors 
was graded as shown in Table 5-5. 
Table 5-5:  Grading of actual venous thromboembolism (VTE) knowledge of 
participating staff 
Number of VTE risk factors spontaneously listed Actual knowledge grading 
3 or 4 Poor 
5 or 6 Average 
7 or 8 Good 
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There was no statistically significant evidence of any difference in actual knowledge 
between staff with below average or average perceived knowledge and those with 
good perceived knowledge (Mann-Whitney test, P = 0.2105). The two staff whose 
knowledge was actually poor were aware of this but three staff who graded their 
own knowledge as average and one who graded their knowledge as good also had 
poor actual knowledge, Figure 5-4. 
Figure 5-4:  Actual and perceived venous thromboembolism knowledge of 
participating staff 
 
5.4.2.1 Estimates of proportion of patients at risk of VTE 
Staff estimates of the proportion of medical patients with VTE risk factors ranged 
from 30% to 90%, only 13/25 (52%) believed that over 80% would be at risk, while 
the majority (21 / 25; 84%) estimated that 20% or fewer of patients would have 
both VTE and bleeding risks.  
Staff were shown a flash card which listed a number of common causes of mortality 
in the UK in descending order of prevalence and asked to indicate where in the list 
they would place VTE (Appendix 11; with answers Appendix 12). It was not possible 
to collect this data for one doctor. Fifteen (15/24; 63%) correctly placed the annual 
number of deaths from VTE as being lower than those from myocardial infarction 
but higher than those from breast cancer. Three (3/24; 12%) estimates were too 
high and six (6/24; 25%) too low. 
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5.4.2.2 Awareness of policies 
Only eight staff (8/25; 32%) reported being aware of any national policies or 
guidance on VTE risk assessment, although the DH working group report was 
published in 2007 and the first DH VTE risk assessment tool was published in 
September 2008, data collection for the study commenced in 2009. None of the 
interviewees had actually seen either of these documents. 
When asked about the Trust VTE risk assessment tool, in November 2009 seven out 
of nine staff, and in January 2010 six out of seven staff, were aware of its availability. 
In November 2009 and January 2010 a paper risk assessment tool was available; in 
April 2010 an electronic tool was in use. The views of staff regarding the ease of use 
of these tools are shown in Table 5-6. The electronic risk assessment tool in use in 
April 2010 proved very cumbersome as it simply transposed the RLUBHT paper 
version (Appendix 20) onto the computer and required a yes / no answer to each of 
14 VTE risks and each of eight bleeding risks. Of the nine doctors interviewed in 
April 2010 following the introduction of this tool one thought that it was time 
consuming and one stated that it was complicated.  
Table 5-6:  Ease of use of venous thromboembolism risk assessment tools 
reported by staff during interviews 
Study 
Period 
Type of tool Easy  OK Complicated Time consuming Not used 
Nov 2009 Paper 1/9 3/9 1/9 1/9 3/9 
Jan 2010 Paper 2/7 1/7 2/7 0 2/7 
April 2010 Electronic 3/9 2/9 1/9 1/9 2/9 
 
Reasons for not using the risk assessment tool given by staff who were aware of its 
availability were that they hadn’t seen any suitable patients (2), and that the tool 
wasn’t available at the time of clerking (1), the reason was not recorded in one case. 
5.4.2.3 Awareness of current VTE prophylaxis prescribing practice 
To assess their knowledge of the current situation regarding prescribing of VTE 
prophylaxis, staff were asked to estimate the proportion of patients for whom VTE 
prophylaxis was indicated that were prescribed a LMWH. A Trust audit in January 
2009 had shown that the proportion was 30%. Overall answers varied from 5% to 
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95% with a mean value of 42%, however, although both the mean and median 
values increased with time, (Table 5-7) this difference was not statistically 
significant, Kruskal-Wallis test P=0.281, indicating that there was no statistical 
improvement in the accuracy of estimates over time. 
Table 5-7:  Staff Estimates of proportion of appropriate prescribing of venous 
thromboembolism prophylaxis reported during interviews 
Study 
Period 
Number of 
responses 
Minimum 
value 
Maximum 
value 
Mean 
value 
Median 
value 
Nov 2009 9 5% 95% 35% 30% 
Jan 2010 7 15% 80% 44% 40% 
Apr 2010 9 20% 80% 49% 60% 
 
5.4.3 Responsibility for VTE risk assessment 
The majority of staff (22/25; 88%) felt that responsibility for VTE risk assessment 
should fall to the clerking doctor or nurse, but 16/25 (64%) felt the actual 
responsibility was unclear.  
5.4.4 Prescribing of pharmacological VTE prophylaxis 
When asked who should prescribe VTE prophylaxis for patients clerked on AMU 
most (22/25; 88%) said that this should be the responsibility of the clerking doctor 
or nurse. The remaining three staff said that the person responsible for writing the 
first prescription chart following admission should prescribe. Regarding timing of 
the prescription the majority (23/25; 92%) spontaneously said that VTE prophylaxis 
should be prescribed when the first prescription chart was written following 
admission, one F2 doctor thought that this should take place on the post take ward 
round and an F1 doctor thought that the medical registrar should prescribe when 
the decision was made to admit the patient. 
When asked which medicine they would prescribe for pharmacological VTE 
prophylaxis all 25 staff stated dalteparin which is the formulary choice in the study 
hospital. When asked the dose which they would prescribe 21/25 staff (84%) said 
5,000 units daily which is the licensed dose for prophylaxis of VTE in medical 
patients205, one F2 doctor said 2,500 units daily and two were unsure and said that 
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they would look the dose up. Surprisingly the two doctors who were unsure were 
more senior an ST1 and an ST5, however this may reflect the fact that they were on 
‘hot block’ on AMU and were not involved in clerking patients on a daily basis. 
Dose reduction of dalteparin for medical prophylaxis is not recommended within 
the product licence in any circumstances, however the Trust Policy for Prevention 
of Thromboembolism206 recommends a reduction to 2,500 units daily in patients 
who have renal impairment with an eGFR <30ml/min. 
When asked about situations in which the dose requires reduction, two (2/25; 8%) 
doctors felt that a dose reduction would be appropriate for elderly patients, 
approximately half (12/25; 48%) said that they would reduce the dose in patients 
known to have severe renal impairment (chronic kidney disease stage 4 or 5, eGFR 
<30ml/min) and 12/25 (48%) also said that they would reduce the dose in patients 
with a low body weight. When asked to specify the weight below which they would 
reduce the dose responses varied from <80kg to <40kg. 
5.4.5 VTE risk assessment process in the Emergency Department 
The ED at RLUH is extremely busy and accepts all major emergencies, to meet 
government targets patients must be seen, assessed and either discharged home or 
admitted to hospital within four hours of arrival. 
As approximately half of medical patients are admitted to AMU following initial 
presentation to the ED, staff were asked whether the VTE risk assessment process 
should be different for these patients and if so in what way. Patients who are seen 
in ED and thought to require hospital admission must be referred to and accepted 
by the medical registrar on call; the initial medication chart is written by the doctor 
who clerks the patient in ED. The additional steps in this admission process 
appeared to make the responsibility for VTE risk assessment less clear than for 
patients admitted directly to AMU, as there was greater variation in views 
expressed by interviewees regarding both who should complete the risk 
assessment and who should prescribe any prophylaxis required (see Table 5-8). 
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Table 5-8: Staff opinions regarding responsibility for venous thromboembolism 
risk assessment and prescribing prophylaxis 
Grade of staff Who should complete VTE 
risk assessment? 
Who should prescribe VTE 
prophylaxis? 
 AMU* 
admission 
ED‡ 
admission 
AMU* 
admission 
ED‡ 
admission 
Clerking doctor /nurse 22 (88%) 17 (68%) 22 (88%) 14 (56%) 
Doctor  who writes 
medication chart 
1 (4%) 3 (12%) 3 (12%) 4 (16%) 
Medical registrar 
accepting patient 
Not applicable 2 (8%) Not applicable 4 (16%) 
Doctor referring 
patient to medical 
registrar 
Not applicable 1 (4%) Not applicable 2 (8%) 
Senior review doctor 0 1 (4%) 0 0 
First doctor to see 
patient in AMU 
Not applicable 1 (4%) Not applicable 1 (4%) 
Triage nurse 1 (4%) 0 0 0 
Anyone suitably 
trained 
1 (4%) 0 0 0 
Total number 
responses 
25 (100%) 25 (100%) 25 (100%) 25 (100%) 
*Acute Medical Unit  
‡
Emergency Department 
Comments of relevance made relating to the ED environment were: 
 “The ED is very busy so the process should be different” (ST2 doctor) 
 “I can’t see how the risk assessment would be done in ED” (F2 doctor) 
 “Patients are sicker so there is more chance of it [VTE risk assessment] getting 
missed” (F1 doctor) 
5.4.6 Role of healthcare staff in VTE prevention 
Staff were asked to identify their own perceived role in preventing medical patients 
developing a VTE, their responses are shown in Table 5-9. In general junior medical 
staff felt that their role was to complete the VTE risk assessment and prescribe 
prophylaxis if appropriate, senior medical staff felt that their role was to check that 
the patient had been risk assessed and that any prophylaxis prescribed was 
appropriate. One consultant commented that his role was also to lead good 
practice. 
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Table 5-9:  Staff views of their personal roles in venous thromboembolism (VTE) 
prevention 
Role Grade of staff 
Both complete the VTE risk assessment 
and prescribe prophylaxis if appropriate 
11 Foundation 1/2 doctors 
6 Specialist trainee 1/ 2 doctors 
 
Complete the VTE risk assessment and 
prescribe prophylaxis if results available 
 
1 Foundation 2 doctor 
Highlight patients at risk and identify the 
need  to consider VTE prophylaxis to senior 
medical staff 
 
1 Nurse clinician (not prescriber) 
1 Foundation 1 doctor 
Check that risk assessment has been 
completed and that any prophylaxis 
prescribed is appropriate 
 
2 Specialist trainee 4 / 5 doctors 
1 Specialist Registrar 
1 Consultant 
Lead good practice 
 
1 Consultant 
F1/2 Foundation year doctor 1 -2 years post qualification 
ST Specialist trainee doctor 3-5 years post qualification 
5.4.7 Reasons for low VTE risk assessment rates 
The most frequent reasons given as explaining the low VTE risk assessment rates 
were lack of training (11/25) and lack of clarity regarding the individual(s) 
responsible for completing the assessment (10): 
“This is a senior doctor’s decision but F1s are expected to do it. Juniors are 
wary of prescribing medicines not requested by a consultant “(F1 Doctor) 
Three staff felt the tool was complicated and four said that the process was time 
consuming: 
“[The clerking process is] rushed - anything that isn't active treatment gets 
missed, regular medication gets missed too" (F2 Doctor) 
Five doctors alluded to the complexity of patient care contributing to the failure: 
“Complex patients, [there is] lots to think about, lack of awareness [of VTE], 
[you] focus on [the] history, [and] investigations” (F1 Doctor) 
“Importance [of VTE risk assessment and prophylaxis is] underestimated in 
AMU – [the] patient comes in with several problems and you concentrate on 
[the] reason for admission” (F1 Doctor) 
Senior doctors also felt that the initial clerking of patients was complicated and risk 
assessment forms were a useful prompt: 
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“Green sheets [VTE risk assessment forms are] very helpful… Too much to 
remember, patients are very complex - thinking about diagnosis, treatment, 
investigations, results” (ST2 Doctor) 
However two comments from senior doctors demonstrated that personal beliefs 
and values may also have an impact: 
“[VTE risk assessment] doesn't save lives, prophylaxis isn't treatment, [there 
has been] no litigation” (Consultant) 
“[I] can’t be bothered, [it’s] yet another form [to fill in], I didn't realise the 
risk” (ST1 Doctor) 
5.4.8 Suggestions for improving VTE risk assessment rates 
Recommendations for improving VTE risk assessment rates related mainly to 
increasing training and raising awareness of the risks (8/25). However the need to 
clarify roles (1/25) and for strong leadership (1/25) were also identified. One F1 
Doctor said that VTE risk assessment should be mandatory and nurses should be 
empowered to refer the patient back to the doctor if it has not been completed. 
Examples of interview responses are shown in Table 5-10. 
Table 5-10:  Extracts from interviews – suggestions for improving venous 
thromboembolism (VTE) risk assessment rates 
Key themes Extracts from VTE interviews 
Training / raising 
awareness 
“Add to [Trust] induction – lecture style teaching is OK – but 
[it] must be short” – ST1 doctor 
“All doctors should do [the] e-learning module” – ST5 doctor 
“More publicity needed – education campaign”- Consultant 
“Put large posters in the doctors’ office”-F2 doctor 
Clarify roles “Clarify about whose job it is” – F2 doctor 
Leadership “you need strong leadership to re-enforce” – Nurse  
F1/2 Foundation year doctor 1 -2 years post qualification 
ST Specialist trainee doctor 3-5 years post qualification 
 Triangulation of observation and interview data 5.5
A total of 51 patients, admitted by 24 staff, were observed. All of these observed 
staff participated in the interview pertaining to VTE risk assessment and prophylaxis. 
Data from the doctor who was interviewed but not observed have been excluded 
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from this part of the analysis. Eleven VTE risk assessments were carried out by 
seven doctors (two F1, one F2, two ST1, one ST2 and one consultant), five of whom 
reported having had VTE training and assessed knowledge of VTE was good for 
three and average for four. Of the 17 staff who did not complete a VTE risk 
assessment eight reported having had training and assessed knowledge of VTE was 
good for six, average for nine and poor for two. There was no statistical difference 
in the number of staff who reported receiving VTE training between those who did, 
and those who did not, complete a VTE risk assessment (chi-square P=0.276). The 
numbers were too small to enable a statistical analysis of assessed knowledge and 
completion of VTE risk assessment.  
Prophylactic LMWH was indicated for 20 of the 51 patients for whom both 
observation and staff interview data were available. Prescribing of LMWH by seven 
doctors for nine (9/20; 45%) of these patients was witnessed during observations, 
four of these doctors also completed the risk assessment for five of the nine 
patients. Three of the seven doctors who prescribed LMWH reported having had 
VTE training and actual knowledge of VTE was assessed as good for four and 
average for three. 
 Case Note Review 5.6
A total of 1015 patients were identified during the four study periods of which 930 
(91.6%) were followed up. Case notes were followed up until an attempt had been 
made to review those of at least 90% of the patients admitted in each data 
collection period and the target of 200 available sets of notes for each period was 
exceeded. In 54 cases the relevant admission documentation was not available in 
records, leaving 876 cases suitable for analysis. The prescription chart was missing 
for a further 73 cases resulting in their exclusion from the analysis relating to 
prescription of LMWH prophylaxis.  
5.6.1 VTE and bleeding risk factors 
The numbers of patient notes reviewed in each study period are shown in Table 
5-11, together with details of risk factors present. Of the 876 patients, 719 (82.1%) 
had at least one VTE risk factor and 222 (25.3%) had at least one bleeding risk on 
admission. Almost a fifth of all admissions (171; 19.5%) had risk factors for both VTE 
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and bleeding (Table 5-11), therefore 23.8% (171/719) of the patients admitted with 
a VTE risk factor also had a bleeding risk, requiring additional clinical judgment 
before prescribing prophylaxis. However it was noted that the rationale for the 
decision to prescribe or withhold LMWH was very rarely documented in the case 
notes, although these details were not specifically recorded during the study. 
Table 5-11:  Frequency of venous thromboembolism (VTE) risk factors and 
bleeding risks identified from case notes 
Study period November 
2009 (1) 
January 
2010 (2) 
April 2010 
(3) 
April  
2011 (4) 
Totals 
 
Total admitted 265 255 239 256 1015 
Case notes 
available 
232/265 
(87.5%) 
216/255 
(84.7%) 
204/239 
(85.4%) 
224/256 
(87.5%) 
876/1015 
(86.3%) 
At least 1 VTE risk 
factor* 
 
95% Confidence 
interval  
192/232 
(82.8%) 
 
(77.3%- 
87.4%) 
172/216 
(79.6%) 
 
(73.6% -
84.8%) 
161/204 
(78.9%) 
 
(72.7%-
82.3%) 
195/224 
(87.1%) 
 
(82.9%-
91.1%) 
719/876 
(82.1%) 
 
(79.4-
84.6%) 
At least one 
bleeding risk 
factor* 
 
95% Confidence 
interval  
44/232 
(19.0%) 
 
 
(14.1% -
24.6%) 
62/216 
(28.7%) 
 
 
(22.8%-
35.2%) 
53/204 
(26.0%) 
 
 
(20.1%-
32.6%) 
63/224 
(28.1%) 
 
 
(22.3%-
34.5%) 
222/876 
(25.3%) 
 
 
(22.5%-
28.4%) 
Risk factors for 
both VTE and 
bleeding* 
95% Confidence 
interval 
34/232 
(14.7%) 
 
(10.4%-
19.9%) 
44/216 
(20.4%) 
 
(15.2%-
26.4%) 
43/204 
(21.1%) 
 
(15.7%-
27.3%) 
50/224 
(22.3%) 
 
(17.0%-
28.3%) 
171/876 
(19.5%) 
 
(16.9%-
22.3%) 
VTE risk and no 
bleeding 
risk*(LMWH‡ 
indicated) 
95% Confidence 
Interval 
158/232 
(68.1%) 
 
 
(61.7%-
74.1%) 
128/216 
(59.3%) 
 
 
(52.4%-
65.9%) 
118/204 
(57.8%) 
 
 
(50.7%-
64.7%) 
145/224 
(64.7%) 
 
 
(58.1%-
71.0%) 
549/876 
(62.7 %) 
 
 
(59.4%-
65.9%) 
* No significant difference between study periods  
‡
Low molecular weight heparin 
There appeared to be an increase in the proportion of patients who had both VTE 
and bleeding risk factors during the course of the study however when the study 
periods were compared (all groups in a single analysis) this did not reach statistical 
significance (chi-square P = 0.170). Over the period of the study there was a gradual 
increase in the complexity of patients treated, as bed pressures resulted in more 
patients with minor conditions receiving ambulatory care which may explain this 
trend. 
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5.6.1.1 Prevalence of VTE risk factors 
The prevalence of individual VTE risk factors in the 876 patients for whom case 
notes were available is shown in Table 5-12. The majority of risk factors were 
identified from the case notes as VTE risk assessment forms often could not be 
located or were incomplete, factors which were identified more frequently on risk 
assessment forms than in the case notes were obesity and probability of remaining 
immobile for >3 days. The most common factors in decreasing order of occurrence 
were: age over 60 years (64.2%), acute infection (36.4%), acute or chronic lung 
disease (21.9%) and active cancer (11.2%). It proved difficult to verify the 
immobility and obesity risk factors documented on the VTE risk assessment forms 
with the case notes. 
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Table 5-12: Comparison of prevalence of venous thromboembolism risk factors 
documented on Trust risk assessment forms and those identified from case notes  
Risk Factor Number of 
patients 
affected- 
from case 
notes  
Documented 
on risk 
assessment 
form and 
verified from 
case notes  
Documented 
on risk 
assessment 
form but NOT 
verified from 
case notes 
Total 
number 
of 
patients 
affected 
Age > 60 years 562/876 
(64.2%) 
137/562 
(24.3%) 
1/876 (0.1%) 
563/876 
(64.3%) 
Acute infectious disease 
(e.g. pneumonia) 
319/876 
(36.4%) 
17/319 (5.3%) 0 
319/876 
(36.4%) 
Acute or chronic lung 
disease 
192/876 
(21.9%) 
32/192 
(16.7%) 
0 
192/876 
(21.9%) 
Active cancer or 
myeloproliferative disorder 
97/876 
(11.1%) 
15/97 (15.5%) 1/876 (0.1%) 
98/876 
(11.2%) 
Acute or chronic 
inflammatory disease 
28/876 
(3.2%) 
9/28 (32.41%) 1/876 (0.1%) 
29/876 
(3.3%) 
Personal or family history of 
DVTa or PEb 
23/876 
(2.6%) 
7/23 (30.4%) 0 
23/876 
(2.6%) 
Expected to be immobile 
for 3 days or more 
23/876 
(2.3%) 
10/23 (43.5%) 46/876 (5.3%) 
69/876 
(7.9%) 
Chronic heart failure 
16/876(1.8%) 7/16 (43.8%) 0 
16/876 
(1.8%) 
Obesity: BMI > 30 11/876 
(1.3%) 
2/11 (18.2%) 15/876 (1.7%) 
26/876 
(3.0%) 
Diabetic hyperosmotic 
hyperglycaemic state 
8/876 (0.8%) 1/8 (12.5%) 0 
8/876 
(0.8%) 
Hormone therapy 
containing oestrogen (HRTc 
or OCPd) 
2/876 (0.2%) 0 1/876 (0.1%) 
3/876 
(0.3%) 
Varicose veins with 
phlebitis 
2/876 (0.2%) 0 0 
2/876 
(0.2%) 
Pregnant or ≤ 6 weeks post-
partum 
2/876 (0.2%) 1/2 (50%) 0 
2/876 
(0.2%) 
Known thrombophilia 
1/876 (0.1%) 0 1/876 (0.1%) 
2/876 
(0.2%) 
Nephrotic syndrome 
1/876 (0.1%) 0 0 
1/876 
(0.1%) 
Lower limb paralysis 
(excluding acute stroke) 
0 0 0 0 
a
Deep vein thrombosis, 
b
Pulmonary embolism, 
c
Hormone replacement therapy, 
d
Oral contraceptive 
pill 
Overall 720/876 (82.2%) of patients had at least one VTE risk factor, see Figure 5-5, 
the mean number (± standard deviation) of risk factors per patient was 1.53 ± 1.07. 
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Figure 5-5:  Number of venous thromboembolism risk factors identified per 
patient from case notes 
 
 
5.6.1.2 Prevalence of bleeding risk factors 
As for VTE risk factors, bleeding risk factors were more often identified from the 
case notes than VTE risk assessment forms. However interestingly nine cases of 
active bleeding were documented on risk assessment forms but it proved 
impossible to confirm this with documentation in the case notes. The prevalence of 
individual bleeding risk factors is shown in Table 5-13, the most common factors in 
decreasing order of occurrence were: active bleeding (7.4%), low platelet count 
(6.4%), taking warfarin or other anticoagulant (5.0%) and severe liver disease (4.9%). 
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Table 5-13:  Comparison of prevalence of bleeding risk factors documented on risk 
assessment forms and those identified from case notes 
Risk Factor Number of 
patients 
affected- 
from case 
notes  
Documented 
on risk 
assessment 
form and 
verified from 
case notes  
Documented on 
risk assessment 
form but NOT 
verified from 
case notes 
Total 
number of 
patients 
affected 
Active bleeding 
65/876 (7.4%) 17/65 (26.2%) 9/876 (1.0%) 
74/876 
(8.4%) 
Known platelet 
count < 100 
56/876 (6.4%) 3/56 (5.4%) 1/876 (0.1%) 
57/876 
(6.5%) 
Taking warfarin or 
other anticoagulant 
or antiplatelet 
therapy 
44/876 (5.0%) 5/44 (11.4%) 2/876 (0.2%) 
46/876 
(5.3%) 
Severe liver disease 
(PT* raised above 
normal or known 
varices) 
43/876 (4.9%) 2/43 (4.6%) 0 
43/876 
(4.9%) 
Severe renal 
disease (eGFR  
<30ml/min) 
38/876 (4.3%) 0 0 
38/876 
(4.3%) 
Acute stroke in 
past month 
(haemorrhagic or 
ischaemic) 
8/876 (0.9%) 1/8 (12.5%0 0 
8/876 
(0.9%) 
Lumbar puncture in 
previous 4 hours or 
indicated now 
4/876 (0.5%) 0 0 
4/876 
(0.5%) 
Blood pressure > 
200 systolic or 120 
diastolic 
4/876 (0.5%) 2/4 (50.0%) 0 
4/876 
(0.5%) 
Hypersensitivity to 
heparin 
1/876 (0.1%) 0 0 
1/876 
(0.1%) 
Haemophilia or 
other known 
bleeding disorder 
0 0 0 0 
History of Heparin 
Induced 
Thrombocytopenia 
(HIT) 
0 0 0 0 
Infective 
endocarditis 
0 0 0 0 
*Prothrombin time 
Overall  222/876 (25.3%) patients were at risk of bleeding, 187 had just one 
bleeding risk factor, 29 had two and six had three risk factors.  
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5.6.2 VTE risk assessment 
The proportion of patients with a documented completed VTE risk assessment rose 
from 6.9% in study period 1 to 18.5% and 19.6% in periods 2 and 3 respectively, 
following local initiatives, but to 98.7% in period 4 following the imposition of 
payment-related government targets (Table 5-14). These changes were statistically 
significant (chi-square test P<0.001).  Three sub-analyses showed that comparisons 
of periods 1 to 2 and 3 to 4 both gave P<0.001 and these were therefore statistically 
significant even when the Bonnferroni correction was applied.  The comparison of 
period 2 to 3 was non-significant (P = 0.884). 
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Table 5-14  Frequency of venous thromboembolism (VTE) risk assessment and 
appropriate prescribing of low molecular weight heparin (LMWH) 
Study period 
 
November 
2009 (1) 
January 
2010 (2) 
April 
2010 (3) 
April 2011 
(4) 
Total admitted 
A
ll 
ad
m
is
si
o
n
s 
265 255 239 256 
Case notes available 232/265 
(87.5%) 
216/255 
(84.7%) 
204/239 
(85.4%) 
224/256 
(87.5%) 
VTE risk assessment 
completed* 
16/232  
(6.9%) 
40/216 
(18.5%) 
40/204 
(19.6%) 
221/224 
(98.7%) 
     
Prescription charts and case 
notes available  
205/265 
(77.4%) 
201/255 
(78.8%) 
189/239 
(79.1%) 
209/256 
(81.6%) 
LMWH indicated 
 
Confidence Interval 
147/205 
(71.7%) 
(65.0%-
77.8%) 
115/201 
(57.2%) 
(50.1%-
64.3%) 
115/189 
(60.8%) 
(53.5%-
67.8%) 
135/209 
(64.6%) 
(57.7%-
71.1%) 
LMWH prescribed 
appropriately* (Patient has VTE 
risk factors and no bleeding 
risks)  
Confidence interval 
73/147  
(49.7%) 
 
(41.3%-
58.0%) 
71/115 
(61.7%) 
 
(52.2%-
70.6%) 
78/115 
(67.8%) 
 
(58.5%-
76.2%) 
126/136 
(92.6%) 
 
(86.9%-
96.4%) 
     
LMWH contra indicated 
 
Confidence Interval 
32/205 
(15.6%) 
(10.9%-
21.3%) 
49/201 
(24.4%) 
(18.6-
30.9%) 
39/189 
(20.6%) 
(15.1%-
27.1%) 
43/209 
(20.6%) 
(15.3%-
26.7%) 
LMWH prescribed 
inappropriately** 
Confidence Interval 
1/32 (3%) 
(0%-16%) 
9/49 
(18%) 
(9%-32%) 
3/39 (8%) 
(2%-21%) 
14/43 
(33%) 
(19%-49%) 
      
Number of admissions observed 
O
b
se
rv
at
io
n
s 
16 21 14 20 
VTE risk assessment completed 
Confidence Interval 0/16 (0%) 
(0%-17%) 
7/21 
(33%) 
(15%-
60%) 
4/14 
(29%) 
(8%-58%) 
15/20 
(75%) 
(51%-91%) 
LMWH prescribed appropriately  
Confidence Interval 9/16 (56%) 
(30%-80%) 
12/21 
(57%) 
(34%-
78%) 
7/14 
(50%) 
(23%-
77%) 
12/20 
(60%) 
(36%-81%) 
LMWH prescribed 
inappropriately 
Confidence Interval 
0/16 (0%) 
(0%-17%) 
2/21 
(10%) 
(1%-30%) 
0/14 (0%) 
(0%-19%) 
1/20 (5%) 
(0%-25%) 
Significant differences between study periods * P <0.001; ** P = 0.002 
5.6.3 Prescribing of VTE prophylaxis 
The proportion of patients with VTE risk factors and no bleeding risks that were 
appropriately prescribed LMWH rose from 49.7% in November 2009 to 61.7% and 
67.8% in January and April 2010 respectively and finally to 92.6% in April 2011. This 
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change was statistically significant between periods 3 and 4 (chi-square test, 
P<0.001). However there was also a statistically significant rise in the proportion of 
patients who had bleeding risks and were prescribed LMWH when the data from 
April 2011 were compared with the three earlier study periods, chi-square test 
P=0.002 (Table 5-14). Three sub-analyses of periods 1, 2 and 3 to period 4 were 
carried out with Bonnferroni correction. Comparison of periods 1 to 4 and 3 to 4 
were statistically significant (P=0.002 and P=0.006 respectively). The comparison of 
period 2 to 4 was non-significant (P=0.117).  
Twelve patients for whom VTE prophylaxis did not appear to be indicated on 
admission were prescribed this later in their hospital stay following review of the 
patient and results of their investigations by a senior doctor. None of these patients 
were straightforward as eight had evidence of both VTE risks and bleeding risks 
therefore a clinical decision was required to decide whether the patients individual 
risk of VTE was higher than their risk of bleeding or vice versa. For three patients 
evidence of bleeding risk was found in the case notes but no clear evidence of VTE 
risk and for one patient no evidence of either VTE risk or bleeding risk was 
identified from the case notes (Figure 5-6). 
Thirty-three patients had at least one bleeding risk, but received LMWH. 
Independent review of all 33 case summaries by four AMU consultants achieved 
consensus agreement in 24 cases, with the remaining nine requiring discussion 
before consensus was reached. In six cases it was agreed that LMWH was 
appropriate, but was inappropriately prescribed in the remaining 27, (Appendix 17, 
Appendix 18 and Appendix 19). 
Patients taking oral anticoagulants on admission are included in those for whom 
LMWH was contra-indicated in Table 5-14. Six patients were prescribed TED 
stockings in addition to LMWH, two in period 1, one in period 2 and three in period 
4, no patients used foot pumps during the study.  
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Figure 5-6:  Overview of VTE risks and treatment with LMWH for all study patients 
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5.6.3.1 Effect of number of VTE risk factors per patient on prescribing of 
prophylaxis 
Prescribing of VTE prophylaxis increased as the number of VTE risk factors increased. 
This change was statistically significant as the number of risk factors increased from 
1 to 2 (chi-square P<0.001) and 2 to 3 (chi-square P=0.047) but non-significant 
when patients with three risk factors were compared with those with four risk 
factors (chi square P=0.632), see Figure 5-7.  
Figure 5-7:  Effect of number of venous thromboembolism risk factors per patient 
on prescribing of low molecular weight (LMWH) prophylaxis 
 
5.6.3.2 Dose of LMWH prescribed 
The licensed dose of dalteparin for VTE prophylaxis for medical patients205 is 5,000 
units daily, the manufacturers make no specific recommendations regarding 
reduction of dose in patients with renal impairment but the Trust policy206 
recommends a dose of 2,500 units daily for patients with an eGFR<30ml/min. 
Of the 317 patients prescribed prophylaxis 230 (72.6%) were prescribed dalteparin 
5,000 units daily and 87 (27.4%) 2,500 units daily, 20/87 (23%) of these patients had 
both VTE and bleeding risk factors. Of the patients prescribed a reduced LMWH 
dose six had a low body weight (28-48kg), 20 patients had impaired renal function 
(eGFR<30ml/min) and 22 were elderly, age range 74 -95 years mean age 85 years. 
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No reason for the dose reduction could be identified from the case notes for the 
remaining 39 patients so it is likely that overall 67 patients were undertreated. 
5.6.3.3 Rationale for delay in prescribing LMWH 
For 52 patients LMWH was not prescribed on admission but was prescribed 
sometime later during their hospital stay. Seven patients required a computerised 
tomography (CT) scan of the head, to identify any intracranial haemorrhage which 
may have explained their presenting symptoms, before LMWH could be safely 
prescribed. Other reasons for the delay in prescribing VTE prophylaxis were 
identified for a further ten patients (see Table 5-15) but no justification for the 
delay could be found for the remaining 35 patients.   
Table 5-15:  Reasons for delay in prescribing prophylactic low molecular weight 
heparin 
Reason Number of 
patients 
Invasive investigation required 3 
Abnormal clotting –prolonged Prothrombin time (PT) or raised 
international normalised ratio (INR) 
3 
Investigated for bleeding 3 
Acute kidney injury 1 
 
5.6.4 Monitoring of LMWH 
The use of heparin is associated with a low incidence of heparin induced 
thrombocytopenia (HIT) and therefore current guidance207 states that all patients 
who are to receive heparin should have a baseline platelet count. The first NICE VTE 
risk assessment tool issued in September 200834 indicated that a platelet count of 
<100 x 103 /mm was considered a bleeding risk, however this was subsequently 
reduced to a platelet count of <75 x 103 /mm in the revised version published in 
March 2010.201 Medical patients receiving LMWH do not require routine monitoring 
however if the platelet count falls by more than 30% between days 4 and 14 of 
treatment a diagnosis of HIT should be considered.207  
The results show that 347/359 (96.7%) patients who received LMWH had a baseline 
platelet count, of these 13 were less than 100 x 103 /mm and therefore these 
patients were classified as having a bleeding risk. Of these only four had a platelet 
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count of <75 x 103 /mm on admission and the consultant consensus was that the 
benefits of prophylaxis outweighed the risks in three of these four patients. The 
fourth patient had metastatic breast cancer and had previous pulmonary emboli, 
she was treated with therapeutic LMWH and factor Xa levels were monitored to 
minimise the risk of bleeding. 
Over half of patients stayed in hospital five days or longer (578/930; 57.8%). Repeat 
platelet monitoring was carried out for 90 patients (90/347; 25.9%), there had been 
a fall of more than 30% in eight (8/90; 9%) of these patients. Four had not received 
any heparin as it was not prescribed; two were very unwell and later died one due 
to metastatic lung cancer and the other due to multi-organ failure. One patient had 
a high platelet count on admission and received a single dose of LMWH; the fall to 
the normal range is more likely to be due to the stabilisation of their clinical 
condition than the effect of the LMWH. The final patient was admitted to a 
respiratory ward for 17 days as a result of a viral respiratory infection and received 
prophylactic LMWH throughout, during this time their platelet count dropped from 
285 to 157 (45%) however there was no suggestion that this was due to HIT. 
5.6.5 Adverse outcomes  
Adverse outcomes in terms of VTE, PE or bleeding during admission were recorded 
in order to detect the risks, and or benefits, associated with administration of 
LMWH as DVT prophylaxis. Sixty nine patients of the total of 930 admitted during 
the study died in hospital (7.4%), case notes were retrieved for 60 of these patients 
the remaining nine could not be retrieved. 
5.6.5.1 DVT and PE 
Three patients developed a DVT, three developed a PE, and one developed both a 
DVT and a PE during their admission. This latter patient died two days after 
admission, the primary cause was cardiac arrest but secondary causes were listed 
as DVT and PE. One of the three patients who developed a DVT died a month after 
admission, the primary cause of death was decompensated dilated cardiomyopathy 
but again VTE was cited as a secondary cause. Two of the three patients who 
developed PE died a week after admission, prostate cancer was the primary cause 
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of death in one and multiple organ failure in the other but in both cases PE was 
cited as a contributory factor.  
All seven patients had at least one VTE risk factor; all patients who developed a DVT 
had received prophylactic LMWH. However one patient who subsequently 
developed a PE was not prescribed prophylaxis on admission, he had three VTE risk 
factors (age > 60 years, acute infection, active cancer) but also had a raised 
prothrombin time of 29.1 seconds (normal range 9 – 13 seconds) and was therefore 
at risk of bleeding if given LMWH, TED stockings were not used. 
5.6.5.2 Bleeding 
Three (3/876; 0.3%) patients who were prescribed prophylactic LMWH developed 
bleeding while in hospital, one had a gastrointestinal bleed, one had epistaxis and 
one bleeding from a femoral line.  The patient who developed the gastrointestinal 
bleed was given dalteparin 5,000 units daily for six days; the patient who had 
epistaxis had 2,500 units daily for two days and the patient who had the femoral 
line bleed 2,500 units for nine days. 
 Triangulation of VTE interview and case note data 5.7
5.7.1 Ranking of VTE risk factors  
Staff were asked to rank 16 VTE risk factors in order of importance where a score of 
1 was not very important and a score of 5 was extremely important to ascertain 
whether patients who had risk factors perceived to be more important were more 
likely to be prescribed prophylaxis, (Appendix 13). The results are shown in Table 
5-16 in decreasing order of importance. 
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Table 5-16:  Staff ranking of venous thromboembolism risk factors by importance 
Risk Factor Mean Score 
(max 5) 
Active cancer or myeloproliferative disorder 4.76 
Known thrombophilia 4.76 
Personal or family history of DVTa or PEb 4.56 
Expected to be immobile for 3 days or more 4.52 
Pregnant or ≤ 6 weeks post-partum 4.48 
Lower limb paralysis (excluding acute stroke) 4.44 
Diabetic hyperosmotic hyperglycaemic state 4.24 
Obesity: BMI > 30 3.92 
Hormone therapy containing oestrogen (HRTc or OCPd) 3.92 
Acute or chronic inflammatory disease 3.88 
Nephrotic syndrome 3.88 
Varicose veins with phlebitis 3.80 
Chronic heart failure 3.60 
Acute infectious disease (e.g. pneumonia) 3.48 
Acute or chronic lung disease 3.36 
Age > 60 years 3.32 
a
Deep vein thrombosis, 
b
Pulmonary embolism, 
c
Hormone replacement therapy, 
d
Oral contraceptive 
pill 
There were 110 patients who had at least one of the top five most important risk 
factors identified by staff and required LMWH prophylaxis, active cancer 66, known 
thrombophilia 0, personal or family history of VTE 22, immobility 21, pregnant 1. 
However of these only 82 (75%) actually received it. Of the remaining patients who 
had VTE risk factors but no bleeding risks 266/403 (66.0%) were prescribed LMWH. 
There was no significant difference in the prescribing of LMWH between these two 
patient groups, chi-square test P=0.089. 
5.7.2 Bleeding risks 
Similarly staff were asked to rank 12 bleeding risk factors in order of importance 
where a score 1 was not very important and 5 was extremely important, to 
ascertain whether patients with bleeding risks thought to be more important were 
less likely to be prescribed LMWH prophylaxis, (Appendix 13), the results are shown 
in Table 5-17. The number of patients with bleeding risks who were prescribed 
LMWH was too small to enable further analysis. 
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Table 5-17:  Staff ranking of bleeding risk factors by importance 
Risk Factor Mean Score 
(max 5) 
Active bleeding 4.96 
Taking warfarin or other anticoagulant or antiplatelet therapy 4.56 
Haemophilia or other known bleeding disorder 4.56 
Hypersensitivity to heparin 4.48 
History of Heparin Induced Thrombocytopenia (HIT) 4.36 
Severe liver disease (PT* raised above normal or known varices) 4.28 
Acute stroke in past month (haemorrhagic or ischaemic) 4.00 
Known platelet count < 100 3.68 
Lumbar puncture in previous 4 hours or indicated now 3.60 
Severe renal disease (eGFR  <30ml/min) 3.60 
Blood pressure > 200 systolic or 120 diastolic 3.52 
Infective endocarditis 2.88 
* Prothrombin time 
 Discussion 5.8
This part of the study provides an interesting insight into changing practices with 
regard to VTE risk assessment during a period in which increasing government 
pressure was applied to drive up standards of care. Patient demographics during 
the study periods were very similar to the Trust data208 for the years in which the 
data were collected. The Trust mean length of stay is slightly shorter as in the study 
the length of stay was rounded up, (0 to 24 hours = 1day, >24 hours – 48 hours = 2 
days etc.) whereas length of stay in the Trust is recorded to the nearest minute, 
Table 5-18. 
Table 5-18:  Comparison of Trust and study patient demographics 
Data collection 
period 
Mean 
Age 
Minimum 
Age 
Maximum 
Age 
% 
Male 
Mean Length of 
Stay (days) 
Study periods 2009, 
2010 and 2011 
64 16 98 43.5 9.9 
RLBUHT 2009 62 16 106 44.8 9.0 
RLBUHT 2010 64 16 102 45.6 8.3 
RLBUHT 2011 64 16 106 47.5 7.8 
 
The patient demographics differed from those in a large international VTE study68 in 
that a smaller proportion of patients were male and the average age in the present 
study was slightly lower possibly due to national variations. The most common 
causes for admission also differed; this was most likely due to the local policy of 
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directing patients with acute cardiac conditions to a HEC. They also differed from 
those in a UK VTE study,209 partly as the latter study excluded patients younger than 
40 years of age and also as a result of the local cardiac triage policy; however this 
was unlikely to affect staff behaviour.  
5.8.1 Awareness of VTE risk factors 
In general the VTE risk factors ranked by the staff as being most likely to be 
associated with development of a clot i.e. active cancer, known thrombophilia, 
personal or family history of DVT or PE and pregnancy, matched those which have 
been shown to be associated with a high risk for medical patients in the literature.76, 
210-212 Anticipating that the patient was likely to be immobile for three days or more 
was ranked fourth in order of importance for VTE by staff. However the significance 
of immobility is difficult to assess as many studies do not define immobility and 
differing periods of immobility have been used in published papers.213 In addition it 
has been shown that acute but not chronic immobility is associated with increased 
risk of DVT.211, 214 Therefore staff were generally aware of the major risk factors for 
VTE.  
5.8.2 Knowledge of VTE 
Researchers from Nottingham in 2002 interviewed 21 junior medical staff and 
concluded that their knowledge of VTE was good 65 which contrasts with the results 
of the present study which show that only 9 / 25 (36%) of staff had good knowledge. 
This is likely to be due to the small numbers involved in both studies and the 
differences way in which knowledge was assessed. The Nottingham researchers 
based their conclusions on a very limited number of questions in a questionnaire, in 
the present study staff were asked to spontaneously list risk factors as it was felt 
this would be more representative of their ability to identify patients at risk. Overall 
the present study showed that staff knowledge of VTE was average to good with 
only two staff assessed as having poor knowledge. 
5.8.3 Awareness of VTE policies 
The present study showed that only about one third of staff interviewed were 
aware of any local or national policies in contrast to a study carried out in 
Southampton in 2008215 which showed that 90% of staff were aware of local VTE 
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guidelines. However in Southampton the guidelines had been introduced six 
months prior to the audit and there had been associated Trust wide educational 
VTE sessions, whereas in the study hospital there had been very little local 
education provided and VTE awareness was generally poor during the course of the 
study. 
5.8.4 Proportion of patients with VTE risk factors and bleeding risk 
factors 
Overall 82.2% of patients in the present study had at least one VTE risk factor, a 
finding which is in line with other published studies which have shown that over 80% 
of medical patients admitted to hospital have at least one risk factor.74, 77 A 
significant proportion of patients (25.3%) had at least one bleeding risk factor, 19.5% 
had risk factors for both VTE and bleeding. This finding is in line with the findings of 
researchers from Italy who reported that 25% of patients for whom VTE prophylaxis 
was indicated had a contraindication.86 The UK national guidance43, 202 states that if 
the patient has both VTE and bleeding risk factors then prophylaxis with LMWH 
should not be prescribed unless there is a low risk of major bleeding and the 
benefits outweigh the risks, no further advice is offered about how this judgement 
should be made. As patients are often clerked on admission by the most junior 
doctors who often lack the necessary skills to make this judgement this may explain 
both the low initial LMWH prescribing rates and the inappropriate prescribing of 
LMWH for patients with both VTE and bleeding risks.  
5.8.4.1 Importance / ranking of VTE risk factors 
There is currently no published comprehensive list of the relative risk associated 
with VTE risk factors. However there is general agreement in the literature that the 
risk factors ranked first, second and third in order of importance by the staff 
interviewed (thrombophillic disorders, personal or family history of VTE and active 
cancer) are all associated with high risk for medical patients.70, 76, 210, 216, 217 The staff 
ranked age over 60 years as having the lowest risk of the 18 VTE risk factors listed. 
However, age over 40 years is known to increase VTE risk and it has been reported 
that the risk approximately doubles with each subsequent decade of life,76 those 
aged 85 and older have 15 fold increase in risk of VTE when compared to those 
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aged 45 to 54 years.218 Hence studies which used a lower aged limit of over 4076 
rate the importance of age as a risk factor lower than studies which used age over 
75 years as their criterion.216  
The use of a scoring system for risk factors to identify those patients at greatest risk 
of VTE has been considered 70  however it has been shown that junior staff may not 
be able to use such tools reliably.216 
5.8.5 VTE risk assessment 
5.8.5.1 Improvement in VTE risk assessment 
During the first three observation periods, from November 2009 until April 2010, 
VTE risk assessments were not routinely carried out during the hospital admission 
process and on occasion staff made a deliberate decision not to complete an 
assessment, as shown by forms being discarded. There was no evidence that staff 
who had received VTE training were any more likely to carry out risk assessments. 
Despite this, the majority of the staff interviewed felt that the admitting doctor or 
specialist nurse was the most appropriate person to conduct the VTE risk 
assessment due to the complexity of data needed and the clinical interpretation 
necessary for safe, appropriate prophylaxis.  
The dramatic increase in both the number of patients risk assessed for VTE and the 
number appropriately treated with LMWH in period 4, April 2011, followed the 
introduction of national mandatory data collection in June 2010. A similar increase 
was seen by researchers at Kings College Hospital in London, where in the first nine 
months following the launch of the national programme in 2010 documented VTE 
risk assessment rates rose from 40% to 90%.219 In the present study there was an 
associated increase in the number of patients who received LMWH inappropriately. 
However as there were a minimum of three initiatives between each of the data 
collection periods it is difficult to attribute the changes to any particular 
intervention. The apparent impact of national mandatory data collection may have 
been as a result of increased uptake of local initiatives, see Figure 5-1, page 70 and 
section 5.2, page 69. 
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5.8.5.2 National change in VTE risk assessment 
Mandatory collection of VTE risk assessment figures was introduced in England as 
part of the NHS Outcomes Framework in June 2010.98 This government led 
approach had limited success, with uptake of VTE risk assessment guidance slow 
and many NHS hospitals struggling with its implementation. The published national 
data show that it took 18 months for the national target of 90% of patients to be 
risk assessed on admission to hospital to be achieved by acute NHS trusts.99 A 
comparison between the rate of uptake of VTE risk assessment in the study hospital 
and the national uptake is shown in Figure 5-8. The study hospital achieved the 90% 
national target several months ahead of the national average and the Trust quality 
accounts show that it was sustained throughout 2011/12 and 2012/13.13, 220 A study 
carried out in four hospitals in the NHS South of England region showed similar 
significant increases in the proportion of patients VTE risked assessed when 2009 
data were compared with that from 2010 for the three teaching hospitals, the 
fourth hospital a smaller foundation trust had significantly better rates in 2009 and 
showed a small improvement in 2010.221 
Figure 5-8:  Venous thromboembolism risk assessment rates in the study hospital 
and nationally 
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5.8.6 Prescribing of LMWH 
The present study showed an increase in the proportion of patients appropriately 
prescribed LMWH as VTE prophylaxis from 49.7% to 92.6%. This is in contrast to the 
similar study carried out in NHS South of England which collected data in 2009 and 
2010 for comparative purposes and showed little change in the proportion of 
patients who appropriately received prophylaxis despite a significant increase in 
those with a documented risk assessment.221 However in the latter study 80% 
patients received VTE prophylaxis in 2009, as two of the hospitals were exemplar 
sites for VTE, compared to 50% in the present study resulting in less opportunity for 
improvement to be demonstrated. Thus it would seem that initiatives in the study 
hospital were successful in reducing the risk of patients developing a VTE following 
hospital admission. 
However the present study also showed an associated increase in inappropriate 
prescribing (from 3% to 33%) for patients who had bleeding risks, an Italian study 
showed a similar increase following implementation of VTE guidelines, the number 
of patients with minor contraindications (history of peptic ulcer, renal disease, and 
liver impairment) who received LMWH rose from 29.4% to 55.2%.222 The NHS South 
of England study showed little change in the number of patients with 
contraindications who received LMWH which remained at about 15%.221 This is not 
surprising as there was minimal change in the proportion of patients prescribed 
LMWH overall. A study from London223 also reported an increase in patients in AMU 
being prescribed prophylactic LMWH although they were not eligible according to 
the Trust policy. However this study does not specify whether these patients had no 
VTE risk factors and so LMWH was not indicated or whether they were at risk of 
bleeding and so LMWH was contraindicated. The authors note that there appeared 
to have been a change in culture such that patients who did not need VTE 
prophylaxis were prescribed it, which has financial consequences and may also 
have patient safety implications. Therefore although the implementation of the VTE 
risk assessment had benefits for most patients there were some unexpected 
adverse outcomes and for a small number of patients the bleeding risk was 
increased by the prescribing of LMWH. 
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In the study hospital an early initiative (January 2009) involved the use of pre-
printed stickers stating “Dalteparin 5,000 units daily” attached to medication charts 
as a reminder for medical staff. The intention was that this “prescription” would 
either be completed by a prescriber, by signing and dating, if appropriate for the 
patient or it would be discontinued. Unfortunately this initiative resulted in a 
number of incident reports citing situations in which nursing staff had administered 
LMWH although the prescription on the sticker had not been signed. As it was only 
a matter of time before a major bleed resulted, this scheme was withdrawn in mid-
2009. 
5.8.6.1 Dose prescribed 
The dose of dalteparin recommended by the manufacturers for medical patients is 
5,000 units daily irrespective of age or body weight.205 However over a fifth of 
patients who were prescribed dalteparin received a lower dose of 2,500 units daily, 
and for almost half (39/87; 45%) of these no valid rationale could be identified from 
the case notes. Approximately a quarter (20/87; 23%) had both VTE and bleeding 
risks and a lower dose may have been used in an attempt to balance the risks and 
benefits of LMWH in this patient group. The remaining patients who were 
prescribed the lower dose were elderly age >75 years, had a low body weight <50kg 
or had severe renal impairment. As during the interviews two doctors said they 
would prescribe a reduced dose for elderly patients and approximately half of 
interviewees said they would reduce the dose for patients with a low body weight it 
appears that there is some confusion regarding the appropriate dose of dalteparin 
for medical patients. This may be partly due to the medical rotas as F1 doctors 
spend some of their first year working in surgery where 2,500 units of dalteparin is 
used for lower risk patients / procedures, educational input may therefore be 
beneficial to improve prescribing practice. 
5.8.7 Incidence of bleeding 
In the present study significant bleeding was seen in six patients, 0.3% of the total. 
This  is in line with a meta-analysis (which included the PRIME,224 PRINCE75 and 
PREVAIL225 studies) published in 2011226 which reported major bleeding rates of 0.3% 
- 1.1%  in patients treated with enoxaparin, another LMWH licenced for VTE 
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prophylaxis. The PREVENT study which investigated the use of dalteparin for VTE 
prophylaxis in medical patients reported a bleeding incidence of 0.49%.67 An 
American study which investigated the unintended consequences of implementing 
routine VTE prophylaxis found that there was a significant rise in bleeding events 
following implementation.227 
Trust data for incidence of gastro intestinal (GI) haemorrhage as a discharge 
diagnosis for the duration of the study are shown in Table 5-19. This shows a 
significant increase in GI haemorrhage from 2009 to 20111 (chi-square test 
P<0.001). This is interesting as the increase appears to mirror the increase in the 
prescription of prophylactic LMWH in the Trust, however much more detailed 
analysis of the individual cases would be required to ascertain whether this increase 
can be attributed to the use of LMWH or some other factor. It is not known from 
these data whether the bleeding was present on admission and therefore not 
attributable to LMWH or whether it occurred during admission and therefore 
potentially attributable to prescription of LMWH. 
Table 5-19:  Incidence of bleeding in Royal Liverpool & Broadgreen University 
Hospitals NHS Trust 2009 - 2011 
Discharge diagnosis 2009 2010 2011 
Gastro intestinal haemorrhage (% of total) 91 (0.7%) 126 (1.0%) 163 (1.3%) 
Total number of diagnoses 12,856 12,349 12,504 
5.8.8 Heparin induced thrombocytopenia 
The use of heparin is associated with a low incidence of HIT and therefore current 
guidance207 states that all patients who are to receive heparin (unfractionated or 
LMWH) should have a baseline platelet count. The results show compliance with 
this guidance as over 95% of patients who received LMWH had their platelet count 
measured on admission. Medical patients do not require routine monitoring 
however if the platelet count falls by more than 30% between days 4 and 14 of 
treatment a diagnosis of HIT should be considered. Almost half of patients were 
discharged within five days and therefore did not require monitoring, the results 
showed that only 8/90 patients who had repeat platelet monitoring had a platelet 
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count fall of >30% and none were thought to be due to HIT. This is to be expected 
as HIT only affects approximately 0.5% of patients treated with LMWH.207 
5.8.9 Incidence of VTE 
A meta-analysis in 200881 which included all seven major studies of VTE prophylaxis 
in medical patients showed that the incidence of VTE in medical patients could be 
halved by the use of prophylactic LMWH or fondaparinux. During the present study 
seven patients (0.8%) developed a VTE, three DVT, three PE and one both a DVT 
and a PE, six of these seven patients had received prophylactic dalteparin during 
their admission. This is in line with the findings of the PREVENT study which 
reported a rate of 0.56% symptomatic VTE at day 21 despite prophylactic 
dalteparin.67 Higher rates of VTE have been reported in medical patients treated 
with enoxaparin as prophylaxis, 5.5% in the MEDENOX trial66 and 8.3% in the 
PRINCE study.75 However these trials used venography to identify any possible VTE 
rather than clinical symptoms and it is known that 50% to 80% of DVTs and PEs are 
asymptomatic,228 hence the significant difference in the reported incidences.  
5.8.10 Strategies to improve VTE prophylaxis 
Meta-analyses of strategies to improve VTE prophylaxis found that passive 
dissemination of guidelines was generally ineffective229 and the use of multiple 
rather than single strategies229, 230 were more effective which supports the findings 
of the present study that the individual initiatives prior to June 2010 resulted in 
limited improvement. Multiple strategies including policy dissemination, education, 
use of a VTE risk assessment tool and reminder sticker on medication charts and 
audit feedback increased both documented VTE risk assessment and appropriate 
prescribing of prophylaxis in an Australian study.231 Education alone has been 
shown to have a modest benefit.232 A large study carried out in Australia and New 
Zealand233 evaluated the impact of a dedicated nurse educator who provided 
education sessions, paper and verbal reminders and fed back audit results. This 
strategy improved the proportion of acutely ill medical patients who appropriately 
received LMWH prophylaxis from 37.9% to 54.1% which, although a significant 
increase, still resulted in almost half of patients failing to receive effective 
prophylaxis. A similar increase (from 43% to 58%) was shown in an American 
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study234 which used both formal education sessions and clinical pharmacists on 
ward rounds to promote the VTE message. A recent Cochrane review232 concluded 
that an approach with multiple strands including alerts appeared to be more 
effective than the use of either education or alerts alone. 
Other work has demonstrated the value of opinion leaders in guideline 
implementation,139 which was the most likely reason for the significant 
improvement achieved in the last study period, one interviewee also identified 
strong leadership as a necessity for improved practice. A recent study from 
Nottinghamshire95 found that attaching a prompt sheet to the medication chart 
increased the proportion of patients appropriately prescribed prophylaxis from 75% 
to 98%, however in the present study VTE risk assessment forms placed inside 
medication charts as a reminder proved unsuccessful as they were either not 
completed or actively removed. Other strategies used in London which proved 
successful in improving VTE risk assessment rates were the use of checklists on 
ward rounds and e-mail messages to medical staff.223 In the study Trust junior 
medical staff do not routinely use their Trust e-mail accounts as they rotate 
hospitals every few months, maintaining a list of current personal e-mail addresses 
for all junior doctors was deemed impractical. Following the introduction of 
mandatory data collection, government targets and associated financial penalties in 
June 2010, VTE risk assessment became consultant-led as a result of pressure from 
Trust managers. This, together with continuous reminders during ward rounds, 
frequently by a pharmacist, emphasised the importance of VTE risk assessment to 
junior staff and the target of at least 90% of patients having a risk assessment 
performed on admission was exceeded. In addition, a Trust requirement for risk 
assessment to be completed by a senior doctor in the event of its omission during 
initial admission resulted in almost 100% of patients having been assessed within 
24 hours. An American study published in 2012 235 has shown that introduction of a 
mandatory computerised decision support tool had a similar significant beneficial 
effect on both VTE risk assessment and prescription of appropriate prophylaxis. 
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5.8.11 Effect of financial penalties 
VTE risk assessment was one of the first quality standards with a financial sanction 
to be issued by the Department of Health in 2010. While the results show that the 
90% VTE risk assessment target was achieved in April 2011, this standard will need 
to be maintained in a culture of organisational change and additional targets. 
Financial targets are a relatively new concept in secondary care in the NHS: they 
have been used more widely in primary care. A recent Cochrane review 236 found 
that there was little evidence either for or against their use in primary care and it 
has been suggested that there may be unintended consequences,236, 237 for example 
MRSA targets may increase the risks to patients with other healthcare associated 
infections.238 In the present study there was a significant increase in patients with 
known bleeding risks receiving LMWH prophylaxis. 
 A study carried out in four Trusts in the south west of England showed that all four 
hospitals showed an improvement in VTE risk assessment following the 
introduction of the national target, three hospitals received a financial reward 
whilst the fourth hospital noted that as their VTE CQUIN was linked to another 
factor it was impossible for them to be rewarded for their efforts in VTE risk 
assessment.239 In addition an analysis of Commissioning for quality and innovation 
(CQUIN) targets in London published in 2012 showed that only 38% of London 
Trusts achieved the full payment for the VTE CQUIN in 2010/11 and that 
performance in a CQUIN indicator does not always correlate with other quality 
indicators.240 However researchers from London223 felt that in their Trust VTE risk 
assessment was likely to remain a priority due to the significant funding associated 
with achieving the target. A checklist has recently been published241 to help decide 
whether a financial incentive is appropriate in a particular clinical scenario and if so 
provide some guidance for the development of a successful initiative. 
5.8.12 Recent developments 
The VTE CQUIN has been strengthened for the 2013/14 financial year. The 
proportion of patients who must be VTE risk assessed on admission to hospital has 
been increased from 90% to 95% and all cases of hospital acquired VTE, those who 
develop a VTE while in hospital or within 90 days of discharge, are to be subject to a 
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root cause analysis.242 However as it is known that 50% to 80% of DVTs and PEs are 
asymptomatic228 and LMWH is only effective for the prevention of VTE in 
approximately 50% medical patients,81 both the practicality and value of this 
requirement are unclear. In addition as patients may be admitted to several 
different hospitals within a short timeframe, each of which may be unaware of 
previous admissions to neighbouring hospitals due to the lack of a single patient 
record, accurate data collection is likely to prove challenging. Interestingly no data 
are required regarding the number of patients prescribed LMWH, the 
appropriateness of the dose, whether or not prescribed doses were administered 
or the incidence of acute haemorrhage. 
The present study shows that a national financial sanction resulting in a consultant 
led approach was associated with significant improvement in the number of 
patients VTE risk assessed and prescribed LMWH prophylaxis. However it remains 
to be seen whether the level of achievement can be maintained as existing targets 
are increased and new ones are added in a culture of organisational change. VTE 
risk assessment and appropriate prescribing of LMWH has proved to be more 
complex than originally thought due to the significant proportion of patients who 
have both VTE and bleeding risk factors and therefore clinical judgement is required 
to decide whether or not LWMH is indicated. 
 Summary 5.9
The results relating to VTE risk assessment and prescribing of LMWH prophylaxis 
have been discussed above; the results relating to medicines reconciliation are 
presented in the next chapter. a 
  
                                                     
a
 Some of the findings in this chapter have been published in BMJ Open in 2012: Basey AJ, Krska J, 
Kennedy TD, Mackridge AJ. Challenges in implementing government-directed VTE guidance for 
medical patients: a mixed methods study. BMJ Open. 2012;2(6).  Available from: 
http://bmjopen.bmj.com/content/2/6/e001668.full  
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Chapter 6 Results and Discussion: Medicines Reconciliation 
This chapter presents the results for the medicines reconciliation arm of the study 
and discusses them in the context of the current published literature. 
 Overview 6.1
During the four data collection periods a total of 71 patient admissions involving 36 
staff were observed and 930 sets of case notes were reviewed, details are shown in 
Table 6-1. Interviews were carried out with a total of nineteen staff including all 12 
staff observed in period 4 and an additional seven staff who were purposively 
selected to ensure that all grades of staff working on AMU at that time were 
represented. Similar numbers of admissions observed and case notes reviewed 
were included in all four periods, a larger number of medication histories were 
checked in period 4 as more rotational pharmacist hours were allocated to AMU in 
this period to provide this service. 
Table 6-1:  Subject numbers in each study period - medicines reconciliation data 
 Period 1 
(Nov 2009) 
Period 2 
(Jan 2010) 
Period 3 
(Apr 2010) 
Period 4 
(Apr 2011) 
Total 
Number of patient 
admissions observed 
16 21 14 20 71 
Number of staff observed 8 7 9 12 36 
Number of staff both 
observed & interviewed 
0 0 0 12 12 
Total number of staff 
interviewed 
0 0 0 19 19 
Number of patients 
admitted 
265 255 239 256 1015 
Number of case notes 
reviewed 
243 / 265 
(91.7%) 
232 / 255 
(91.0%) 
221 / 239 
(92.4%) 
234 / 256 
(91.4%) 
930 / 1015 
(91.6%) 
Number of patients with 
documentation available 
207 / 243 
(85.2%) 
202 / 232 
(87.1%) 
190 / 221 
(86.0%) 
211 / 234 
(90.2%) 
810 / 930 
(87.1%) 
 Observations 6.2
During the four data collection periods a total of 71 patient admissions were 
observed, involving one nurse clinician and 35 doctors (four consultant/specialist 
registrars, four specialist trainees (ST) year 4/5, nine specialist trainees year 1/2/3 
and 18 foundation (F)). All staff who were approached to be observed gave 
informed consent, however two finished their AMU shifts before a suitable 
opportunity arose. An overview of the observation data is shown in Figure 6-1. 
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 Figure 6-1:   Overview of medicines reconciliation completed and prescription charts written for observed patients 
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The mean age of the patients was 68 years, 39% were male and the most frequent 
presenting complaints were infection, pain, abnormal biochemistry, shortness of 
breath and vomiting or diarrhoea, details are shown in Table 6-2 
Table 6-2:  Demographic details of patients included in case note reviews and 
observations (Reproduced here from Chapter 4, page 46 for ease of reference) 
Characteristic Case note review Observations 
Number of case 
notes retrieved 
930 71 
Relevant admission 
notes available 
876 67 
Sex - male (% ) 381 / 876 (43.5%) 28 / 67 (39%) 
Age range (mean) 
 
16 -98 (64) years 16 – 98 (68) years 
Average length of 
stay (median) 
1 – 182 (5.5) days 1 – 47 (5.0) days 
Most frequent 
presenting 
complaint 
(descending order 
of occurrence) 
 
 
Infection (285; 32.5%) 
Pain (72; 8.2%) 
Cardiac cause (60; 6.8%) 
Shortness of breath (54; 6.2% 
Abnormal biochemistry* (51; 
5.5%) 
Possible VTE‡ (46; 5.3%) 
Infection (15; 22%) 
Pain (8; 12%) 
Abnormal biochemistry* (8; 
12%) 
Possible VTE‡ (7; 10%) 
Shortness of breath (5; 7%) 
Vomiting or diarrhoea (5; 7%) 
 
*Results outside of the normal range for haemoglobin, glucose, thyroid hormones, sodium, 
potassium, magnesium, or calcium 
‡
Venous thromboembolism 
6.2.1 Questions asked about medicines 
The number of questions asked of patients about their medicines ranged from zero 
(14 patients) to four (4 patients), details of grade of staff and medicine-related 
question frequency are shown in Table 6-3 and Figure 6-2. As the number of 
patients seen by the more senior grades of staff was small the doctors were divided 
into two groups to enable analysis, junior doctors comprising grades F1 and F2 and 
senior doctors grade ST1 and above, the nurse was excluded from this part of the 
analysis. When the two groups were compared there was no significant difference 
between them in terms of the number of questions asked relating to medicines, 
Mann-Whitney U test P=0.069. The Mann-Whitney test was chosen as the data 
cannot be assumed to be normally distributed. 
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Table 6-3  Number of questions asked about medicines by grade of staff observed 
Grade of staff Number of 
Staff 
Number of patients 
admitted 
Mean number of 
questions asked per 
patient 
Nurse clinician 1 3 1.0 
F1 doctor 11 18 1.6 
F2 doctor 7 12 2.3 
ST1 doctor 6 19 1.5 
ST2 doctor 2 6 1.2 
ST3 doctor 1 1 1.0 
ST4 doctor 1 1 3.0 
ST5 doctor 3 4 1.5 
Specialist Registrar 1 2 0.5 
Consultant 3 5 1.2 
F1/2 Foundation year doctor 1 -2 years post qualification 
ST Specialist trainee doctor 3-5 years post qualification 
 
Figure 6-2: Number of questions asked about medicines by different staff grades 
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Most patients (57/71; 80%) were asked at least one question about their medicines 
by the member of staff clerking their admission to hospital: 
 “Do you take any regular medication?” (41; 69%) 
 “Do you have your medicines with you?” (20; 28%)  
 “Do you have a list of your medicines with you?” (13; 18%) 
  “Do you know which medicines you take?” (4; 6%) 
  “Do you buy any medicines ‘Over the Counter’ – from community pharmacies 
or herbal preparations?” (5; 7%)  
 Doses and /or frequencies of administration clarified (14; 20%)  
 “Why are you taking [name of medicine]?” (5; 7%) 
The majority of questions asked were closed although patients often responded 
with additional information such as responding “yes – blood pressure tablets” or 
providing a written list of medicines, or their own medicines. Open questions were 
used to clarify indications or doses and /or frequencies. 
Of the five patients asked about OTC medicines one had taken aspirin during the 
previous 2 weeks for phlebitis, another had taken paracetamol for a headache 
following a ‘blackout’ and the remaining three patients had not taken any OTC 
medicines recently. 
Healthcare staff were sometimes unable to interpret the responses given by 
patients for example one patient said she used “blue, grey and purple inhalers” and 
the member of staff was unfamiliar with the standard colours used for different 
types of inhalers. Another patient had his medicines in a ‘blister’ pack but indicated 
that he didn’t take “the yellow one or the white one”; the doctor was unable to 
identify these tablets from the information on the blister pack. In both of these 
instances the pharmacist was asked for assistance to resolve the problem. Some 
patients were obviously frustrated by the routine questions repeatedly asked on 
admission to hospital one stated “you always ask the same questions” and another 
said “there is a list in the file”. In both of these cases the way in which the questions 
were asked probably contributed to the unhelpful patient response. In the first case 
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the doctor spoke very quickly and used medical terminology which the patient had 
difficulty in following, in the second case the doctor’s first language was not English, 
she was tired as she was working an extra shift and the patient had difficulty in 
comprehending the questions asked. 
Six patients were asked if they had taken any new medicines recently to ascertain 
whether this may have explained their presenting complaint or symptoms, three of 
these patients were clerked by the same ST1 grade doctor. Potential side effects 
prompted this question in most cases, a patient who presented with ‘black vomit’ 
could have experienced a gastrointestinal bleed due to a non-steroidal anti-
inflammatory drug (NSAID), a patient’s headache could have been drug-induced, a 
patient who presented with chest pain and was gasping for breath could have had 
an allergy to a new medicine, acute onset of confusion could have been explained 
by a new medicine as could new onset of diabetes. A possible drug interaction 
prompted the doctor to ask a patient about new medicines as his raised 
international normalised ratio (INR) could have been explained by interaction 
between warfarin and another medicine. However the cause of the symptoms was 
not thought to be medication related in any of these cases. 
On two occasions patient responses were not followed up, the first patient was 
asked if she took any medication and responded “not at the moment”. The member 
of staff clerking the patient did not ask any further questions to clarify this 
statement. This patient presented with shoulder pain following a fall and had 
severe arthritis which restricted her ability to walk and climb stairs; she stated that 
she drove whenever possible to avoid having to walk. It would have been useful to 
know which medicines she had tried and why they had been stopped in order to 
prescribe appropriate analgesia. The second patient indicated that she had not 
taken her fluoxetine for a few days; the doctor did not ask her why. She had been 
sent to AMU as she was short of breath and was found to have low serum 
haemoglobin; it is possible that she was suffering from a gastro intestinal bleed due 
to fluoxetine. 
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The dose and/or frequency of medicines were clarified with 14 patients. Regimens 
for medicines which were prescribed to be taken less frequently than daily were 
clarified as there was insufficient detail in the General Practitioner (GP) summaries 
provided e.g. the days of the week for alfacalcidol capsules and co-trimoxazole 
tablets taken three times a week on Mondays, Wednesdays and Fridays, the day of 
the week for a weekly dose of alendronate. Two patients had two different 
strengths of the same medicine (digoxin and olanzapine) listed on their GP 
summary so the member of staff had to confirm with the patient whether they 
were taking just one of the strengths of these tablets or both. 
Five patients were asked why they were taking one or more of their regular 
medicines and in one case, the patient was asked to provide the indication for all 
nine of their regular medicines. One patient was asked why he was taking 
lansoprazole and amoxicillin, the remaining three patients were asked about 
buprenorphine patches, prednisolone tablets and pyridostigmine tablets. 
Sixteen patients (23%) were not asked any questions relating to medicines despite 
this being an integral part of the standard hospital clerking model,20 for five of 
these patients information from either a care home MAR chart or the referring 
hospital medication chart was used. All but one of these 16 patients was taking 
regular medication. 
In 69 (97%) cases, the researcher assessed that the patient or their carer was able 
to discuss medication issues; two patients were too unwell to do so. However, 14 
(20%) of the patients or their carers who were able to provide information were not 
asked any questions relating to their medicines and 13 (93%) of these were taking 
regular medication. Of the two patients unable to provide verbal information, the 
nursing home MAR chart was used for one and the medication chart from the 
referring hospital for the other.  
6.2.2 Problems observed during the admission process 
Numerous problems were observed during the process of obtaining a medication 
history for patients involving communication, missing or incomplete medication 
information and out of date information. 
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6.2.2.1 Communication 
Difficulties in communication were observed when either the doctor or the 
patient’s first language was not English, a friend interpreted for one patient who 
spoke limited English. A doctor spoke particularly quickly and patients had difficulty 
in following the questioning, another used medical terminology which a patient had 
difficulty comprehending. Intoxication due to alcohol also proved a challenge when 
clerking another patient as he was unable to provide consistent responses to 
questions asked. 
6.2.2.2 Missing or incomplete information 
Problems relating to the sources provided by either GPs or patients to inform the 
admission prescription were also noted, information was often missing or 
incomplete see Figure 6-3. 
Figure 6-3:   Missing or incomplete information for patients on admission to 
hospital 
 
 
 
 
 
 
 
 
 
 
 
Letters from GP Practices: 
No letter provided, patient referred by telephone  
Missing medication doses and types of inhaler in hand-written letter 
Medication which patient has not used for several months listed as current 
 
Letters from Community Matron: 
Acute medication only listed (antibiotics, steroids, nebules) – no repeat 
medication details 
 
From Patients: 
Out of date GP repeat form (5 months old) – doses had changed 
 
Patients Own Medicines: 
Dispensing labels missing – especially inhalers 
Dosette Box unlabelled 
Medication very old and label illegible 
Loose / strips of tablets – no box or dispensing label 
Incomplete – blister pack with patient but inhalers left at home 
All medicines accidentally left in ambulance 
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6.2.2.3 Other healthcare providers 
Obtaining an accurate medication history for patients who had recently received 
care from healthcare providers other than their GP proved particularly challenging. 
In one case the patient’s son contacted the Community Psychiatric Nurse (CPN) to 
find out her dose of donepezil which wasn’t listed in the GP summary, in another 
the patient’s old case notes had to be retrieved to ascertain the correct dose of 
prednisolone which had been prescribed at a previous outpatient appointment, 
unfortunately as these prescriptions are dispensed by a community pharmacy this 
information is not available on the hospital pharmacy computer system. 
 A sample case study illustrating some of the problems encountered in 
documenting an accurate medication history for one patient in whom it proved 
particularly difficult is shown in Figure 6-4, details of all 71 case studies are available 
in Appendix 16. 
Figure 6-4:  Case Study - illustrating problems in documenting an accurate 
medication history 
 
 
 
 
 
 
 
 
 
 
 
 
Patient clerked by F2 doctor 
Patient takes 9 regular medicines 
 
Sources available for medication history 
Patient’s verbal information - used 
GP repeat prescription order form - used 
Patient’s own hand written list – not used 
Patient’s own medicines – not suitable for use (see below) 
 
Problems encountered 
Initially no referral information, GP summary later found beside fax machine 
Patient’s own medicines in unlabelled Dosette box 
Patient initially gave the doctor just page 2 of the GP repeat prescription order 
form, the doctor had to ask for page 1. 
GP repeat prescription order form not current, dose of one medicine has been 
reduced 
 F2 Foundation year doctor 2 years post qualification 
 
 
 
Outcome 
7 medicines accurately prescribed, 2 with held due to current clinical condition 
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6.2.3 Medication histories 
No medication history was completed for one patient. Some information about 
their current medication was brought into hospital by 27 (27/65; 42%) patients who 
were admitted from their own homes. Twenty three (23/65; 35%) had their own 
medicines with them, of these four (4/65; 6%) had their own medicines and their 
GP repeat order form and one patient (1/65; 1%) had their own medicines together 
with a hand written list.  Two patients had their GP repeat order form with them 
and two had a handwritten list of their medication. The most common sources used 
to obtain the medication history for the remaining patients were: printed letters 
from the GP, Community Matron or Walk-In Centre (34; 48%), the patient 
themselves (29; 41%) the patient’s own medicines (19; 27%) and hand written 
letters from the GP (14; 20%), see Table 6-4. Of the 14 hand-written letters 
received, nine were incomplete, five did not contain any information about the 
patient’s current medication and four listed the drug names only, no doses and / or 
frequencies were stated. The information provided in printed GP summaries was 
misinterpreted on four occasions leading to prescribing errors, as shown in Figure 
6-5. Only six patients had their GP repeat prescription with them, five of these were 
used by medical staff.  
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Table 6-4:  Sources used by staff to obtain medication histories during 
observations 
Source Available and used 
(Total no. patients  
of 71) 
Available but not 
used (Total no. of 
patients 71) 
Total available 
(Total no. of 
patients 71) 
GP Summary 34 (48%) 8 (11%) 42 (59%) 
Handwritten letter 14 (20%) 6 (8%) 20 (28%) 
Patients verbal list 29 (41%) 8 (11%) 37 (52%) 
Patients own written list 2 (3%) 1(1%) 3 (4%) 
Relatives / carer provided 
verbal list 
6 (8%) 1(1%) 
7 (10%) 
Other hospital drug chart / 
letter 
3 (4%) 1(1%) 
4 (6%) 
EMIS Web1 5 (7%) Not known Not known 
ICE discharge prescription2 3 (4%) Not known Not known 
Old medication chart / 
discharge prescription 
from case notes 
2 (3%) 2 (3%) 4 (6%) 
GP repeat order form 5 (7%) 1(1%) 6 (8%) 
Renal Proton system3 1 (1%) Not known Not known 
Patients own medicines 19 (27%) 4 (6%) 23 (32%) 
Medication Administration 
Record (MAR) chart 
3 (4%) 2 (3%) 5 (7%) 
1. EMIS Web is an electronic web based system which enables authorised medical, nursing and 
pharmacy staff to view the patient’s medication history held on the GPs computer system.  
2. ICE is an electronic pathology results system 
3. Proton is an ‘in house’ hospital system used to record medication and test results for patients of 
the renal directorate 
 
Figure 6-5:  Problems observed in staff interpretation of GP summaries 
 
 
 
 
 
 
 
 
 
 Summary states Fragmin (dalteparin) 25,000 units /ml 0.6ml daily 
Doctor initially prescribed 2,500 units daily and when challenged changed 
this to 25,000 units daily, dose should be 15,000 units daily (pharmacist 
intervened) 
 Buprenorphine patch 5mcg/hour weekly  4 
Doctor interpreted as 4 patches every week rather than 1 patch every 
week, 4 weeks supply 
 Spironolactone 2 od (daily) on at the bottom of page 1, strength 25mg at 
the top of page 2 of GP summary 
Doctor assumed strength was 100mg and prescribed 200mg daily, should 
be 50mg daily 
 Fluticasone 250mcg / salmeterol 25mcg inhaler (Seretide 250 evohaler) 
2puffs twice daily 
Prescribed as fluticasone 250mcg inhaler 2 puffs twice daily 
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A single source of information was used to document the medication history in 
almost half of cases (32/70; 46%) although for 17 of these additional information 
sources were overtly available but not used. Two sources were used in 29 cases, 
three in eight cases and four sources in one case. There was no evidence of any 
difference in the number of sources used when F1/F2 doctors were compared with 
more senior doctors (Mann-Whitney U test, P=0.904). Further sources of 
information regarding medication were overtly available during the observations 
for a total of 23 of the 71 patients but were not used by staff. Details are shown in 
Table 6-4.  
6.2.4 Requests for pharmacist assistance 
The pharmacist researcher was asked for assistance with prescribing on 13 
occasions during the four study periods, three queries related to the prescribing of 
parenteral anticoagulation. All queries were answered as succinctly as possible to 
reduce the possibility of the focus of the study becoming known to participants, 
details are shown in Figure 6-6. 
Figure 6-6:  Research pharmacist assistance sought during observations 
 
 
 
 
 
 
 
 
 
 
 Dose therapeutic dalteparin based on body weight 
 Dalterpain dose reduction for a patient with renal impairment 
 Identifying inhalers from patient descriptions of colour and shape 
 Confirming appropriateness of medication:  Oramorph (morphine sulphate 
oral liquid) for breathlessness in patient with severe chronic obstructive 
pulmonary disese 
 Identification of white and yellow tablets in a blister pack 
 How to prescribe tiotropium inhaler 18 micrograms daily 
 Identification of new diabetes tablet beginning with ‘S’ – sitagliptin 
 How to prescribe calcium carbonate 1.5g / cholecalciferol 400umits – Adcal 
D3 
 To access GP summary using EMIS web1 – passwords not issued to rotational 
medical staff 
 Dose of paracetamol in liver disease? 
 Appropriate non-steroidal anti-inflammatory drug (NSAID) to be started 
 Dose of fondaparinux for probable pulmonary embolism  as patient is allergic 
to dalteparin 
 Appropriate antibiotic for patient who has a chest infection, penicillin allergy 
and had recent course of erythromycin from GP 
 1 Web based computer system used by many GPs 
  
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6.2.5 Prescribing errors witnessed 
Prescribing errors were witnessed during nine of the observations, one ST1 doctor 
made an error in the prescription of four out of the five patients whose admissions 
were observed. As an experienced clinical pharmacist the researcher was able to 
intervene if she felt that the error was likely to result in a significant adverse clinical 
impact and felt that it was appropriate to do so on three occasions. One patient 
was prescribed Calcichew tablets instead of cinacalcet tablets, Calcichew is a 
calcium supplement and cinacalcet is used for the treatment of hypercalcaemia 
caused by secondary hyperparathyroidism in patients with end-stage renal disease. 
The second patient was admitted on dalteparin for the treatment of a known DVT, 
at first the doctor prescribed a subtherapeutic dose and when challenged changed 
this to a dose in excess of the maximum recommended by the manufacturer, the 
details are shown in Figure 6-7. Errors occurred particularly when dosing regimens 
were less frequent than once a day and when generic names rather than brand 
names were used for combination products such as inhalers and calcium and 
vitamin D preparations. The third patient was penicillin allergic and had had a 
recent course of erythromycin from her GP. The doctor prescribed clarithromycin 
however since this was unlikely to be effective following a recent course of 
erythromycin the pharmacist suggested levofloxacin as an alternative in line with 
Trust policy. 
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Figure 6-7:  Prescribing errors witnessed during observations and associated 
pharmacist interventions 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.2.6 Prescription charts written 
A prescription chart was written by the admitting doctor during the admission 
process for 56 (79%) patients, for 13 (18%) patients no chart was written and in two 
(3%) cases a chart had been written by another doctor elsewhere in the hospital 
prior to clerking. A prescription chart was written by another prescriber later in the 
patient’s stay for 10 of these 13 patients. The nurse specialist was not registered as 
a prescriber at the time of the study therefore prescriptions were not written 
during clerking for any of the three patients whom she clerked. In the 56 cases 
where the prescription was written on admission, this was confirmed with the 
patient in only 12 cases (21%), while in 37 cases (66%) the prescriber made no 
attempt to confirm with the patient that the prescription written matched the 
 Tiotropium inhaler missed off prescription (F2 doctor) 
 MST (morphine sulphate SR tabs) prescribed as 40mg Mane and 30mg 
Nocte using a blister pack, should be 30mg BD but 40mg BD on Mondays 
and Thursdays when the patient has dressing changes (Consultant) 
 Ramipril prescribed 5mg daily, should be twice daily and furosemide 20mg 
3od prescribed as 20mg mane (ST2 doctor) 
 Tacrolimus prescribed, should be prescribed by brand – Prograf (ST1 
doctor)* 
 Calcichew prescribed, should be cinacalcet (pharmacist intervened) (ST1 
doctor)* 
 Calcichew prescribed should be Calcichew D3 Forte (ST1 doctor)*† 
 Regular medication fluoxetine and vitamin B compound strong omitted 
for no apparent reason (ST1 doctor)* 
 Patient is allergic to penicillin, has had recent course of erythromycin from 
GP., Has pneumonia – clarithromycin prescribed, changed to levofloxacin 
(pharmacist intervened) (ST1 doctor) 
 GP summary states Fragmin (dalteparin)25,000 units /ml 0.6ml daily 
Doctor initially prescribed 2,500 units daily and when challenged changed 
this to 25,000 units daily, dose should be 15,000 units daily (pharmacist 
intervened) (ST1 doctor)*† 
*Same ST1 doctor 
†
 Same patient  
F1/2 Foundation year doctor 1 -2 years post qualification 
ST Specialist trainee doctor 3-5 years post qualification 
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medicines which they were actually taking. In two (4%) only urgently required 
medication was prescribed and one patient was taking only acute medication prior 
to admission, in five (9%) cases patient confirmation was not possible due to illness.  
6.2.7 Medicines reconciliation by a pharmacist 
Medicines reconciliation was carried out by a pharmacist independent of the 
admission process for 42 of the 56 prescription charts written on admission during 
the observations, 25 charts (59%) were found to be accurate, eight (19%) contained 
one prescribing error, seven (17%) two errors and two (5%) had three errors. 
 Interviews 6.3
Twenty doctors were approached to participate in the interviews, 14 had agreed to 
be both observed and interviewed; 12 were actually both observed and interviewed. 
The remaining two doctors completed their AMU shifts before a suitable 
opportunity for observation arose however both participated in the interviews. A 
further six were asked to participate in the interviews in order to ensure that each 
grade working in AMU was represented, all agreed. Unfortunately one of these six 
doctors had a prolonged period of annual leave (honeymoon) and then moved 
Trusts so was unable to participate. Interviews were carried out as soon as possible 
following the observations in study period 4 to try to minimise the opportunities for 
discussion about the content between participants. 
A total of nineteen doctors were interviewed, two consultants, five ST years 
3/4/5/6, four ST years 1/2 and eight F years 1/2 (Table 6-5). Two of the six AMU 
consultants involved in admissions had already participated in earlier VTE 
interviews and were as such not eligible for this part of the study in accordance 
with the study protocol, a third consultant was part of the research team and hence 
also ineligible. The group interviewed comprised 76% of the 25 doctors working on 
AMU during study period 4, 12 of the 19 interviewed were responsible for 
admitting 20 of the patients observed in the study. The group had a wide range of 
experience covering both medical and surgical disciplines, their chosen or proposed 
specialties were also varied, general medicine (8), GP (3), AMU or ED (4), surgery (2), 
psychiatry (1), and histopathology (1). 
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Table 6-5  Number of medical staff available on Acute Medical Unit (AMU) rota 
and number interviewed 
Grade of Staff Number on AMU rota per 
week 
Number interviewed 
Junior ( F1,F2,ST1,ST2) 12 12 
Senior (ST3, ST4, ST5, ST6) 6 5 
Consultant 7 (4 part time) 2 (4 ineligible) 
Total 25 19 
F1/2 Foundation year doctor 1 -2 years post qualification  
ST Specialist trainee doctor 3-6 years post qualification 
6.3.1 Training in taking a medication history 
 Sixteen doctors (84%) reported having received training in taking a medication 
history at university; however three were unable to recall having any training, two 
of whom were aged less than 30 years. Most (9/16; 56%) were unable to recall the 
details, three said that the duration of training was less than 2 hours, four said it 
lasted longer than 2 hours. Training had been received at a variety of medical 
schools mostly in the North of England: Liverpool (5), Manchester (4), Leeds (3), 
Oxford (1), Swansea (1), and Sudan (1). Two doctors said that training to take a 
medication history was included in the general medical history taking training, two 
specifically mentioned pharmacists being involved in their training one from 
Liverpool University and the other from Leeds University. 
Of the 14 doctors who were able to recall some details of the training which they 
had received 12 said that they felt that it was adequate but two felt that it was 
inadequate. One doctor indicated that they had to “learn on the job”, another said 
that they were “not prepared for prescribing”, they were able to take drug history 
but “lacked of pharmacological knowledge regarding interactions etc.” These two 
individuals had attended different universities.  
6.3.2 Awareness of the prevalence of prescribing errors 
The majority of doctors were unaware of the proportion of patients at risk of 
prescribing errors with 13/19 estimating that no more than 30% of medication 
charts written on admission would have a prescribing error and 16/19 estimating 
that 10% or fewer of these errors would have the potential to have a serious impact. 
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There was no obvious correlation between the grade of doctor and their estimate 
of the prevalence of prescribing errors on admission, Figure 6-8. There was no 
significant difference in the estimates of F1/F2 doctors in comparison to other 
doctors (t-test; P=0.852, equal variances assumed). 
Figure 6-8:  Individual doctors estimate of proportion of prescription charts with a 
prescribing error 
 
F1/2 Foundation year doctor 1 -2 years post qualification 
ST Specialist trainee doctor 3-6 years post qualification 
6.3.3 Knowledge of medication history taking  
Self-rated knowledge of medication history taking was ‘good’ in seven (37%) and 
‘average’ in twelve (63%), no one felt that their knowledge was ‘below average’. As 
a prescribing error was identified for only three of the 20 patients admitted by 
these doctors it was not possible to draw any conclusions as to whether or not 
perceived knowledge of medicines reconciliation correlated with accuracy of 
prescribing. When asked about local and national guidance relating to medicines 
reconciliation only one doctor was aware of the local Trust policy and two thought 
that there was national guidance but were unable to recall any details.  
6.3.4 Current medication history taking practice 
When asked to list the sources they used to obtain a medication history the most 
common responses were the patient (17; 89%), patients own medicines (16; 84%), 
GP repeat medicines form (15; 79%), previous discharge prescription (14; 74%), 
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telephone GP for information (13; 68%), GP / Walk In centre letter (10; 53%). The 
total number of sources cited as being used ranged from four to eight.  
When asked if they would ever use more than one source for a medication history 
fourteen of the 19 interviewees indicated they would sometimes use more than 
one source and a further four said that they would always do so. Reasons given for 
using more than one source were that information given by patients alone was not 
reliable (6 doctors) and that patients may not take their medication as listed in GP 
summaries (3 doctors). Five interviewees stated that clinical anomalies also 
prompted them to check medication more thoroughly, examples they gave were: a 
patient with a history of epilepsy who has brought their own medication into 
hospital but has no antiepileptic medicines with them, a patient taking letrozole but 
no history of breast cancer. Extracts from the interviews are shown in Table 6-6. 
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Table 6-6:  Extracts from interviews - reasons for using more than one source of 
information for medication histories 
Key theme Extracts from medicines reconciliation interviews 
Unreliable patient 
information 
“If you [just] talk to the patient you often find they are 
wrong” - – ST1 doctor 
“”When talking to patients [you] find they are not sure 
or there is some contradiction”– ST3 doctor 
“Unwell patients are unreliable”- F1 doctor 
Patient may not take 
medicine as listed in GP 
summary 
“Patients don't take medicines as they are supposed to, 
[you need]run through list with patient and make sure 
they are taking them all” –ST1 doctor 
“[The] patient may not be taking all medicines [listed]” – 
ST5 doctor 
Clinical anomalies “”If there are discrepancies e.g.[the] patient says they 
take antiepileptics but they are not in patients bag of 
medicines”– Consultant 
“If there is a contradiction e.g. they are on a beta 
blocker and [rate controlling] calcium channel blocker”- 
ST5 doctor 
“…. miss match of condition and medication” – ST6 
doctor 
“If [there is]discrepancy between patient history and 
medication e.g. on letrozole but no history of breast 
cancer”.– F1 doctor 
F1/2 Foundation year doctor 1 -2 years post qualification 
ST Specialist trainee doctor 3-6 years post qualification 
6.3.5 Problems in confirming medication histories 
Interviewees were asked to describe any problems which they encountered when 
trying to ascertain patients’ medication histories. Difficulties were experienced 
when patients were unable to provide information and did not have their usual 
medication with them. One doctor commented on the problems when information 
has not been documented in the ED notes and the necessary documents or 
medicines are then lost in the transfer process between ED and AMU. Warfarin and 
insulin were cited as causing particular problems in identifying the current dosage 
regimen, as this information is not usually included on the pharmacy dispensing 
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label, and the difficulties in obtaining accurate information outside of normal 
working hours when GP surgeries are closed were highlighted. Extracts from the 
interviews are shown Table 6-7. 
Table 6-7:  Extracts from interviews – problems experienced in confirming 
medication histories 
Key theme Extracts from medicines reconciliation interviews 
Not all medication with 
patient 
“Patient has no medication with them and doesn’t 
know” - – ST5 doctor 
“ -  they have no drugs with them” – ST3 doctor 
“Patients don’t always bring everything in”- 
Consultant 
Patient unable to recall 
information about medication 
“Patient can’t remember [which medicines they 
take]” – ST3 doctor 
“Patient doesn’t have accurate knowledge [of 
medication] – [he / she is] confused” – ST4 doctor 
“Patient doesn’t know what they are taking” – ST1 
doctor 
“Confused patients” – 2 F1 doctors 
Difficulties ‘out of hours’ “At night – no GP letter – no information out of 
hours” – ST4 doctor 
“[There are] problems if it’s after 5pm”- ST1 doctor 
“In the middle of the night – can’t contact GP” – F1 
doctor 
“ [You] can only phone the GP 9am to 5pn” – F2 
doctor 
F1/2 Foundation year doctor 1 -2 years post qualification 
ST Specialist trainee doctor 3-5 years post qualification 
6.3.6 Documenting medication histories 
As there was evidence from the observations that medication histories are not 
always documented in the case notes in the study hospital participants were asked 
if there were any situations when they wouldn’t document a medication history in 
the case notes. Fifteen doctors stated that they would always document a 
medication history even if the patient was taking no regular medication; two 
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doctors said that this may be omitted if the patient was very ill in the resuscitation 
suite when the focus would be on the current acute problem. One doctor stated 
that this may not be possible due to lack of information and another said that when 
working busy nights and if feeling tired she may leave a space in the notes for the 
medication history when clerking a patient at the bedside and forget to complete it 
later. When asked what action they would take if it was not possible to complete a 
medication history at the time of clerking most doctors (16/19) indicated that this 
was only likely to happen “out of hours” and they would document in the case 
notes that the medication history needed to be completed for action either by the 
medical team or pharmacy staff when information from the GP was available. One 
experienced doctor stated that “[you] can usually find something if you try hard 
enough”.  
6.3.7 Writing a medication chart 
As the observations had shown that a medication chart was not always written for 
patients on admission doctors were asked to describe situations in which they felt a 
medication chart was not necessary. Ten doctors thought that all patients should 
have a medication chart written, one commented that a chart was needed so that 
any medication allergies could be recorded. Six doctors thought that a chart was 
unnecessary if the patient was unlikely to be admitted and would be discharged 
within a few hours, two said it would be unnecessary if the patient was taking no 
regular medication and no new medication was indicated and one said that if a DVT 
proforma was used (for patients admitted with a suspected DVT) no medication 
chart was necessary. 
6.3.8 Discussion with patients 
Over half of doctors (11; 58%) indicated that they would confirm medication with 
patients at least sometimes before writing the admission prescription, two stated 
that they would discuss newly initiated medicines but not the patients ‘regular’ 
medicines. Reasons given for not discussing with patients were generally if patients 
were incapacitated due to illness, however one doctor indicated that this would 
take too much time. 
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6.3.9 Checking of prescriptions 
All doctors thought that prescriptions should be checked, 18/19 indicated that a 
check should be carried out within 24 hours of prescribing and that pharmacists 
were the most appropriate staff group to perform the check. However it was 
recognised that anyone involved with the patients medication should also take the 
opportunity to check e.g. doctors on the post take ward round and nurses 
administering medicines. Five doctors indicated that they had a responsibility to 
self-check any prescriptions which they had written. 
6.3.10 Suggestions to reduce prescribing errors 
Suggestions for reducing prescribing errors included better access to GP 
prescription data (6 doctors) especially out of hours possibly by the use of an 
integrated IT system and improved training for medical students and F1 doctors (10 
doctors). Two senior interviewees suggested that increased availability of a 
pharmacist ‘at the front door’ to obtain an accurate medication history before the 
patient was clerked by a doctor may be the solution. Examples of interview 
responses are shown in Table 6-8. 
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Table 6-8:  Extracts from interviews – suggestions for reducing prescribing errors 
Key theme Extracts from medicines reconciliation interviews 
Improved access to GP 
prescription data 
“Access to GP records for admitting doctors” – ST3 doctor 
“Easier access of information between AMU and GP – if GP 
refers he should send a patient summary” – ST1 doctor 
“GPs to send information routinely about medicines” – ST2 
doctor 
“Make sure an up to date list [of medicines] comes with 
the patient from the GP” –  F1 doctor 
“Central record of medication for hospital and GP use – 
electronic with access at all times” – ST1 doctor 
 
Training “Better training for doctors, there is too much information 
given at induction. Maybe early teaching session after 
induction” – F2 doctor 
“Do a refresher for F1s on medicines reconciliation” – F1 
doctor 
“Re-education at Grand Round and F1 teaching [sessions]” 
–F1 doctor 
“Training on induction, continue risk sessions on Grand 
Round, increase training at medical school” –ST5 doctor 
Pharmacist 
involvement 
“Could a pharmacist do a medication history at the front 
door before the doctor clerks?” – ST6 doctor 
“Have a pharmacist 24 hours a day on AMU” -Consultant 
F1/2 Foundation year doctor 1 -2 years post qualification 
ST Specialist trainee doctor 3-6 years post qualification 
6.3.11 Ranking of sources commonly used for medicines reconciliation 
At the end of the interview staff were asked to indicate how often they would use 
sources commonly used for medicines reconciliation, assuming they were available, 
using a list provided. They were then asked to rank a list of sources on a scale of 1 
to 5 where 1 is not very useful and 5 is extremely useful (Appendix 14). 
The six sources most commonly cited as being used, in decreasing order of 
frequency of use were: referral letter from primary care, GP repeat prescription 
order form, MAR chart from nursing home, patients own medicines, information 
provided by the patient, relative or carer and patients own medication list. The 
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least frequently used sources were the renal Proton system which provides some 
information including medication for renal patients at RLUH and EMIS Web which 
allows access to GP medication records for the majority of GPs in Liverpool 
provided the patient gives consent for their record to be accessed. Only one doctor 
had previously worked in the renal directorate and therefore had access to the 
Proton system, most doctors were either unaware of the information available via 
EMIS Web or were unaware that pharmacists were able to access this system. 
Access to EMIS Web is restricted to consultant medical staff and pharmacists. 
The most useful sources in decreasing order were: GP repeat prescription order 
form, MAR chart, primary care referral letter, GP surgery; information provided by 
the patient, relative or carer; patients own medication list. The least useful were 
the renal proton system or EMIS Web for the reasons stated above, see Figure 6-9. 
Figure 6-9: Doctors rating of how useful they find various sources for medication 
histories 
 
*Proton is an ‘in house’ hospital system used to record medication & test results for renal patients of 
the renal directorate 
**EMIS Web is an electronic web based system which enables authorised medical, nursing and 
pharmacy staff to view the patient’s medication history held on the GPs computer system 
 Case note review 6.4
Study participation is shown in Figure 6-10 and the demographic details of the 
patients admitted during the study are shown in Table 6-2, page 114. A total of 
1015 patients were identified during the study periods 930 (91·6%) were followed 
0 1 2 3 4 5
GP repeat from
Medication Administration Record chart
GP / Walk in centre / Matron letter
Patients own medicines
GP surgery (phone)
Patient, relative, carer
Patients own medication list
Previous discharge prescription
Previous medication chart
EMIS Web* *
Renal Proton system*
Mean Score out of maximum of 5 
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up. Cases were followed up until an attempt had been made to review the notes of 
at least 90% of the patients admitted in each data collection period and the target 
of 200 available sets of notes for each period, which was calculated for the VTE part 
of the study, was exceeded. In 120 cases the relevant admission documentation 
was not available in records, either the case notes relating to the admission or the 
original medication chart or both were missing, leaving 810 cases suitable for 
analysis. The majority of patients were admitted via the Emergency Department (ED) 
(56·0%) or directly from their GP (38·6%), the remaining patients were referred by 
out-patient clinics (1.9%), other hospitals (1.5%) walk in centres (1.4%), or specialist 
community nurses (0.6%). 
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Figure 6-10:  Study numbers – medicines reconciliation case note review 
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6.4.1 Difference between study periods 
The dataset for period 4 is slightly larger as more pharmacist hours were allocated 
to AMU resulting in more medication histories being checked, the difference 
between the study periods was statistically significant (chi-square test P=0.035) and 
more patients who experienced an error were identified (chi-square test P=0.025), 
but other than this similar numbers of admission observations, interviews and case 
note reviews were included in all four periods (Table 6-1, page 112 and Table 6-9, 
page 139). The number of patients experiencing an error of omission and the 
proportion of red, amber and green errors were also broadly similar in all four 
periods (chi-square test P=0.201), the data were therefore pooled for analysis. 
6.4.2 Medicines reconciliation by a pharmacist 
Medicines reconciliation was completed by a pharmacist for 688 (84.9%) patients 
overall. It was attempted for three further patients but was not possible as they 
were admitted and discharged between Friday evening and Monday morning when 
their GP surgery was closed and no other sources of information were available, 
two patients were transferred from another hospital within the Trust so a new 
medication chart was not required. Prescriptions for the remaining 117 patients 
were not reviewed by a pharmacist prior to discharge or death, about a third of 
these patients (42; 35.9%) stayed in hospital for less than 24 hours, 51; 43.6% for 
24-48 hours (see Figure 6-10) and 30 (25.6%) were admitted on a Friday. The 
proportion of patients for whom medicines reconciliation was completed rose from 
80.2% in period 1 to 82.7% in period 2, 87.9% in period 3 and 89.1% in period 4, this 
change was statistically significant when all groups were tested in a single analysis 
(chi square test P=0.011). 
Medicines reconciliation should be carried out within 24 hours of hospital 
admission according to both national35 and international108 guidelines. Over the 
course of the study this proportion varied from 43.0% in period 1 to a maximum 
67.4% in period 3 (see Table 6-9 and Figure 6-11), the change from period 1 to 
period 4 was statistically significant (chi-square P<0.001). The increase in the 
number of medication histories checked from period 1 to 4 was also statistically 
significant (chi-square P=0.035). The number of pharmacist hours allocated to AMU 
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on the pharmacy rota increased from 33 to 60 per week over the period of the 
study. 
Table 6-9  Medicines reconciliation completed by pharmacists for study patients 
 Period 1 
(Nov 
2009) 
Period 2 
(Jan 
2010) 
Period 3 
(Apr 
2010) 
Period 4 
(Apr 2011) 
Total 
Number of case notes 
reviewed 
243 / 
265 
(91.7%) 
232 / 
255 
(91.0%) 
221 / 239 
(92.4%) 
234 / 256 
(91.4%) 
930 / 1015 
(91.6%) 
Number of patients with 
documentation available 
207 202 190 211 810 
Number of pharmacist 
hours allocated to AMU 
during study week 
33 35 35 60  
Number of medication 
histories checked* 
166 / 
207 
(80.2%) 
167 / 
202 
(82.7%) 
167 /190 
(87.9%) 
188 / 211 
(89.1%) 
688 / 810 
(84.9%) 
Medication histories 
checked within 24 hours 
89 / 207 
(43.0%) 
107 / 
202 
(53.0%) 
128 / 190 
(67.4%) 
137 / 211 
(64.9%) 
461 / 810 
(56.9%) 
Number of prescribing 
errors identified/number 
items which should be 
prescribed 
163 / 
897 
18.2% 
201 / 
1016 
19.8% 
190/961 
19.8% 
297/1281 
23.2% 
851/4155 
20.5% 
*Number restricted by number of rotational pharmacist hours allocated to AMU 
 
Figure 6-11: Proportion of medication histories (MH) completed by study period 
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The percentage of patients for whom medicines reconciliation was completed 
within 24 hours varied according to their admission day of the week. Fewer patients 
were likely to have their medication checked by a pharmacist if they were admitted 
on a Friday or Saturday than if they were admitted on other days of the week 
(Figure 6-12). This difference was statistically significant when Fridays and 
Saturdays were compared with Mondays (chi-square test P<0.001; chi-square test 
P<0.001). 
Figure 6-12: Percentage of medication histories checked within 24 hours by day of 
the week 
 
6.4.3 Prescribing errors 
From the 688 medication charts for which a pharmacist completed medicines 
reconciliation, 4,155 medicines should have been prescribed (mean 6.0 per patient) 
and 851 errors were identified, therefore 20.5% of items which should have been 
prescribed had an error. The errors involved 318 (46.2%) patients, each of whom 
experienced a mean of 2.7 errors, the most common type of error was 
unintentional omission of a medicine (737; 86.7%). Other errors identified were 
dosage error (86; 10.1%), medicine accidentally restarted (14; 1.7%), medicine 
device error (11; 1.3%) and wrong medicine prescribed (2; 0.2%) see Table 6-10, 
page 142. The overall error rate for individuals where medicines reconciliation was 
carried out was 1.2 errors per patient (see Figure 6-13).  
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The proportion of items with a prescribing error increased from 18.2% in period 1, 
to 19.8% in periods 2 and 3, and finally to 23.2% in period 4 (see Table 6-9, page 
139). This change was statistically significant (chi-square test P=0.026). Three sub 
analyses showed no significant difference between periods 2 and 4 and periods 3 
and 4 when the Bonnferroni correction was applied (chi-square test P=0.049 and 
P=0.052 respectively). However there was a significant difference between periods 
1 and 4 even when the Bonnferroni correction was applied (chi-square test 
P=0.005). 
Figure 6-13: Histogram showing number of prescribing errors per patient 
 
A slightly higher proportion of errors per item was associated with patients 
admitted via the ED who were then transferred to AMU (522/2433; 21.4%; 95% 
confidence interval 19.8% - 23.1%) when compared with other routes of admission 
(328/1722; 19.0%; 95% confidence interval 17.2% - 21.0%). However this difference 
was not statistically significant (chi-square test, P=0.058). Patients admitted via ED 
were statistically no more likely to experience a prescribing error (201; 49.2%) 
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when compared with other routes of admission (117; 41.8%) (Chi-square test 
P=0.053).  
6.4.4 Assessment of potential harm from prescribing errors 
As the majority (86.7%) of the prescribing errors in the present study were 
omissions, the UKMI tool176 which was specifically developed to estimate the 
potential impact of omitted medicines was used to categorise them. Using this tool 
94/737; 12.8% were assessed as red or amber and as such had the potential for a 
significant long or short term effect on the patient. Details of the types of 
prescribing errors identified in the 688 charts for which a pharmacist completed 
medicines reconciliation and the potential impact are shown in Table 6-10. 
Table 6-10:  Details of prescribing errors identified during the study 
 Number of errors 
(proportion of total)  
Number of patients 
with error (some 
patients had more 
than 1 type of error) 
Number of 
prescribed items 
with error 
(proportion) 
Error type 
Omitted medicines 737/ 851 (86.7%) 252 / 688 (36.6%) 737 / 4,155 
(17.7%) 
Dosing error 86 / 851 (10.1%) 73 / 688 (10.6%) 86 / 4,155 (2.1%) 
Re-started in error 14 / 851 (1.7%) 11 / 688 (1.6%) 14 / 4,155 (0.3%) 
Incorrect device 11 / 851 (1.3%) 11 / 688 (1.6%) 11 / 4,155 (0.3%) 
Wrong medicine  2 / 851 (0.2%) 2 / 688 (0.3%) 2 / 4,155 (0.05%) 
Totals 851 (100%) 688 (100%) 4,155 (100%) 
Potential impact of omitted medicine (UKMI tool) 
Red (significant or 
catastrophic, long term 
patient impact) 
7 / 737 (1.0%) 6 / 252 (2.4%) 7 / 4,155 (0.2%) 
Amber  (significant, 
short term patient 
impact) 
87 / 737 (11.8%) 66 / 252 (26.2%) 87 / 4,155 (2.1%) 
Green  (negligible 
patient impact) 
643 / 737 (87.2%) 239 / 252 (94.8%) 643 / 4,155 
(15.5%) 
Potential Impact of other errors (Adapted NPSA tool) 
Major 2 / 113 (1.8%) 2 / 91 (2.2%) 2 / 4,155 (0.1%) 
Moderate 67 / 113 (59.3%) 55 / 91 (60.4%) 67 / 4,155 (1.6%) 
Minor 44 / 113 (38.9%) 34 / 91 (37.4%) 44 / 4,155 (1.1%) 
 
A small proportion of errors of omission (7; 1.0%) were as classified as red 
(significant or catastrophic, long term patient impact), most of these involved 
omission of antiepileptic medicines (5/7). The remaining errors were classified using 
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an adapted version of the NPSA risk assessment tool121 as used in a Welsh study in 
2007.48 Two were classified as having the potential to have major adverse effects 
Figure 6-14. 
Figure 6-14:  Red (significant or catastrophic) / Major prescribing errors identified 
during the study 
 
6.4.5 Rectifying prescribing errors 
The majority of errors (502; 59.0%) were rectified within 24 hours and over two-
thirds (587; 69.0%) within 48 hours of being identified and documented in the case 
notes by pharmacists. Therefore errors identified were corrected within 24 hours 
for 224/318 (70%) patients. Both the ‘NPSA major’ errors were rectified as soon as 
they were identified and four of the ‘red’ errors (all antiepileptic medicines) within 
24 hours. However it took between 24 and 48 hours for carbamazepine, an 
antiepileptic medicine, to be prescribed for one patient who had been admitted 
following a stroke and longer than 72 hours for azathioprine, an 
immunosuppressant, to be prescribed for a patient who was admitted with an 
infective exacerbation of COPD. It was impossible to determine the time taken to 
rectify the Humalog insulin error as either the medicines reconciliation record or 
the prescription had not been dated. 
 Discussion 6.5
This part of the study provides a novel insight into how prescriptions are written on 
admission to hospital and the possible causes of prescribing errors on admission, 
which are widely reported in the literature as forming a significant proportion of all 
prescribing errors. 
Omission  
• Azathioprine 
• Carbamazepine x 2 
• Humalog insulin 
• Sodium valproate x 3 
 
Wrong dose / medicine  
• Calcichew should be 
cinacalcet 
• Dalteparin - too low - pt 
has pulmonary embolism 
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6.5.1 Information sources 
The sources actually used for obtaining medication histories during the 
observations matched those most frequently cited by staff during the interviews as 
being sources they commonly used. Although almost all of doctors interviewed 
indicated that they would sometimes or always use more than one source to 
confirm medication histories the observations showed that a single source was 
used in almost half of cases. This is at variance with national guidance for England 
and Wales from NICE35 and other published guidance44, 105, 106 which suggests that 
at least two sources should be used. The WHO definition for “Best Possible 
Medication History” also states that the patient should be interviewed where 
possible and that the medication currently being taken by the patient should be 
verified with more than one source.103 The observations showed that even when 
printed information is provided this can be misinterpreted leading to prescribing 
errors, further supporting the published guidance which states that more than one 
source should be used whenever possible. The observations provide useful 
information about the actual sources used by doctors when determining 
medication histories as there are no data available in published literature.  
6.5.2 Communication with patients 
From the observations it was apparent that several patients or their carers were 
able to provide information but were asked no questions relating to medicines, 
despite this being an integral part of the standard hospital clerking model.20 The 
numbers in the study were too small to suggest any particular reason for this 
omission however during the interviews six doctors did allude to the perceived 
unreliability of information provided by patients.  
Although seven of the twelve doctors interviewed who were also observed 
indicated that they would confirm current medication with the patient, the 
observations showed that these doctors only did so in two of the 20 patients they 
admitted between them, suggesting that although the theory is understood, 
application in practice is less simple. Overall, confirmation of the prescription with 
the patient occurred infrequently despite overt acknowledgement by three doctors 
that patients may not take their medicines as prescribed. A UK study has shown 
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that as many as 11% of errors identified on admission may be as a result of a 
patient decision to alter their treatment regimen.126 It has been shown that 
patients make decisions about taking medication based on personal experience, 
financial issues and their relationship with their GP over time.243 Other studies have 
also highlighted the differences between the perceived and actual practices of 
healthcare professionals.244, 245 One doctor commented that time pressures were an 
issue when talking to patients about their medication. A recent study showed that 
medication history taking for medical patients takes a considerable length of 
time,126 NICE suggests that 15 minutes will be needed for the ‘average’ non elective 
patient,104 complex medical patients are likely to require longer. As the RCP states 
that all patients should have an action plan together with review criteria in place 
within four hours of arrival on AMU,22 at busy times of the day medical staff may 
struggle to achieve this goal. Both the EQUIP study109 and the PROTECT 
programme114 reported time pressures and high workload as being contributory 
factors to prescribing errors. 
6.5.3 Medicines reconciliation rates 
The present study showed that overall pharmacists completed medicines 
reconciliation for 84.9% of patients and that 56.9% were carried out within 24 
hours of admission. These results are similar to those found in a study carried out 
50 acute Trusts in East and South East England in 2010 which found that medicines 
reconciliation was completed for 87% of patients, with 52% within 24h of 
admission,129 in 2013 a large Welsh study showed that 55% were complete within 
24 hours.246 Delays arise particularly when patients are admitted between Friday 
night and Monday morning when most hospital pharmacies offer a limited service 
which often does not include medicines reconciliation. There is currently no 
benchmarking figure for the proportion of medicines reconciliations which should 
be carried out within 24 hours of admission. The technical patient safety solution 
published by NICE in 200735 simply states that medicines reconciliation should be 
carried out on admission to hospital, no time frame is specified, however the 
associated costing template is based on the assumption that it will be completed 
within 24 hours of admission.104 The RPS published professional standards for 
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hospital pharmacy services in 2012 and state that ideally medicines reconciliation 
should be completed within 24 hours,38 key performance indicators are currently in 
development. The current data both from the present study and the South East of 
England study which show that medicines reconciliation is completed for only 50% 
of patients within 24 hours of hospital admission is unlikely to remain acceptable, 
local or national targets are likely to be much higher but achievement of near 100% 
is likely to require a move to 7 day a week shift patterns in line with government 
policy.247 Any targets will need to define clearly the time of hospital admission to 
enable accurate comparison of Trusts as this may be defined as the time the patient 
arrived at the hospital or the time at which it was decided that they required 
admission, these times may differ by several hours. 
6.5.4 Prescribing error rates 
The error rates found in the present study are similar to those reported elsewhere, 
although there are difficulties in making comparisons between studies as 
‘prescribing error’ is not always defined248 and the results may be expressed in 
different ways e.g. number of errors per 100 bed days, number of errors per 
admission.115, 117 The present study found an overall error rate of 1.2 errors per 
patient admitted  which is slightly higher than the rate of 0.93 per patient reported 
in a Canadian study by Cornish et al.122 However in the latter study data were 
collected 48 hours after admission to enable usual practices in the hospital to 
correct any errors made whereas in the present study the data collected included 
all errors made on admission, whether or not they had been corrected at the time 
of the case note review, which may account for the difference. The present study 
showed a much lower error rate 48 hours after admission, 264 errors affecting 
94/688 patients, 0.38 errors per patient admitted possibly due to pharmacists’ 
vigilance in highlighting errors to medical staff. The present study found prescribing 
errors in 20.5% of the medicines which should have been prescribed which is 
comparable to results published in a recent English study which reported a rate of 
16.3% for medical admissions.112 A systematic review found that overall prescribing 
errors affect 50% of patients115 which is similar to the rate of 46.2% found in the 
present study. The average number of medicines which should have been 
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prescribed per patient was 6.0 which is slightly higher than the figure of 5.4 
reported in a Dutch study by Lau et al,249 the data for this study were collected 
between 1993 and 1995 which may account for the difference, but is identical to 
the number quoted in a similar study carried out in the study hospital in 2004.46 The 
most common error in the present study was omission of a medicine usually taken 
by the patient, 737/851; 86.6% of cases, which is in line with the findings of studies 
from Belgium,47 Sweden250 and Wales.48 Patients admitted to AMU via the ED 
rather than being referred directly to AMU from primary care were no more likely 
to experience a prescribing error. This was a surprising finding as it has been 
suggested in the literature that patients in the ED may be at greater risk of an 
error.251, 252 This may be partly explained by the fact that EMIS-Web, the prescribing 
system used by the majority of GPs in Liverpool is available in the ED department 
although a limited number of staff are able to access it.  
Although the error rate in the present study is similar to that in the published 
literature and the majority of errors were unlikely to cause significant harm to the 
patient it is unacceptable that one in every two patients is likely to experience a 
prescribing error on admission to hospital. The present study showed that a third of 
errors which had the potential to have a significant clinical impact on patients 
involved either insulin or antiepileptic medication. Highlighting the increased 
potential for a serious error to medical and nursing staff and prioritising these 
patients for early pharmacist review may help minimise the risk of a long term 
patient impact. 
6.5.5 Training of medical staff 
All doctors on qualification should be able to establish an accurate medication 
history,19 and this has been highlighted as a core skill necessary for safe prescribing 
by the British Pharmacological Society curriculum for teaching safe and effective 
prescribing.253, 254 Limited information is available in the literature regarding the 
most effective way to train medical students to prescribe,255, 256 and only two 
papers providing specific guidance about medicines reconciliation for medical 
students or junior doctors have been identified.44, 105 These papers confirm the 
need for at least two sources to be used for medicines reconciliation and highlight 
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some of the common pitfalls. In the present study two of the doctors did not feel 
that their training had prepared them adequately for their prescribing role. 
Similarly an Australian study in 2008257 found that medical students felt ill-prepared 
to undertake prescribing and concluded that more work is needed to prepare them 
for this role. A recent (2010) study from New Zealand showed that a campaign 
targeted at junior medical staff including teaching sessions, reminders and posters 
was effective in reducing prescribing errors on admission to hospital.258 
6.5.6 Impact of prescribing errors 
As the majority (737/851; 86.7%) of the prescribing errors in the present study were 
omissions, a tool specifically developed to estimate the potential impact of omitted 
medicines was used to categorise these errors,176 12.8% were assessed as red or 
amber and as such had the potential for some clinical impact on the patient. 
However the majority of omissions were likely to have a minimal impact on patient 
care which is in line with the findings of a recent meta-analysis.259 
Few studies have attempted to assess the impact of prescribing errors and those 
that have used different tools. A study from Wales using an adapted version of a 
tool developed by the NPSA121 classified 20% of errors as ‘major’ or ‘moderate’,48 
other studies using consensus panels to estimate impact have reported 32.9% of 
errors could potentially cause moderate discomfort or clinical deterioration257 and 
26% were potentially serious.123 The majority of doctors interviewed were unaware 
of the proportion of patients at risk of prescribing errors with the majority 
underestimating error rates as below 30%, in contrast to the 50% reported in the 
literature115 and the proportion in the present study of 46.2%. Dean et al260 note 
that this may be partly due to the fact that pharmacists frequently identify and 
correct errors without reference to the prescriber. Following up errors takes 
considerable time and if prescriptions are handwritten it may be difficult to identify 
the prescriber from the medication chart.261 Doctors may prescribe for patients on 
many different wards when on call so signatures may be unfamiliar to the regular 
ward staff, the increasing use of electronic prescribing systems in the NHS should 
overcome this difficulty. In addition the restriction of doctors working hours by the 
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European Working Time Directive (EWTD)262 means that they have often gone off 
duty when their errors are discovered. 
6.5.7 Effect of admission at weekends 
The present study showed that patients were significantly less likely to have their 
medication reconciled by a pharmacist within 24 hours of admission if they were 
admitted on a Friday or a Saturday. The Doctor Foster report published in 2011263 
showed that patients who are admitted to hospital on a Saturday or Sunday when 
fewer senior doctors are available have an increased mortality rate when compared 
with patients admitted on weekdays. As the process of clerking a patient on 
admission takes several hours medicines reconciliation by pharmacists is frequently 
carried out on the day following admission, on a Saturday for Friday admissions and 
on a Sunday for Saturday admissions. The pharmacy in the study hospital has a 
reduced service on Saturdays and Sundays which explains the delay in medicines 
reconciliation for many patients admitted on Fridays or Saturdays. A study carried 
out in 56 Acute Trusts in England in 2008129 found that limited weekend availability 
of pharmacy services had a limited impact on both the extent and time scale of 
delivery of medicines reconciliation. However it is difficult to make a direct 
comparison with this study due to the differences in methodology, in addition this 
study was carried out shortly after the NICE alert was issued and enthusiasm may 
have faded in the interim. It is possible that lack of accurate information regarding 
patients’ medication is a contributory factor in the increased weekend mortality 
rate but further research is needed to investigate the impact. 
6.5.8 Suggestions for reducing prescribing errors 
Some simple procedural changes may help reduce errors for example keeping any 
medication which patients bring into hospital with them throughout their journey 
through the hospital. In ED doctors often use the patient’s own medicines to write 
the initial prescription and then return it to the relatives and advise them to take it 
home. However it is extremely difficult to ensure that patients’ own medicines are 
not sent home in a large organisation in which medical staff change jobs frequently, 
the study hospital ED has over 20 junior doctors who rotate every four months. 
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A meta-analysis published in 2012 concluded that there are limited data regarding 
the most effective interventions to improve medicines reconciliation264 however 
the present study did suggest some actions which may prove particularly successful. 
Raising awareness of both the level of risk and the potential seriousness of many 
errors may help to achieve a reduction, but doctors may also require practical 
guidance regarding the need to check more than one source, and especially the 
need to confirm the medication history with the patient before prescribing, 
whenever possible. Training in areas in which knowledge was found to be lacking 
for example different colours and types of inhaler, preferably by supervising 
medical students while taking medication histories and providing feedback 
information to staff about actual errors may also be beneficial. Education is also 
needed to ensure that medication histories are written up fully in the case notes 
and a prescription chart is prepared for each patient who is admitted, even if no 
regular medication is taken, as considerable time can be wasted searching for 
missing charts and finding an appropriate doctor to prescribe. However, training 
alone may not result in a significant reduction in errors as doctors appeared to 
know the theory but failed to apply it in practice which suggests that some other 
factors are contributing to the problem. Two other studies in the literature highlight 
the differences between perceived and actual practice, the first involves dentists 
and their treatment practices and used questionnaires and audit of the actual 
records,244 the second, a large international study, used semi-structured interviews 
and case note review and showed that the knowledge of primary care physicians of 
the symptoms of heart failure was not reflected in the audit of their practice.245 
Staff comments about difficulties arising out of normal working hours when access 
to GP information was limited are also important considerations. Expanding the use 
of systems such as EMIS web265 or a system similar to the emergency care summary 
(ECS) used in Scotland266 which enable all authorised NHS staff to view the patients 
current medication and any allergies, may go some way to addressing this issue. 
Access should be extended to junior grades of staff who provide the ‘out of hours’ 
services in hospitals, frequently it is restricted to ‘consultant only’. 
151 
Earlier involvement of the pharmacy team in the admission process was suggested 
by two of the doctors. Studies from Scotland,267 Australia268 and the USA269 have 
shown that fewer doses are missed if a pharmacist completes a medication history 
in the ED, before relatives depart home, taking with them the vital information 
available from patients own medication. In addition studies in the UK,46, 270 USA110 
and Belgium47 have repeatedly demonstrated that pharmacist–documented 
medication histories are more accurate than those gathered by doctors. This finding 
is supported by the request for assistance from the pharmacist researcher during 
13 (19%) of the 68 admissions observed and the need to intervene on two 
occasions to prevent a serious prescribing error.  
 Summary 6.6
The results relating to medicines reconciliation have been discussed above; this 
concludes the presentation of the results of the study, the final discussion and 
suggestions for further research are presented in the next chapter.b 
 
                                                     
b
 Some of the findings in the chapter have been published in BMJ Quality and Safety 2013: Basey AJ, 
Krska J, Kennedy TD, Mackridge AJ. . Prescribing errors on admission to hospital and their potential 
impact: a mixed-methods study.   BMJ Qual Saf. 2014;23:17-25. 
Available from: http://qualitysafety.bmj.com/content/early/2013/08/06/bmjqs-2013-001978.full 
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Chapter 7 Overall Discussion and Conclusion 
The previous three chapters have presented and discussed the findings of the study 
for the medical admissions process, VTE risk assessment and medicines 
reconciliation. This chapter draws together these results and provides the overall 
conclusions for the study. 
 Critique of methodology 7.1
It has been suggested that qualitative methods, particularly observation, are 
valuable when investigating errors in healthcare.271 However although non-
participant observation of the consultation process has been used in studies of 
various aspects of healthcare, such as patient dignity and patient mealtimes,152, 153, 
155, 156, 272, 273 there are few studies in which this methodology has been used to gain 
insight into the hospital admission process. One study, investigating the 
documentation of allergies in children on admission to hospital,163 has used similar 
methodology during the admission process. However there are no studies in the 
literature which have used non-participant observation to investigate the admission 
process as a whole or specifically either VTE risk assessment or medicines 
reconciliation, non-participant observation is therefore a novel methodology in this 
setting. A recent study used observations, questionnaires and audit to investigate 
organisational safety cultures and quality of care274 but no studies in healthcare 
using observations, staff interviews and audit of case notes were identified.  
In order to gain as much information as possible the present study employed both 
qualitative methods in the observations and interviews and quantitative methods 
for the case note audit. In depth information about current practices on admission 
to hospital was gained by triangulation of the findings from these three 
methodologies. 
7.1.1 Difficulties experienced in carrying out the study 
Observing a significant number of patient admissions during a shift proved difficult 
to achieve, considerable time was spent waiting for a member of staff to 
commence clerking as the process takes over an hour and it was impossible to 
predict when a doctor or nurse would be free to see the next patient. As patients 
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referred by GPs generally arrived between 11am and 6pm and few patients were 
clerked between 3pm and 5pm due to the post-take ward round, it was frequently 
necessary to stay late into the evening to complete the data collection. Early in the 
study it became apparent that patients would often refer to the pharmacist 
researcher rather than the clerking doctor / nurse, probably due to her seniority, so 
whenever possible she stood out of the line of vision of the patient to minimise her 
impact on the staff / patient interaction. 
Arranging interviews proved challenging as appointments were often cancelled at 
very short notice due to the unpredictable nature of hospital work. Securing an 
interview often involved bleeping staff on multiple occasions to see if they were 
free at that time, even when this strategy was used on occasion by the time the 
researcher arrived on the ward there had been an unexpected development which 
resulted in cancellation. Venues therefore could not be booked in advance and so 
the most suitable available location close to the relevant ward area had to be used, 
frequently waiting areas, coffee bars and changing rooms which were not ideal. 
The most effective method of retrieving information from case notes proved to be 
visiting the ward on the day of or the day after patient discharge, before the case 
notes were returned to the Trust case note library. As the library is off site notes 
which had been returned to file had to be ordered and frequently the correct 
volume and /or the medication chart were missing. Auditing the notes on the ward 
allowed desks and filing trays in the ward area to be searched for missing 
medication charts enabling a more complete data collection than would otherwise 
have been achieved but necessitated working several seven day weeks. 
As the researcher was a regular member of AMU staff she was frequently asked for 
advice or to carry out tasks such as authorising discharge prescriptions while she 
was waiting to observe staff. Where possible questions were answered and short 
tasks carried out, where this would not compromise data collection, in order to 
maintain good working relationships, otherwise an apology and explanation about 
the research project was given. 
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7.1.2 Strengths 
The research instruments were developed in a robust way with input from both 
experienced health services researchers and a senior clinician working on the AMU, 
they were piloted prior to the study to ensure that they were of an appropriate 
standard to meet the study requirements. 
The case note review provided real outcome data and included all the observed 
patients plus the population admitted during study periods and enabled the 
representativeness of the observed patients to be assessed. The main strength of 
this study is in the triangulation of data derived from interviews with a proportion 
of the staff observed, for both the VTE and medicines reconciliation arms, helping 
to explain some of the findings from the observations. This is in contrast to many 
published VTE studies which focus on audits of risk assessments and less frequently 
appropriate prescribing of prophylaxis rather than investigating the possible causes 
for poor compliance with guidance. Similarly the majority of papers about 
prescribing errors focus on the number of prescribing errors rather than 
investigating the cause of such errors. 
A power calculation was carried out for the VTE case note audit to estimate the 
minimum necessary sample size necessary to facilitate statistical comparison 
between study periods; this was exceeded for all four study periods with a very high 
percentage of case notes being successfully followed up. 
Adequate numbers of observations and interviews were completed to characterise 
practices relating to VTE risk assessment and documenting of medication histories 
in the study hospital. 
A recently introduced national tool was used to assess the impact of errors of 
omission which may allow direct comparison with other published studies in the 
future. Its objective rather than subjective nature is a further strength. 
7.1.3 Limitations 
Limitations are that the study was carried out in one hospital, therefore the 
practices observed and opinions expressed may not be representative of other 
hospitals. Only doctors observed in period 4 were interviewed about medicines 
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reconciliation, but additional interviews maximised the proportion of AMU staff 
included in this arm. All the interviews were carried out sequentially and although 
all staff agreed to keep the subject matter confidential and no evidence was found 
to suggest that it was breached, it is impossible to be certain that confidentiality 
was maintained. The researcher is a regular member of the AMU staff which may 
have impacted on staff behaviour during observations. Staff responsible for clerking 
patients may have modified their usual behaviour as they were aware that they 
were being observed, this is known as the Hawthorne effect.172 The time taken to 
clerk patients was recorded, with hindsight it would have been useful to know the 
time taken to complete a VTE risk assessment and also to write the admission 
prescription. However as these tasks were often carried out in a fragmented way 
throughout the admission process it is likely to have proved difficult to collect 
accurate data. 
The interview schedules were not piloted however the researcher’s extensive 
clinical experience enabled suitable questions to be devised, no problems or 
potential additions were identified during their use. 
For the VTE arm of the study, the staff interviewed were not asked about any 
recent changes to their practice regarding VTE risk assessment. Practices may have 
changed during the study due to local and national pressure, however all VTE 
interviews were completed before the NICE guidance was released or data 
collection became mandatory. 
For the medicines reconciliation arm minor discrepancies such as missing SR or EC 
preparations were excluded from the definition of a prescribing error used in the 
study, which may have resulted in a reduced number of prescribing errors being 
recorded in comparison to other published studies. Independent pharmacist 
medicines reconciliation was only available for 67% of the total number of patients 
admitted during the study periods, due in part to limitations in the capacity of the 
pharmacy service and unavailability of the necessary documentation. However as 
patients’ mean age was very similar for those patients for whom medicines 
reconciliation was and was not completed and the three most common presenting 
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complaints were identical for both groups, there is no reason to suspect that either 
the number of regular medicines or the number of prescribing errors would differ 
between those patients whose prescriptions were, and those whose were not, 
reviewed by a pharmacist. 
 Discussion of main findings 7.2
7.2.1 National guidance 
VTE and medicines reconciliation were selected for investigation as they are both 
known to present particular risks to patients on admission to hospital. The first 
national guidance was issued for both of these risk factors at around the same time, 
an NPSA/NICE patient safety alert was issued for medicines reconciliation in 
December 200735 and the first VTE risk assessment tool was issued by DH in 
September 2008.34 Early audits in the study Trust in 2008/09 showed that 
compliance with both sets of guidance was poor.  
NICE was established in 1999 to minimise the variation in procedures and 
treatments available in the NHS and to promote evidence based practice through 
the issue of clinical guidelines.30 There are now 181 published clinical guidelines all 
of which require implementation across the NHS. In addition 49 quality standards 
have been published with many more in development.31 Whilst not all guidance is 
relevant to all clinical areas a large majority will require implementation in AMUs 
where patients with a wide range of medical conditions are treated.  
This study enabled a comparison to be undertaken in a single setting of the 
implementation of national guidance in two areas, where the source, form and 
nature of the guidance differed. Although the study was limited to one AMU in one 
hospital, it has relevance to hospitals throughout England. National bodies in 
several countries275-279 have also issued similar guidance on these two topics; hence 
the work is also of relevance beyond England.  
7.2.1.1 Venous thromboembolism 
Following publication of the initial VTE risk assessment tool in 2008, NICE guidance 
for VTE risk assessment43 was launched in January 2010 with associated press and 
TV coverage to raise awareness, a revised tool for risk assessment201 was issued in 
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March 2010. Monthly collection of VTE audit data was made mandatory by the 
government in June 2010 and VTE risk assessment was one of the first quality 
standards,280 with financial penalties for failure to achieve the target, to be issued 
by the DH in the same month. Implementation of  VTE guidance in acute hospital 
Trusts has been audited annually by the All-Party Parliamentary Thrombosis Group 
since 2007, the most recent report  being for 2012,281 and VTE has been included in 
the NHS outcomes framework from  2001/1298 to date (2013/14).37 
7.2.1.2 Medicines reconciliation 
Following the circulation of the NICE/NPSA medicines reconciliation alert35 and 
associated costing template104 in 2007, there has been no further guidance or audit 
requirements issued by the government. There is no national target and no 
mandatory audits are required. Medicine reconciliation was included in the 
professional standards for hospital pharmacy services published by the RPS in 
201238 which state that this should take place within 24 hours of admission. 
However these standards are to aid service development, they do not include 
mandatory targets.  
7.2.2 Comparison of VTE and medicines reconciliation results 
The study observations showed that policies and guidelines were frequently 
ignored, at the start of the study no patients had a VTE risk assessment completed, 
contrary to national guidance34 and Trust policy. Medication histories were 
confirmed using a single source by almost half of doctors with the admission 
prescription being checked with the patient in only 21% of cases, again contrary to 
national guidance.35 
The VTE and medicines reconciliation interviews in the present study identified 
some similar themes, doctors were generally unaware of local and national 
guidance for both VTE and medicines reconciliation, they were ignorant of the risks 
of VTE and were oblivious of the proportion of patients who experience a 
medication error on admission to hospital. Lack of time was raised as an issue in 
relation to both completing VTE risk assessment and when discussing medication 
histories with patients.  
158 
The results of the case note audit show that both the number of patients VTE risk 
assessed and the number who received prophylaxis with LMWH appropriately rose 
significantly following the introduction of mandatory risk assessment. Medicines 
reconciliation also improved over the course of the study, there was a significant 
increase in both the number of patients for whom medicines reconciliation was 
carried out and the proportion completed within 24 hours. This was attributed to 
the increased number of pharmacist hours allocated to AMU as there were no local 
or national initiatives or changes in procedure to account for the increased rates.  
However, there were also some adverse outcomes noted in the results. There was a 
statistically significant increase in the number of patients who were inappropriately 
prescribed LMWH prophylaxis as they had bleeding risks. In addition the Trust data 
showed a statistically significant increase in the number of patients with a discharge 
diagnosis of GI haemorrhage from 2009 to 2011 which may be associated with the 
increased use of LMWH. In the medicines reconciliation arm of the study the 
proportion of items with a prescribing error rose, indicating deterioration in the 
quality of medication history taking by medical staff, with a significant difference 
between periods 1 and 4 which is of concern. It is difficult to explain this difference, 
there was no change in workload as the weekly number of admissions in the study 
periods remained constant and there was no change in the staff numbers. It is 
possible that there were differences the competence of the staff group in period 4 
or it could be postulated that the Trust focus on VTE resulted in a lack of focus or 
accuracy in other areas. 
7.2.3 Guideline implementation 
Implementing clinical guidelines in practice is recognised as being difficult.282, 283 
Various systematic reviews have examined the difficulties of implementing 
guidelines, one concluding that there is no ‘magic bullet’ in terms of the most 
effective strategy for implementation in hospitals.283 In addition an international 
survey of agencies responsible for guideline development showed that few had 
dedicated staff or financial resources for implementation.284 Barriers identified to 
guideline implementation have been classified into three broad categories, 
knowledge, including lack of familiarity and awareness, attitudes, including failure 
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to believe that the intervention will have the desired outcome and behavioural 
factors, such as lack of time.133 
It has also been shown that awareness of personal adherence may be a factor in 
implementation of guidelines,285 in the present study many staff were shocked to 
learn of audits showing poor compliance with VTE guidelines and the considerable 
proportion of patients experiencing a prescribing error on admission to hospital. 
Therefore more regular audits together with personal feedback where possible may 
improve guideline implementation. This may be facilitated by electronic prescribing 
systems which should allow prescribers to be identified with ease. 
A meta-analysis published in 2004 showed that single strategies such as 
dissemination of education materials, audit together with feedback and reminders 
led to a small improvement in guideline implementation.286 A study from 2008 
suggested that dissemination of printed materials alone is of limited benefit in 
changing professional practice,287 which is in line with findings of the present study 
as policies for both VTE prophylaxis and medicines reconciliation were initially 
circulated in isolation. For VTE guidance implementation it has been shown that 
multiple strategies are more effective than single strategies.229, 230 As early 
strategies to improve VTE risk assessment in the study were introduced sequentially 
(Figure 5-1, page 68), this may explain why they proved ineffective. 
Small group training with active participation has been found to be effective in 
policy implementation in contrast to courses alone which had mixed effects.288 In 
the present study, most staff had received training in lecture format, whether for 
VTE prophylaxis or medicines reconciliation, which may explain the failure to 
comply with guidelines.  
A recent study from Israel highlights the benefits of verbal reminders from 
colleagues when staff deviate from agreed guidelines.137 In the latter study the 
proportion of staff who wore gloves when inserting an IV cannula or taking a blood 
sample rose from 55% to over 80% when reminded to do so by colleagues. 
Champions or opinion leaders to lead guideline implementation have been 
identified as important facilitators to a successful outcome,289 and appear to be as 
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effective as other strategies to implement evidence based practice.290 In the 
present study VTE risk assessment improved dramatically when the AMU 
consultants took responsibility for leading practice and constantly reminded junior 
staff during ward rounds that VTE risk assessments must be completed for each 
patient.  
7.2.4 Financial incentives and penalties 
NHS England is currently reviewing financial incentives and sanctions and has 
published a discussion document for stakeholders291 in order to determine how to 
ensure that the incentives and penalties deliver both the desired outcomes and 
high quality care. This should help address some of the issues identified by the 
Cochrane review236 and the London analysis of the CQUIN scheme240 such as the 
fact that quality may not equate with performance as comments about this aspect 
are specifically requested. The discussion document also asks whether the current 
range of sanctions is manageable for NHS Trusts which goes some way to 
recognising the resources required to effectively implement change and collect 
audit data. 
7.2.5 Education and training 
A recurrent theme identified during the interviews for both VTE and medicines 
reconciliation was the paucity of specific training provided. Almost half of those 
interviewed about VTE had had no training and although the majority of doctors 
said that they had received training in taking a medication history at university the 
majority were unable to recall any details. The outcomes to be delivered by 
undergraduate medical training are published by the GMC19 however each medical 
school designs its own curriculum to deliver training. Hence students may have had 
very different levels of training or experience in specific aspects of medicine 
depending on the medical school attended, their time since graduation and also 
their clinical placements. The training outcomes to be delivered for newly qualified 
doctors who are provisionally registered are also published by the GMC292 and 
postgraduate medical deaneries are responsible for ensuring that outcomes are 
met, however once again individual experience is variable. If new guidance is to be 
implemented effectively then a comprehensive education strategy is required to 
161 
ensure that all appropriate staff understand the rationale behind it and their role in 
its implementation. 
7.2.6 Admissions process 
There appeared to be no formal induction for medical staff working on the study 
AMU which resulted in reduced efficiency and contributed to delays in the 
admission process and implementation of guidelines and best practice. The 
introduction of a brief induction for all staff in which they are given an overview of 
the AMU working procedures, shown the location of key items such as paperwork 
and the equipment store and the meanings of the various symbols on the 
whiteboard explained should help to improve the situation. As doctors rotate very 
frequently inductions would be required on an on-going basis and would be most 
effective if carried out by a regular AMU staff member such as the nurse clinician 
and/or the senior AMU nurses. A checklist of important tasks to be carried out for 
each patient including VTE risk assessment may also be useful. At the start of their 
first AMU ward round an explanation by the lead consultant of the format of the 
ward round, the reason for the various mandatory risk assessments including VTE 
and the individual’s responsibility in the process may be effective. In the longer 
term moving to a greater proportion of AMU based staff rather than ‘hot-block’ 
rotational doctors would ensure that those responsible for clerking were more 
familiar with the AMU working environment and therefore less likely to make errors. 
 Personal reflections 7.3
For both VTE risk assessment and medicines reconciliation the poor compliance 
with national guidance appeared to stem partly from a lack of awareness, both of 
the guidance and the associated risks, by staff and partly from unwillingness to 
complete additional paperwork. As expected targets imposed by government 
resulted in a focus on VTE by the Trust board, consultants were required to explain 
why results were poor and as a consequence they took a greater interest in VTE and 
led implementation of the guidance. The increase in prescribing errors is more 
difficult to explain. It seems unlikely to be due to a change in the competence of 
medical staff as the numbers and grades remained constant throughout the study. 
The number of patients admitted via AMU also remained constant so it was unlikely 
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to be due to workload pressure. However as the study progressed more beds in the 
hospital were closed resulting in an increasing shortage. It is possible that doctors 
were under pressure to clerk patients more rapidly, so that the bed could then be 
made available for the next waiting patient, resulting in a reduction in attention to 
detail and more prescribing errors.  The increased number of pharmacist hours 
available for medicines reconciliation in the final study period may also have had an 
impact. This additional time may have enabled pharmacists to be more diligent in 
the medicines reconciliation process and allowed identification and/or 
documentation of more errors.  
 Personal skills developed 7.4
As an experienced hospital pharmacist during my career I had gained significant 
experience in five of the six clusters of competencies required for a consultant 
pharmacist293 namely expert professional practice, building working relationships, 
leadership, management and education and training. However I had little 
experience of the final cluster, research and evaluation. As a result of completing a 
PhD I have gained skills in planning a research study, submitting an ethics 
application, using different research methodologies, using data analysis tools such 
as SPSS and Minitab, preparing abstracts and posters and presenting research 
findings orally at conferences. I have also learnt how to write for publication having 
had two papers published prior to submitting my thesis. I have used my research 
skills to help two post graduate pharmacy diploma students to develop proposals 
for audits and hope to assist a newly recruited PhD student with her studies. In the 
future I hope to be able to continue to do some research as part of my consultant 
pharmacist role, publish my findings and further develop my skills. 
 Implications for research and practice 7.5
The use of observations, interviews and audit of case notes proved to be a 
successful methodology for gaining a broad, yet in depth picture of staff 
perceptions, practices and outcomes in relation to the implementation of VTE and 
medicines reconciliation guidance. The use of this methodology may be useful for 
investigating other aspects of healthcare when effecting a change in practice is 
proving difficult and the contributory factors are unknown. 
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 Since data collection was completed the study Trust has made a number of 
changes to improve both efficiency and patient safety as a result of a brief report, 
based on incidental observations made during the study, which was provided at the 
request of the Divisional Medical Director (see section 4.4.7, page 66). However 
further changes, such as providing a brief induction for all new staff and having a 
nominated team leader for ‘hot block’ doctors would also help to improve working 
practices. Staff in Nottingham180 analysed their workload and changed the medical 
rotas to match the peaks in demand, the data presented in the results of this study 
may help  the study Trust to make similar changes.  
Implementing national guidance proved to be suboptimal, which is of concern given 
the quantity of guidance issued by NICE requiring implementation and the number 
of quality standards which have to be adhered to by NHS Trusts. When 
implementing guidance it should not be assumed that all outcomes will be positive 
as this study showed that although implementation of VTE guidance did reduce the 
risk of developing a clot for the majority of patients, there was an increase in the 
number of patients who received LMWH inappropriately and a small minority 
developed bleeding as a result of prophylaxis with LMWH. 
Staff knowledge was part of the reason for failure to implement guidance and 
providing appropriate education in a timely way remains a challenge when staff 
change jobs every few months. The mandatory Trust induction programme is very 
intensive and much of the information provided is soon forgotten as staff have to 
learn their new roles. Information is more likely to be remembered if it is provided 
when needed, an introduction to AMU in general by nursing staff and ward round 
procedures by a consultant as described above may be more effective. Training in 
medicines reconciliation is more likely to be effective if it takes place on the wards 
so that medical students / junior doctors see the real problems, learn how to 
overcome them and the potential adverse outcomes can be discussed. However 
this is very labour intensive for pharmacy staff, who are the medicines experts and 
therefore best placed to provide this training, and so may not be a practical solution 
in all Trusts. 
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Both VTE risk assessment and medicines reconciliation are patient safety issues and 
thus it is extremely important to the study Trust that these risks are minimised. A 
government focus has resulted in a significant reduction in the VTE associated risks 
on admission to hospital although regular audits are required to ensure that 
standards are maintained. However the medicines reconciliation results show that 
almost half of patients have an error in their admission prescription and this 
proportion has increased over time. Both the proportion of patients for whom 
medicines reconciliation was carried out overall and the proportion completed 
within 24 hours of admission out increased when a greater number of pharmacist 
hours were allocated to AMU. This should prompt a review of the provision of 
pharmacy clinical services within the study Trust with a greater focus on newly 
admitted patients to ensure that medication errors are resolved as early as possible 
in the patient’s admission. A recent document published by the Academy of Royal 
Colleges should support reconsideration of pharmacy weekend services.294 
 Suggestions for further research 7.6
Further research is required to assess the applicability of the results from this study 
to different hospital environments e.g. district general hospitals and the private 
sector. Visits to two other local AMUs during the study period demonstrated a 
number differences including bed allocation, such as the inclusion of ‘short stay’ 
beds within the AMU, staffing levels, shift patterns and frequency and duration of 
ward rounds. Investigation of the characteristics and operational procedures of 
different AMUs may help to identify those factors which constitute the ‘ideal’ AMU 
in order to provide the best possible care within the available NHS resources. 
No publications were identified in the literature which used the UKMI tool for 
omitted medicines176 to assess the impact of prescribing errors of omission 
therefore further work is required to validate the results from this study. 
Trust data showed that there was a significant increase in GI bleeds from 2009 to 
2011 when routine VTE prophylaxis with LMWH was introduced for medical 
patients. This requires further investigation of the patients involved to ascertain 
whether the use of LMWH is causative or whether other factors are involved. 
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Staff in both the VTE and medicines reconciliation arms of the study appeared to 
know the theory but failed to apply this in practice, further research is needed to 
understand why this happens in order to improve patient care. A study from The 
Netherlands involving physiotherapists285 investigated the role which personal 
awareness of behaviour has in guideline implementation, those who were aware of 
their own adherence to low back pain guidelines were more likely to comply with 
the guidance. It would be interesting to carry out a similar study to investigate 
prescribing on admission to hospital. As electronic prescribing systems become 
more widely used it should be possible to identify prescribers more easily and 
provide individual feedback on prescribing error rates. The prescribing error rates 
of those who were given personal feedback and those who were not could 
potentially be compared. 
The study raised some issues regarding medical education and how staff keep up to 
date with new guidance and recommended changes in practice. Further research is 
required to better understand the processes involved in implementing new 
guidance effectively including barriers and facilitators. Despite new ways of 
delivering medical education, such as problem based learning, a recent study shows 
that new doctors still feel inadequately prepared for managing acutely unwell 
patients and prescribing,295 hence further research into the most effective methods 
of teaching these skills would be beneficial. Some medical schools including 
Liverpool are now involving pharmacists in medicines reconciliation training, it 
would be interesting to investigate whether or not new doctors who have received 
ward based pharmacy training are able to generate a more accurate medication 
history or make fewer prescribing errors. 
The pharmacist researcher was in demand throughout the data collection period, 
especially when conducting observations outside of pharmacy opening hours, to 
answer a wide variety of queries. In addition once pharmacists had identified 
omissions and/or errors in prescriptions it took considerable time for these to be 
resolved. Research is needed to investigate the potential value of a pharmacist 
confirming the patient’s medication history either shortly before or immediately 
after the clerking process and also the potential value of having a pharmacist 
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available on the ward for extended periods of the day to answer queries and 
provide advice. Pharmacist prescribers are increasing in number and their potential 
value working in an AMU is another area where there is limited published data. 
Pharmacist prescribers are able to review case notes and prescribe or withhold 
omitted medication, taking account of results of investigations and the patient’s 
clinical condition. However one potential drawback of providing a pharmacy 
prescribing service may be the deskilling of junior medical staff. 
 Conclusion 7.7
For VTE risk assessment the study shows that a national financial sanction resulting 
in a consultant led approach was associated with effective implementation of 
guidance. However it remains to be seen whether the level of achievement can be 
maintained as new targets are added in a culture of organisational change. Strong 
clinical leadership appeared to be the most effective way of implementing the 
change in clinical practice. Hospitals should take note of the amount of time, energy 
and effort needed to implement new guidance effectively and be mindful of the 
potential for adverse outcomes as this study showed not only an increased uptake 
of VTE risk assessment but also an increase in the number of patients who were 
inappropriately prescribed LMWH and therefore at increased risk of bleeding. 
The study interviews showed that medical staff have the necessary knowledge to 
establish an accurate medication history and are aware of the potential pitfalls, but 
observations showed that theoretical knowledge is frequently not put into practice. 
Therefore a reduction in prescribing errors could be achieved if a mechanism can be 
found to implement existing guidance effectively. Improved awareness training 
highlighting the extent of the problem may be beneficial, but improving access to 
patient medication histories and alternative strategies for involving pharmacists 
should also be considered. 
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Appendix 2:  RLUH Risk assessment form for study 
Project Acronym: 
Project full name 
R&D number 
VTE 
3862 
Summary Changing practice to reduce the risk of medical patients 
developing venous thromboembolism (VTE) 
Chief Investigator (CI): Miss Basey Employer of CI: RLBUHT 
Intervention:   Sponsor(s): RLBUHT + JMU 
  Funder:   
ISRCTN  (if applicable)  Funder Ref:  
 
Date of Assessment 21/08/2009 
Number of Risk Categories Identified 6 
Range of scores per category (min-max) 2-6 
Minimum Possible  Total Score 
Maximum Possible Total Score  
(Sum maximum score possible i.e. 25 x number of categories) 
6 
150 
Total Score for Trial 
(Sum of scores from all Categories) 
23 
Mean Score for Trial 
(Calculated as total score/number of categories) 
3.8 
Overall % Risk 
 (Calculated as [Total score/maximum possible score] x 100) 
15% 
Category of Risk (circle)  
                 
Low If score ≤ 20% 
Moderate If score  ≥20 to ≤ 50% 
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Specific Hazard Impact (I) 
 
1 Low 
2 Moderate 
3 Significant 
4 Severe 
5 Catastrophic 
Likelihood of it 
happening (L) 
1 Remote 
2 Unlikely 
3 Possible 
4 Likely 
5 Certain 
Risk 
(I X L) 
Management strategies 
of sponsor 
Management strategies of 
CI/PI 
Intervention risk to Patient  
Questionnaire 
Tissue sample 
Interview 
X –ray 
 
Inexperienced clinical Research 
team 
Lack of staff training 
Adverse events from wrong 
administration of intervention 
Withdrawal 
Poor or no consenting 
Breach of patient confidentiality 
 
Organisational complexity of 
1 
 
 
 
 
3 
 
 
 
 
 
 
2 
 
 
 
 
2 
 
 
 
 
 
 
2 
 
 
 
 
6 
 
 
 
 
 
 
Interview schedule will be 
ethically approved 
Staff will be consented for 
observation and interview 
 
 
Academic supervision for PhD 
All data to be held on NHS 
computer, anonymised data only 
to JMU 
 
 
 
 
Should the observer see bad practice 
the observation will be stopped and 
the manager informed 
If the patient or staff appear agitated 
or ask the PI to leave they will do so 
 
 
Withdrawals to be reviewed  
PI doing all data collection 
 
 
 
 
 
                
High If score  ≥ 50 to ≤ 100% 
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Specific Hazard Impact (I) 
 
1 Low 
2 Moderate 
3 Significant 
4 Severe 
5 Catastrophic 
Likelihood of it 
happening (L) 
1 Remote 
2 Unlikely 
3 Possible 
4 Likely 
5 Certain 
Risk 
(I X L) 
Management strategies 
of sponsor 
Management strategies of 
CI/PI 
study 
Protocol violations/deviations  
Communication issues 
Departments/other members of 
health care team not aware of 
study.  
Randomisation 
 
Value of study / rigor 
Insufficient study power 
Poor recruitment 
Fraudulent data 
Violation of eligibility criteria 
Missing outcome results 
Missing data 
 
Service impact 
Departments not approached for 
their involvement 
Opportunity costs not accounted 
for 
Insufficient resources available 
Appropriate licenses not in place 
 
Organisational Hazards 
Intellectual property opportunities 
overlooked. 
2 
 
 
 
 
3 
 
 
 
3 
 
 
 
1 
2 
 
 
 
 
1 
 
 
 
2 
 
 
 
2 
4 
 
 
 
 
3 
 
 
 
6 
 
 
 
2 
PI undertaking all data collection 
Pharmacy has given permission 
for study. 
AMU to be approached 
 
 
Academic supervision from JMU 
as part of PhD 
Recruitment for 1 week per 3 
months for a total of 6 weeks, if 
necessary can be repeated next 
week.  
Pharmacy and AMU to give 
approval prior to start of study 
Research part of PI job 
description 
 
 
As above 
 
 
 
 
 
 
 
 
 
 
 
 
To report any IP if found 
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Specific Hazard Impact (I) 
 
1 Low 
2 Moderate 
3 Significant 
4 Severe 
5 Catastrophic 
Likelihood of it 
happening (L) 
1 Remote 
2 Unlikely 
3 Possible 
4 Likely 
5 Certain 
Risk 
(I X L) 
Management strategies 
of sponsor 
Management strategies of 
CI/PI 
Adverse publicity for Trust 
Insufficient Insurance 
Insufficient finance 
 
 
PI feels IP unlikely 
NHSLA insurance in place 
Pharmacy has agreed time with 
PI 
PI to advise Trust R&D department of 
any publications prior to submission 
to publishers 
 
The following signatories have reviewed and approved this risk assessment 
 
On Behalf of RLBUHT 
 
………………………………………………………….    …………………………………………………  ……………………… 
Signature                                                                              Print Name                                                            Date 
 
The Chief Investigator 
………………………………………………………….    …………………………………………………  ……………………… 
Signature                                                                              Print Name                                                            Date 
191 
 
Appendix 3:  Admission process data collection form 
Medical Admissions Study 
 
Admission Process Data Collection Form 
 
Date :………………………….  Start Time: ……………….Finish time: ………………. 
 
Doctor / nurse number: ……………. 
 
Patient Study Number: ……………. 
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Sources of information   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Information provided by GP / Matron / Walk in centre/ NH / Other? .................................. 
What information was asked of the patient? 
 
What information was taken from the patient’s own medicines? 
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Sources of information  Available?  Used?         For RA or Rx? 
 
GP repeat form    Y  /  N   Y  /  N  RA  /  Rx 
MAR chart    Y  /  N   Y  /  N  RA  /  Rx 
EMIS Web    Y  /  N   Y  /  N  RA  /  Rx 
Previous TTO / Drug chart  Y  /  N   Y  /  N  RA  /  Rx 
Telephone GP surgery   Y  /  N   Y  /  N  RA  /  Rx 
ICE     Y  /  N   Y  /  N  RA  /  Rx 
Old notes    Y  /  N   Y  /  N  RA  /  Rx 
Other ……………………….  Y  /  N   Y  /  N  RA  /  Rx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trust Risk assessment form: 
Available in admission pack?  Yes  No  
Completed?    Yes  No  Partial …………… 
 
 
 
 
 
 
 
 
 
 
 
 
 
Details 
Any other evidence of risk assessment? 
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Outcome 
 
Prophylaxis indicated? Y  /  N  / Lack of information / clinically unclear 
 
 
 
 
 
Any contraindications identified?  Y  /  N 
 
 
 
 
Dalteparin prescribed?  Y  /  N  5,000 units od   2,500 units od   
Reason for dose reduction?…………………………………………………………..……………… 
Alternative prophylaxis prescribed? ……………………………………………….………..… 
TED stockings prescribed?  Y  /  N  Appropriate?  Y / N ……………… 
 
Regular medication prescribed?  Y  /  N  Time of Rx: ……………………… 
 
 
 
 
 
 
Appropriate? 
 
 
 
Date :…………………………. Start Time: ……………….. Finish time: ………………. 
 
Doctor / nurse number: ………… 
Details 
Details 
Accurate?          Y / N 
Complete?          Y / N 
Appropriate?          Y / N 
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Appendix 4:  VTE interview schedule 
Medical Admissions Study 
Interview Schedule for Healthcare Professionals 
Date of interview: ………………...   Doctor / Nurse Study Number: ……….... 
Age:  22-25  26-30  31-35  36-40  40+ 
Grade:  AfC6 AfC7 F1 F2 ST1 ST2 St3 ST4 ST5 Cons 
Other…………. 
 
Are you:  Based in AMU?  How long have you worked in AMU? ........... 
 
Hot block?  On-call? Other.......................................................................... 
 
Specialty experience in last 2 years: .......................................................................................... 
 
Which are you going to specialise in: ......................................................................................... 
 
My research project is about VTE but I would be grateful if you don’t tell other AMU staff this 
information 
 
Training: 
 
Have you had any training in VTE risk assessment?   Where: .............................. 
 
Duration: .....................................How long ago: ..................... Details................................. 
 
How do you rate your current knowledge of VTE risk assessment and prophylaxis? 
 
Below average  average  good 
 
Understanding 
 
i. How many deaths do you think are caused by VTE in the UK each year? (Show flash 
card and ask interviewee to indicate position of death due to VTE in the list provided) 
ii. In your experience what proportion of medical patients do you think have risk factors for 
VTE……… % 
iii. In your experience for what proportion of those at risk do you think have a 
contraindication to LMWH? ……….% 
iv. Which VTE risk factors do you look for in your patients? 
……………………………………………… ……………………………………………….... 
 
v. Are there any situations where you would withhold VTE prophylaxis? 
……………………………………………… ………………………………………………….. 
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Policy 
 
vi. Tell me which policies/ guidance for the prevention of Thromboembolism you are aware 
of? 
local?.........................................................national?........................................................ 
vii. Have you read them?  …………………………or used them? ……................,......... 
viii. Have you seen the Trust VTE risk assessment form? Y / N 
ix. Have you used it?  Y / N   If not why? ................................................. 
x. How easy do you find it to use?  …………      …………………....................................…. 
Complicated?     Time consuming? 
xi. What would you prescribe for VTE prophylaxis?  …………...................Dose? ................. 
Are there any situations when you would use a reduced dose? ........................................ 
 
Roles 
 
Thinking about patients admitted directly to AMU from GP / Walk in centre: 
 
xii. Whose job do you think it is to complete the risk assessment?   ……………………….. 
Is the responsibility clear? ....................................................................................................... 
xiii. Who should prescribe prophylaxis?  ………………………………………………................ 
xiv. At what stage in the admissions process should prescribing take place? ………...……… 
 
xv. What do you think your role is in the prevention of VTE for these patients?  ................... 
 
If the patient is admitted via ED: Should the process be any different....................................... 
 
xvi. Who should complete the risk assessment? ..................................................................... 
 
xvii. At what stage should prophylaxis be prescribed? .....................................By whom?........ 
 
Current position 
 
xviii. What proportion of medical patients for whom VTE prophylaxis is indicated do you think 
currently have it prescribed? ....................... % 
 
xix. Tell them RLUH audit January 2009 showed dalteparin prophylaxis was prescribed for 
approximately 30% of patients for whom it was indicated    Does this surprise you? 
 
xx. Why do you think getting VTE prophylaxis right is proving difficult? ............................. 
 
RA tool? Time?  Responsibility unclear? Training?  Access to policy? 
 
xxi. Have you any suggestions as to how we can increase the number of patients who 
receive appropriate prophylaxis?  
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Appendix 5:  Medicines reconciliation interview schedule 
Medical Admissions Study 
Medicines Reconciliation Interview Schedule for Healthcare Staff 
Date of interview: ………………...    Doctor / Nurse Study Number: ……. 
Age:  22-25  26-30  31-35  36-40  40+ 
Grade: AfC8 F1 F2 ST1 ST2 St3 ST4 ST5 Cons Other :........... 
 
Are you:  Based in AMU?  How long have you worked in AMU? ........... 
 
Hot block?  On-call?  Other............................................................ 
 
Specialty experience in last 2 years: .......................................................................................... 
 
Which are you going to specialise in: ......................................................................................... 
 
My research project is about Med Rec but I would be grateful if you don’t tell other staff this 
information 
 
Training: 
 
Have you had any training in taking medication histories? Where: ................................ 
 
Duration: .................................How long ago: ..................... Details................................. 
 
Do you think the training you received was adequate? ............................................................. 
 
Understanding 
 
i. What proportion of hospital prescriptions do you think contain an error ………………% 
ii. What proportion of the above errors in do you think could potentially have serious 
consequences…….……..% 
 
Tell them GMC report (North West) 2009 13.4% prescriptions contained an error, of 
which 1.74% potentially lethal 
 
iii. How do you rate your current ability to document an accurate medication history? 
 
Below average  average  good 
 
Policy 
 
iv. Tell me which policies/ guidance for the documentation of medication histories you are 
aware of? 
local?..................................................................national?.............................................. 
v. Have you read them.………………………………………………………………………….. 
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Current Practice 
vi. Which sources do you use when you are documenting a medication history? 
……………………………………………… ………………………………………………….. 
 
vii. Do you ever use more than one source to cross check? 
 
Never    Sometimes   Always 
 
viii. Why do you sometimes use more than one source? 
 
ix. Are there any situations when you wouldn’t use the patient as a single source?........... 
 
x. Describe any problems you find in documenting accurate medication histories…….… 
……………………………………………………………………………………….………….. 
xi. Are there any situations where you wouldn’t document a medication history?............... 
……………………………………………… ……………………………………….…………. 
 
xii. What action do you take if you are unable to document a medication history?.............. 
…………………………………………………………………………………………………... 
xiii. How often do you discuss medicines with the patient before prescribing? 
Always  Usually  Sometimes  Rarely  Never 
Are there any situations when you wouldn’t discuss medicines with the patient before 
prescribing? …………………………………………………………….…………………..…. 
 
xiv. Are there any situations when a medication chart is unnecessary? ............................... 
 
Roles 
 
xv. Do you think that prescriptions should be checked? ...................................................... 
xvi. By whom? ...................................................................................................................... 
xvii. How soon after they are written? .................................................................................... 
 
Current position 
 
xviii. What proportion of prescriptions written in AMU do you think contain an error ........... % 
 
Tell them RLUH audit 2009 / 2010 showed 37% had an error (208 / 553) 
 
xix. Does this surprise you? .................................................................. 
 
xx. Have you any suggestions as to how we can reduce the number of prescribing errors? 
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Appendix 6:  Case note data collection form 
Medical Admissions Study 
Case Note Data Collection form 
Patient study number: ………………….  Age: ……..  M  /  F 
Admission date: …………………………  Time: …………………… 
Admission from: GP ED Walk in centre Community Matron OPD Other hosp. 
Principal diagnosis: …………………………………………………………………………….……... 
Risk assessment form completed  Yes  No  Partial……. 
Any other documented risk assessment?  Yes  No  Date ….Time: …. 
 
Details: ………………………………………………………………………………………………….. 
 
VTE risk factors identified:    Documented  Verified 
on form  from notes  
Age > 60 years          
Acute or chronic lung disease       
Chronic heart failure        
Acute infectious disease (e.g. pneumonia)     
Acute or chronic inflammatory disease      
Active cancer or myeloproliferative disorder     
Diabetic hyperosmotic hyperglycaemic state     
Nephrotic syndrome        
Hormone therapy containing oestrogen (HRT or OCP)    
Expected to be immobile for 3 days or more      
Personal or family history of DVT or PE       
Lower limb paralysis (excluding acute stroke)     
Obesity: BMI > 30        
Known thrombophilia        
Varicose veins with phlebitis       
Pregnant or ≤ 6 weeks post partum      
 
 
Bleeding Risk identified     Documented Verified 
        on form  from notes 
Active bleeding          
Taking warfarin or other anticoagulant or antiplatelet therapy    ….. 
Haemophilia or other known bleeding disorder      
Acute stroke in past month (haemorrhagic or ischaemic)     
Blood pressure > 200 systolic or 120 diastolic      ….. 
Infective endocarditis         
Hypersensitivity to heparin        
History of Heparin Induced Thrombocytopenia (HIT)     
Lumbar puncture in previous 4 hours or indicated now     
Known platelet count < 100        ….. 
Severe liver disease (PT raised above normal or known varices)    ….. 
Severe renal disease         ….. 
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Outcome 
 
Prescription 
Dalteparin prescribed? Yes  No  No chart  Other: …... 
Dose?  5,000 units od   2,500 unit od  
Date of first dose: …………………   Date of last dose: …………………………. 
Reason for delay in treatment?  LP          CT scan          None          Other ………… 
Reason for dose reduction:  Elderly    
    Low body weight  ………. kg 
     Renal function  ……….. creatinine mmol / l 
     
    None identified   
 
TED stockings prescribed? Yes    No  
 
 
Discharge date ……………………………. Length of Stay ……………… days 
 
While in hospital developed: 
DVT   Yes   No   Unknown  
PE   Yes   No   Unknown  
Bleeding  Yes   No  Details………………………. 
Date of Death: ……….  Cause……………………………………………………………………… 
 
 
Monitoring 
Platelet count: On admission: ……. After 5 days / on discharge……… Date :….… 
 
 
Medication History taken by doctor / nurse Yes  No  
 
Accurate?  Yes  No  
 
Medication history confirmed by pharmacist Yes  No  Date: …….. 
 
Within 24 hours? Yes  No  
 
Number of discrepancies: significant: …… trivial ….… out of a total of ……………. Items which 
should be Rx 
 
Details: …………………………………………………………………………………………………. 
 
Date discrepancies rectified ………………………………………. Delay: ………………………  
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Appendix 7:  Study information sheet – healthcare staff 
 
 
 
 
Medical Admissions Study – Observations & 
Interviews 
 
 You are being invited to take part in a research study. 
Before you decide it is important that you understand why 
the research is being done and what it involves. Please 
take time to read the following information. Ask me if 
there is anything that is not clear or if you would like 
more information. Take time to decide if you want to take 
part or not. 
 
1. What is the purpose of the study? 
 
The study is looking at the admissions process and the 
roles of the various healthcare staff. Patients may be 
seen by several healthcare professionals, have numerous 
investigations and require various treatments. The process 
is complex; by gaining a better understanding of what 
happens on admission we hope to improve patient care. The 
study is being carried out as part of a PhD research 
project. 
 
2. What do I have to do if I agree to take part? 
 
You will be observed while you clerk in patients to the 
AMU.  You will also be interviewed about your thoughts on 
the admissions process at a later, mutually convenient 
date. You don’t have to do anything differently when 
admitting patients; the researcher will simply document 
Liverpool John Moores University 
and 
Royal Liverpool and Broadgreen 
University Hospitals NHS Trust 
 
Study Information Sheet for 
Healthcare Staff 
202 
 
what she observes if you feel the researcher’s presence is 
having an adverse effect on patient care you can ask her 
to leave at any time. If the researcher observes anything 
which she considers may have a serious adverse impact on 
patient care she will draw this to your attention. 
You may choose to participate in the observations, the 
interview or both.  
 
3. How much of my time will be needed? 
 
The observation part of the study will have no impact on 
your time as the researcher will simply observe what 
happens; you will not be interrupted or asked questions. 
You will be observed for a maximum of four hours.  It is 
estimated that the interview will take approximately 30 
minutes and it is proposed that this is carried out in the 
hospital at a mutually convenient time. 
 
4. Are there any risks / benefits involved? 
 
This is not an assessment of your competence. There are no 
risks to you and there will be no changes to your usual 
routine. You may find it beneficial to discuss the 
admissions process with the researcher. As a result of the 
project we hope to improve the admissions process for 
patients and staff. 
 
5. Will my taking part in the study be kept confidential? 
 
The data collected will be anonymised, so that it will be 
impossible to identify individuals who have participated 
in the study from any of the reports or publications. All 
details recorded will be kept secure and confidential. The 
information collected will be analysed at Liverpool John 
Moores University. It will be destroyed in line with Trust 
policies for confidential data when it is no longer needed. 
 
If there is a serious breach of Trust policy this will be 
reported to the appropriate person. 
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6. Do I have to take part? 
 
No. It is up to you to decide whether or not to take part; 
you may choose to participate in the observations or the 
interviews or both. If you do agree to participate please 
complete the attached consent form. If you do not want to 
take part just tell the researcher who gave you this 
leaflet. You are still free to withdraw at any time and 
without giving a reason. A decision to withdraw will not 
affect your employment by the Trust in any way. 
 
Who should I contact if I have a question? 
 
Miss A J Basey 
Consultant Pharmacist – Acute Admissions 
Royal Liverpool University Hospital 
0151 706 2097 
 
Who should I contact if I have a problem with the study? 
 
Dr T D Kennedy 
Consultant Physician & Rheumatologist 
Royal Liverpool University Hospital 
0151 706 5897 
 
Professor J Krska 
School of Pharmacy and Biomolecular Sciences 
Liverpool John Moores University 
Tel 0151 231 2404 
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Appendix 8:  Study information sheet – patients 
 
 
 
Medical Admissions Study 
 
 This sheet gives you some information about the above 
study. Please take time to read it. Ask me if there is 
anything that is not clear or if you would like more 
information.  
 
1. What is the purpose of the study? 
 
We are looking at how doctors and nurses do their jobs 
when patients come into hospital to make the process 
easier for everyone. 
 
2. What will I have to do? 
 
Nothing, the study will not affect you in any way. The 
researcher will watch what happens and make notes about 
how the doctors and nurses do their job. 
 
3. Are there any risks involved? 
 
There are no risks to you and the study will not affect 
the treatment you receive.  
 
 
 
 
Liverpool John Moores University 
and 
Royal Liverpool and Broadgreen 
University Hospitals NHS Trust 
Study Information Sheet for 
Patients 
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4. Will my taking part in the study be kept confidential? 
 
All details recorded will be kept secure and confidential. 
The information collected will be studied at John Moores 
University. All personal data will be destroyed within 3 
months of completing the study. 
  
5. What should I do if I’m not happy with you being here? 
 
Just tell the doctor or nurse and I will leave. 
 
Who should I contact if I have a question? 
 
Miss A J Basey 
Consultant Pharmacist – Acute Admissions 
Royal Liverpool University Hospital 
0151 706 2097 
 
Who should I contact if I have a problem with the study? 
 
Ask to speak to the Senior Nurse on duty for the Acute 
Medical Unit 
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Appendix 9:  Consent form – staff 
 
 
 
Consent Form for Healthcare Staff     
Medical Admissions Study – Observations & Interviews 
             Initial 
1. I confirm that I have read and understand the 
information provided for the above study. I have had 
the opportunity to consider the information, ask 
questions and have had these answered satisfactorily 
 
2. I understand that my participation is voluntary and 
that I am free to withdraw at any time, without 
giving a reason and that this will not affect my 
legal rights. 
 
3. I understand that any personal information collected 
during the study will remain confidential and that 
anonymised quotes may be used in publications. 
 
4. I agree to take part in the observations for the 
above study 
 
5. I agree to take part in the interviews for the above 
study  
 
Name of Participant ……………... Signature: ………… Date: ………. 
 
Name of Researcher: ……………Signature: ……………...Date: ……..…… 
 
Researcher : 
Miss A J Basey 
Consultant Pharmacist - Royal Liverpool University Hospital 
and PhD Student -  School of Pharmacy and Biomolecular Sciences 
Liverpool John Moores University 
Note: When completed 1 copy for participant and 1 copy for 
researcher  
Liverpool John Moores University 
and 
Royal Liverpool and Broadgreen 
University Hospitals NHS Trust 
Consent Form for Healthcare Staff  
Consent Form for Healthcare Staff 
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Appendix 10:  Case study template – patient admissions observed  
 
Patient Study Number: Patient age: 
Admission time:  
Duration of clerking: 
Staff grade: 
Information provided: 
Interruptions:  
 
 
 
 
 
Summary of case: 
 
 
 
 
VTE RA details: 
 
 
 
Outcome: 
 
VTE 
 
Meds rec: 
 
Timeline: 
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Appendix 11:  Flash card for VTE interviews 
 
 
 
The following causes of death in the UK are listed in order 
of prevalence in the UK – number 1 is the most prevalent. 
 
Where would you place death due to VTE in this list? 
  
a 
 
1. Death from Myocardial Infarction 
 
b 
 
2. Death from Breast Cancer 
 
c 
 
3. Death from Road Traffic Accidents 
 
d 
 
4. Death from MRSA infection 
 
e 
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Appendix 12:  Flash card for VTE interviews - answers 
 
The following causes of death in the UK are listed in order 
of prevalence in the UK – number 1 is the most prevalent. 
 
Where would you place death due to VTE in this list? 
  
a 
 
1. Death from Myocardial Infarction (33k per annum) 
 
b (VTE 25k per annum) 
 
2. Death from Breast Cancer (11k per annum) 
 
c 
 
3. Death from Road Traffic Accidents (6k per annum) 
 
d 
 
4. Death from MRSA infection (1.5k pert annum) 
 
e 
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Appendix 13:  VTE Ranking Form 
Ranking Form for Risk Factors 
 
Interview Date…………     Study no ……………. 
 
Rank the following VTE risk factors where 1 is not very important and 5 is extremely 
important: 
       1 2 3 4 5 
Age > 60 years            
Acute or chronic lung disease         
Chronic heart failure          
Acute infectious disease (e.g. pneumonia)       
Acute or chronic inflammatory disease        
Active cancer or myeloproliferative disorder       
Diabetic hyperosmotic hyperglycaemic state       
Nephrotic syndrome          
Hormone therapy containing oestrogen (HRT or OCP)      
Expected to be immobile for 3 days or more        
Personal or family history of DVT or PE        
Lower limb paralysis (excluding acute stroke)       
Obesity: BMI > 30          
Known thrombophilia          
Varicose veins with phlebitis         
Pregnant or ≤ 6 weeks post partum        
 
Do the same for the following bleeding risk factors – 1 is not very important and 5 is 
extremely important: 
       1 2 3 4 5 
Active bleeding           
Taking warfarin / anticoagulant or antiplatelet therapy      
Haemophilia or other known bleeding disorder       
Acute stroke in past month (haemorrhagic or ischaemic)      
Blood pressure > 200 systolic or 120 diastolic       
Infective endocarditis          
Hypersensitivity to heparin         
History of Heparin Induced Thrombocytopenia (HIT)      
Lumbar puncture in previous 4 hours or indicated now      
Known platelet count < 100         
Severe liver disease (PT above normal or known varices)     
Severe renal disease          
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Appendix 14:  Medicines Reconciliation Ranking Form 
 Medicines Reconciliation Ranking Form 
 
Interview Date…………     Study no ……………. 
 
How often would you use the following sources of information when documenting a 
medication history? 
 
Source Never (Why 
not?) 
Sometimes Always 
GP / Walk in centre / Matron / Summary or 
Letter 
   
GP repeat form (green)    
GP surgery (by telephone)    
Patient    
Relative / Carer    
Patients own medication list    
Patients own medicines    
MAR chart from Nursing Home    
Previous medication chart    
Previous TTO    
EMIS web    
Renal Proton system    
Other source (please state)    
 
 
Rank the following information sources according to how useful you find them; 1 is 
not very useful and 5 is extremely useful: 
1 2 3 4 5 
EMIS web           
GP / Walk in centre / Matron / Summary or Letter      
GP repeat form (green)         
GP surgery (by telephone)         
MAR chart from nursing home        
Patient / Relative / Carer         
Patients own medication list         
Patients own medicines         
Previous medication chart         
Previous TTO           
Renal proton system           
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Appendix 15:  Case Summary template – LMWH contraindicated but 
prescribed  
Patient number: Patient age: 
 
Medical problems: 
 
Number of VTE risk factors:  
Details: 
 
Numbers of bleeding risk factors: 
 Details: 
 
Benefit outweighs risk: Yes / No 
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Appendix 16:  Case studies – patient admissions observed (71 patients) 
 
Patient A1 (46 M) 
Admission time: 11.26 (Monday) 
Clerking time: 11.55 – 12.45 (50 minutes) 
Staff: F2 doctor 
Information provided: GP proforma 
Interruptions: None 
Summary 
Patient presented with pain in calf; hot red leg. Previous DVT following knee surgery 15 years 
ago. The doctor asked if the patient had taken any painkillers however when they patient 
indicated that they had taken analgesia no further questions were asked at this stage. The 
doctor asked if the patient had ever had warfarin, they said not and were unsure when asked if 
they had ever had Fragmin before. When asked, the patient said they took no regular 
medication but had taken OTC aspirin 300mg 4 hourly for the past 2 weeks 
Doppler ordered – ICE confirmed previous thrombus 
 
VTE RA – not available 
 
MH – Nil regular; medication chart not written 
 
Outcome 
Dalteparin not prescribed as doctor was not sure if therapeutic dalteparin would be needed. 
Asked for my advice re the use of therapeutic dalteparin; I explained the need for the patients 
weight and asked the nurse to weigh the patient. Dalteparin was had not been prescribed 
when the clerking was completed. Length of stay 8 days. 
 
 
Patient A2 (57 M) 
Admission time: 11.37 (Monday) 
Clerking time: 12.45 – 13.55 (70 minutes) 
Staff: F2 doctor 
Information provided: GP proforma 
Interruptions: None 
Summary 
Presented with painful left knee, 3 – 4 weeks duration. Has an orthopaedic appointment at 
Broadgreen in 2 weeks time. Pain affecting quality of life as unable to walk Patient listed 
medicines diclofenac 50mg bd to tds, tramadol 100mg BD, co-codamol 3/500 approx 4 od, 
Nexium / ? omeprazole 20mg od; patient not sure of product. 
 
VTE RA – not available 
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Outcome 
Doppler results awaited before prescribing dalteparin – may need therapeutic dose. Regular 
medication prescribed – no errors 5 items. Length of stay 2 days. 
 
 
Patient A10 (63 M) 
Admission time: 12.40 (Wednesday) 
Clerking time: 15.25 – 17.05 (90 minutes) 
Staff: F2 doctor 
Information provided: GP summary 
Interruptions:  15.55 by colleague re patient seen earlier – returned at 16.15 
16.15 by consultant re ECG for patient seen earlier – had to order 
investigations on ICE  
Pt with sore venflon site – nurse asked doctor to review 
 
Summary 
Patient was seen with carer; carer provided information. Patient has had recent fall and has 
had a headache since. Also complaining of whistling in ears and numbness in arms and legs. 
When asked about medicines, the carer produced some Venalinks and said the patient also 
uses inhalers. The doctor made no notes during the interview but took patients own medicines 
to the doctors office at the end of the examination and copied the details from the labels into 
the case notes 
 
VTE RA – not available 
 
Outcome 
Dalteparin not indicated ?sub dural haematoma following fall however drug chart was not 
written at the time of clerking. Medication history was not checked by a pharmacist but 
comparison of prescription with MAR chart from NH – tiotropium inhaler missing. Length of 
stay 1 day. 
 
 
Patient A3 (77F) 
Admission time: (16.39 Monday) 
Clerking time: 17.15 – 17.50 (35 minutes) 
Staff: Consultant 
Information provided: GP letter 
Interruptions:  None 
 
Summary 
Patient has not been eating and drinking - ?UTI. Dehydrated and drowsy. 
Patients daughter present and has Venalink containing MST 30mg BD + 10mg om Mon & 
Thurs am (dressing changes). Daughter also offered information re recent antibiotics – 
flucloxacillin for infected leg ulcers 
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VTE RA – Not available 
 
Outcome 
Dalteparin not prescribed – regular medication prescribed. 1 error out of 4 items MST 
prescribed as 40mg om and 30mg nocte; should be 30mg BD except Mon and Thurs when 
40mg BD. Length of stay 47 days. 
 
 
Patient A4 (61 F) 
Admission time: 18.00 (Monday) 
Clerking time: 17.50 – 18.25 (35 minutes) 
Staff: Consultant 
Information provided: GP letter 
Interruptions:  None 
 
Summary 
Had leg swelling last week, GP prescribed antibiotics. Previous DVT, scan today shows clots. 
For lifelong warfarin 
 
VTE RA – Not available 
 
Outcome 
Therapeutic dalteparin, warfarin loading dose prescribed on OP form, referral to anticoagulant 
clinic. Length of stay 1 day. 
 
 
Patient A5 (86 F) 
Admission time: 21.38 (Tuesday) 
Clerking time: 09.40 – 10.15 (35 minutes) 
Staff: SpR 
Information provided: GP summary and MAR chart 
Interruptions:  None 
 
Summary 
Patient had been admitted previous day and was seen by SpR for a Senior review. Had hip 
operation June 2009. Admitted with vomiting (black) and diarrhoea. The doctor asked if the 
patient had started any new medicines; patient was not able to respond. 
 
VTE RA – Not available and no evidence of RA carried out by admitting doctor 
 
Outcome 
VTE risk assessed, although not documented, dalteparin prescribed. No drug chart - regular 
medication copied from MAR chart onto drug chart; unable to assess accuracy as chart not 
available in case notes at time of audit. Length of stay 9 days. 
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Patient A6 (72 M) 
Admission time: 08.46 (Tuesday) 
Clerking time: 10.20 – 10.55 (35 minutes) 
Staff: SpR 
Information provided: MAR chart 
Interruptions:  Bleep – Patient in resus needs SpR review 
  Bleep – ED referral / advice (10 mins) 
 
Summary 
Patient admitted with acute SOB from NH. The patient was confused and had had a previous 
stroke so communication was with his wife. Diagnosis was CAP – CURB 65 = 3 (no urea 
available). There was no discussion regarding medication. 
 
VTE RA Not available and no evidence of RA carried out by admitting doctor 
 
Outcome 
 The medication chart had been written by the ED doctor, the SpR added Fragmin 5,000 units. 
There were no blood results available on ICE so a note was made to check his renal function 
later. The medication had been prescribed accurately 0 errors out of 9 items. Length of stay 32 
days. 
 
 
Patient A7 (65 F) 
Admission time: 12.21 (Tuesday) 
Clerking time: 13.10 – 14.00 (50 minutes) 
Staff: Nurse 
Information provided: GP summary 
Interruptions:  None 
 
Summary 
Presented with shoulder pain following a fall; right arm is also numb - ? stroke. Patient has 
arthritis in hips and knees – unable to walk to bus stop and avoids climbing stairs – drives if 
possible. Asked: “Do you take painkillers?” – Response: “No – I prefer not to” “Do you take 
any routine medication?” – response “Not at the moment” Patient said that she had tried 
glucosamine for her knees; she thinks it may have helped but she stopped taking it in July 
 
VTE RA – Not available 
 
Outcome 
Blood results not available at the end of the clerking. Paracetamol stat dose prescribed on 
AMU chart. Medication chart not written as patient will probably go home later and nurse 
cannot prescribe – patient actually was admitted for 3 days – medication chart written later – 0 
errors out of 0 items of regular medication. Length of stay 3 days. 
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Patient A8 (55 F) 
Admission time: 13.51 (Tuesday) 
Clerking time: 14.10 – 15.15 (65 minutes) 
Staff: Nurse 
Information provided: GP summary 
Interruptions:  None 
 
Summary 
Patient admitted with tingling in arms and legs, pins and needles and numbness, she has 
reduced grip strength.  It starts in her fingers then moves to her hands and face. It started 90 
minutes ago today. She has had similar symptoms when she was given pamidronate and 
developed hypocalcaemia; she now has to take calcium tablets before she has pamidronate. 
Asked “What do you take for pain?” – response “Solpadol” 
 
GP had provided a list of medicines although it was not accurate when I checked with the 
patient; the nurse didn’t look at the list of medication. The patient had some loose tablets in a 
pill box which were probably Solpadol.  
 
VTE RA – Not available 
 
Outcome 
Medication chart not written, nurse cannot prescribe and patient will probably go home later 
today. The patient did go home the same day; there was no medication chart in the case notes 
when they were audited. Length of stay 1 day. 
 
 
Patient A14 (64 M) 
Admission time: 11.25 (Friday) 
Clerking time: 11.50 – 12.25 (55 minutes) 
Staff: Nurse 
Information provided: Letter from Clatterbridge 
Interruptions:  Charge Nurse came to take patient’s blood 
  ECG during clerking 
 
Summary 
Known prostate cancer – treated with Zoladex implant and radiotherapy at Clatterbridge. 
Presented with jaundice for the last 4 days. Also has dry mouth and is SOB, blood results 
show abnormal LFTs. Initially no questions were asked re medication, nurse went back to ask 
while she was writing up the clerking – PRN paracetamol 
 
VTE RA – Not available 
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Outcome 
No VTE RA or prophylaxis prescribed – patient at risk due to age and active cancer but results 
not yet available. Nurse cannot not prescribe; no medication chart written. 0 errors in 0 items 
when case notes audited. Length of stay 7 days. 
 
 
Patient A13 (71 F) 
Admission time: 16.30 (Thursday) 
Clerking time: 17.10 – 20.10 (180 minutes) 
Staff: F1 
Information provided: GP repeat dated 24.08.2009 (5 months ago) 
   Blue copy of TTO dated 15.09.2009 (4 months ago) 
   Patients own medicines 
  
Interruptions:  17.30 Daughter arrived 
  17.55 Doctor went to take blood sample but patient was on her way to X-Ray 
  19.15 Doctor asked to prescribe blood for a different patient 
  19.20 Patient with a low K+ needs IV potassium prescribing 
 
Summary 
No letter. Patient referred by ? Community Matron. Information from triage nurse illegible. 
Letter from Community Matron found with patients own medicines during consultation. 
Presented with SOB, tired, can’t lie flat – worse over last month. Had headaches for last 3 
days. 
Doctor asked re medicines “Blue, grey, purple inhalers” Doctor asked about previous 
antibiotics – unclear how to find out whether she has recently had antibiotics and if so which. 
Medicines were transcribed from GP repeat complete with doses into the case notes (the TTO 
was actually more up to date).  The doctor did not refer to the patient so listed Movelat Gel 
and Chlorhexidene mouthwash which the patient had not used for some months. At 20.00 the 
F1 discussed the patient with the SHO; it was agreed to monitor blood gases then refer to a 
senior doctor possibly for antibiotic treatment 
 
Outcome 
Drug chart written; pharmacist prevented prescription of 2 items not currently being taken; 2 
further errors out of 16 items identified when MH completed – Nicotinell patch and 
dihydrocodeine missed off. No consideration of VTE risk, prophylaxis indicated (age, COPD) 
but not prescribed. Length of stay 5 days. 
 
 
Patient A9 (77 M) 
Admission time: 10.39 (Wednesday) 
Clerking time: 11.40 – 13.55 (135 minutes) 
Staff: ST1 
Information provided: GP summary 
Interruptions:  To supervise LP 
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Summary 
Presented with cough / fever /lethargy for last 7 days. Gasping for breath, chest feels tight. 
Wife volunteered “Steroids and inhaler from GP” – doctor did not follow up. Doctor asked if he 
had taken any antibiotics recently – response “No” Has had previous MI patient said he is on 
clopidogrel not aspirin. Says he also has hypertension and is on medication doctor said “we 
have a list from your GP”. 
Previously had a beta blocker which made him pass out due to  a slow pulse rate – patient 
doesn’t know what the beta blocker was for – he doesn’t think he has a heart rhythm problem. 
Doctor asked re family history of clots – None. Asked if patient on warfarin – No. Explained 
that patient has AF which increases risk of clots explained need for Fragmin (treatment dose) 
to patient. 
Doctor started writing drug chart before seeing patient, while reading notes. Completed after 
watching F2 perform LP 
 
VTE RA – Not available 
 
Outcome 
Therapeutic Fragmin for AF 
Regular medication prescribed – 0 errors out of 9 items. Length of stay 6 days. 
 
 
Patient A11 (67F) 
Admission time: (11.12 Thursday) 
Clerking time: 11.40 – 13.20 (100 minutes) 
Staff: ST1 
Information provided: GP summary, LHCH medication chart 
Interruptions:  None 
 
Summary 
Patient transferred from Wd 9 LHCH with decreased oxygen saturation. Consultation difficult 
as patient unwell. Patient known to have RA – previously treated with methotrexate – not 
taking currently. Patient needs urgent blood gases – ST1 asked the other SHO to take the 
blood as access is difficult. Doctor rang radiology for an urgent chest X-ray then went to ED X-
Ray to arrange– yesterday there was 2 hours delay; this patient can’t wait 2 hours. Discussed 
with Med Reg at 12.55 – admit to 6x for BIPAP. 13.00 spoke to ID registrar – recent admission 
to 3x. ID reg knows patient well – very sensitive to oxygen – type 2 respiratory failure – oxygen 
stopped. Med Reg arrived 13.05 – patient handed over. 13.10 went to discuss with patients 
relative13.20 complete 
 
VTE RA – Not available 
 
Outcome 
No LMWH on copy of chart from LHCH – admission date 30/10/09 (6 days ago) – 14.05 ?PE –
wt 35kg dalteparin 7,500 units od prescribed; 14.30 – not PE changed to 2,500 units od 
Regular medication prescribed from LHCH chart – no case notes from Nov 2009 unable to 
confirm accuracy. 
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Patient A12 (76F) 
Admission time: 13.52 (Thursday) 
Clerking time: 14.40 – 16.15 (95minutes) 
Staff: ST1 
Information provided: GP summary 
Interruptions:  None 
 
Summary 
Patient from Ghana; consultation via friend acting as interpreter as patient doesn’t speak 
English. Presenting complaint hypertension. Patient did not attend appointment at 
hypertension clinic yesterday – went to the GP for tablets and the GP sent her to hospital. BP 
218/99 Left arm; 232 / 100 right arm. Blood tests and cardiac ECHO ordered – doctor then 
rang Medical Reg for advice. The doctor did not ask any questions regarding medication. 
 
VTE RA - Not available 
 
Outcome 
LMWH contra indicated due to current hypertension – not prescribed. Medication chart written 
using GP summary - no strength on alendronate and day of week not noted. Adcal D3 missed 
off – 2 errors out of 7 items. Length of stay 5 days. 
 
 
Patient A15 (67M) 
Admission time: 12.25 (Friday) 
Clerking time: 13.25 – 14.25 (100 minutes) 
Staff: F2 
Information provided: Matron’s letter, patients own medicines 
Interruptions:  13.45 – discussion with CT1 re paracentesis for another patient 
  14.00 – personal telephone call in foreign language 
 
Summary 
Matrons letter provided – details of recent antibiotics and steroids but no information re current 
medication.  The doctor was tired having just worked nights the patient had difficulty in 
comprehending the questions asked (doctors first language not English) and became 
frustrated and “fed up” – “you always ask the same questions” Patient has been admitted with 
SOB, when asked about current medication he answered “inhalers” but had his own medicines 
with him which the doctor said she would look at later. Following the history and examination 
the doctor wrote up the case notes leaving a space for medication. She then started to write 
the medication chart but had to go back to the patient to retrieve his medicines – inhalers, 
Venalink, co-amoxiclav and prednisolone. The medicines were used to write the drug history 
in the case notes; she struggled with the prednisolone as there was no dose on the carton, I 
suggested that she opened the carton and looked on the actual container – which was labelled. 
The medication chart was then written using the list in the case notes. The patient took 
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Oramorph 5mg PRN for breathlessness, the doctor was surprised as she hadn’t come across 
this before and had to confirm with me that this was appropriate before prescribing. 
 
VTE RA – Not available 
 
Outcome 
LMWH not prescribed, indicated due to age and respiratory disease however blood results not 
available. Medication chart 2 errors out of 7 items – salbutamol and Spiriva inhalers missed off 
but patient was prescribed nebules on admission. Length of stay 13 days. 
 
 
Patient A16 (82F) 
Admission time: 14.38 (Friday) 
Clerking time: 15.45 – 16.50 (65 minutes) 
Staff: F1 
Information provided: GP summary 
Interruptions:  None 
 
Summary 
Consultation rushed as slot booked for CT head. Presented with weakness of face and slurred 
speech. Fell over and has large bruise as taking warfarin. Seen initially by Stroke Nurse and 
went for CT scan with Stroke Nurse at 16.05 
Medication copied from GP summary into case notes – no confirmation with patient as they 
were in CT scan. Warfarin dose of 3 – 4mg copied from Stroke Nurse clerking – unclear where 
this was from.  
 
VTE RA – Not available 
 
Outcome 
No evidence of VTE RA but patient on warfarin and? Stroke so LMWH not indicated. Regular 
medication not prescribed initially but remembered as an afterthought – prescribed at 16.45 – 
0 errors out of 7 items. Length of stay 5 days. 
 
 
Patient B1 (61M) 
Admission time: 13.53 (Tuesday) 
Clerking time: 15.45 – 17.05 (80 minutes) 
Staff: F1 
Information provided: GP summary 
Interruptions:  To write drug chart and TTO for another patient (10 minutes) 
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Summary 
Referred with pain in leg and foot; had back pain for 5 days. Doctor gave a good explanation 
of what would happen during the examination. Right leg only affected – swollen. Doctor asked 
re previous clots – none, asked re family history of clots – patient said there was a history of 
“cardiac problems”. The doctor asked for the patient’s medicines but he hadn’t brought any 
with him.  The doctor took notes while interviewing the patient and then used these to write the 
case notes; the patient was complicated so the information was not in a logical order. 
 
VTE RA – Paper – available and completed – all VTE and Bleeding risks considered 
 
Outcome 
Patient at VTE risk due to age but possibility of haematoma on spine; LMWH not prescribed at 
this time. Regular medication prescribed – accurate. (MH not confirmed by pharmacist). 
Length of stay 1 day.   
 
 
Patient B5 (81F) 
Admission time: 14.55 (Thursday) 
Clerking time: 16.10 – 17.25 (75 minutes) 
Staff: F1 
Information provided: None (pt referred by GP) 
Interruptions:  To take ‘difficult’ blood (5 minutes) 
 
Summary 
Patient complaining of lack of energy has had 2 recent courses of antibiotics. Coughing up 
green phlegm and SOB, struggling to get washed and dressed. Patient had brought in own 
medication but frusemide had no label. I used EMIS to confirm the dose of frusemide. EMIS 
and pt own used to write DH in notes – accurate with doses. 
 
VTE RA – Paper available and completed 
 
Outcome 
LMWH indicated – discussed dose with me – calculated GFR – 33ml/min – reduce dose below 
30ml/min (Local arrangement not in SPC) Prescribed 5,000units dalteparin od. CURB score 
calculated = 2 – I asked re X-Ray – shows consolidation therefore treatment for pneumonia 
required amoxicillin and clarithromycin. 
Medication chart written 2 errors out of 7 – vitamin B Co strong prescribed instead of vitamin B 
compound and Cacit D3 missed off. 
Length of stay 10 days. 
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Patient B2 (67F) 
Admission time: 14.11 (Wednesday) 
Clerking time: 14.40 – 15.10 (90 minutes) 
Staff: ST2 
Information provided: GP house visit report, CPN letter 
Interruptions:  None 
 
Summary 
Patient has dementia so history from son. Presenting complaint falling asleep, not eating or 
drinking, Examination was difficult as patient was unable to comply. Doctor asked re 
medication, son said that the CPN had sent them possibly left in ambulance. Son said that the 
patient takes donepezil which wasn’t listed on the home visit report – son telephoned CPN to 
confirm – donepezil 10mg nocte, mirtazapine 30mg nocte. 
 
VTE RA – Paper available and completed 
 
Outcome 
LMWH heparin indicated (age, dehydrated) and prescribed 5,000 units od. Regular medication 
prescribed – donepezil mane – should be nocte. Length of stay 1 day. 
 
 
Patient B3 (76F) 
Admission time: 14.36 (Wednesday) 
Clerking time: 16.10 – 16.55 (45 minutes) 
Staff: ST2 
Information provided: GP summary 
Interruptions:  16.45 AMU reg to complete previous clerking – patient needs PR examination 
16.55 junior doctor re patient seen earlier in the day 
   
Summary 
Patient unable to stand or walk due to pain in legs and neck. Discharged yesterday but legs 
have become numb and patient is drowsy. History was form husband, patient has dementia. 
There was difficulty with the examination, patient unable to comply. GP letter states problem is 
that patient can’t stand or walk but husband says that this is not new. Husband is not always 
able to understand what the patient is saying. 
Patients own medication brought into hospital – Oxcontin and oxynorm in original packs plus 
blister pack. The doctor copied the doses from the patient own medicines into the case notes 
and then onto the medication chart. 
Patient seemed very drowsy, previous thyrotoxicosis, ? treatment. I wondered if now 
hypothyroid and suggested TFTs 
 
VTE RA – Paper available and completed 
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Outcome 
? myeloma, ? fracture. Medication chart written, aspirin should be EC, ISMN written instead of 
isosorbide mononitrate. LMWH not prescribed, patient immobile and aged over 60, previous 
DVT in 2007 on GP summary therefore indicated. MH not confirmed by pharmacist. Length of 
stay 3 days. 
 
 
Patient B4 (88F) 
Admission time: 13.55 (Thursday) 
Clerking time: 14.20 – 15.05 (45 minutes) 
Staff: ST2 
Information provided: GP summary – received by fax while doctor was clerking patient 
Interruptions:  None 
 
Summary 
Doctor communicated with daughter rather than patient. GP called patient house bound, 
unwell 2-3 days, crying. ? Ability to cope at home. Patient says she doesn’t feel unwell now. 
ECG shows AF, doctor explained risks re stroke and need for warfarin – patient doesn’t want 
to stay in hospital. Daughter had brought in patients own medicines; doctor looked at briefly to 
identify any current medical conditions as no information from GP. GP summary used to write 
medication history in case notes – drug and dose recorded but no frequency.  GP summary 
then used to write medication chart. 
 
VTE RA – Paper available and used 
 
Outcome 
AF ?needs therapeutic LMWH then warfarin .Dalteparin 5,000 units od prescribed. Medication 
chart – 2 errors – ramipril prescribed od should be BD, frusemide 20mg 3od prescribed as 
20mg om – should be 60mg om. Corrected by pharmacist. Length of stay 9 days. 
 
 
Patient B6 (65F) 
Admission time: 13.50 (Friday) 
Clerking time: 13.45 – 14.30 (90 minutes) 
Staff: Consultant 
Information provided: From Gastro clinic 
Interruptions:  None 
 
Summary 
See and Treat. Presented with SOB and weakness, ?subphrenic collection, ?PE. Doctor 
asked “Have you a list of your medicines”. Doctor asked me to log into EMIS for medication as 
he has forgotten password.   
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VTE RA – Paper available and completed 
 
Outcome 
LMWH not prescribed as clinically unclear – abscess may need draining 
Medication chart written form copy I printed from EMIS. Letter from gastro states prednisolone 
but not on EMIS list, I suggested confirming with ICE TTO – patient said 10mg od – correct. 
Seretide inhaler prescribed as Fluticasone. Length of stay 17 days. 
 
 
Patient B7 (79F) 
Admission time: 13.38 (Friday) 
Clerking time: 14.35 – 15.05 (30 minutes) 
Staff: Consultant 
Information provided: GP summary 
Interruptions:  None 
 
Summary 
Patient presented with vomiting, everything including water, also passing large volumes of 
urine, feels unwell. The doctor asked the patient for a list of their medicines – not available. 
The doctor asked about allergies, when the patient indicated penicillin he asked “what 
happens”, the patient said that her face swells up. Diagnosis UTI. 
 
VTE RA – Paper available and completed 
 
Outcome 
Dalteparin not prescribed as patient takes warfarin. Regular medication prescribed – 
buprenorphine with held as patient is vomiting. 3 errors out of total 8 items. I confirmed – dose 
of warfarin, day of week for buprenorphine patch, and alfacalcidol not being taken (not had 
supply from GP for a while). Length of stay 7 days 
 
 
Patient B8 (67M) 
Admission time: 14.49 (Friday) 
Clerking time: 15.40 – 17.05 (85 minutes) 
Staff: ST4 
Information provided: GP summary 
Interruptions:  None 
 
Summary 
Complicated history; symptoms developed over several months. Oct / Nov – aching legs, lost 
weight, night sweats, decreased appetite, unable to walk very far. The doctor asked “do you 
take tablets” – “Yes – for increased blood pressure”.  The doctor copied the medication listed 
in the GP summary into the case notes; she asked the patient “which day do you change your 
oxybutynin patch”; the patient said that he wasn’t using them anymore. She asked when the 
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lansoprazole was started and why, the patient said “yesterday”. She asked about OTC 
medicines e.g. aspirin, ibuprofen, the patient said “none”. The doctor discussed the priority of 
scans with a consultant (it was Friday afternoon) and then had to ring a radiologist twice to 
arrange.  
 
VTE RA – Paper available but not completed  
 
Outcome 
Regular medication prescribed but most items stopped as not indicated in current acute 
clinical situation, 0 errors in total of 5 items prescribed. No LMWH prescribed – Hb 8.9g/dl – 
patient possibly bleeding. Final diagnosis vasculitis.  Length of stay 15 days. 
 
 
Patient B45 (65M) 
Admission time: 11.08 (Monday) 
Clerking time: 12.15 – 12.55 (40 minutes) 
Staff: ST1 
Information provided: GP summary 
Interruptions:  12.50 – by another doctor re patient in ED (while writing drug chart) 
 
Summary 
Difficult history – non specific symptoms. Tired, dizzy, cold, SOB. Went for endoscopy last 
week but BP was too low. The doctor asked if the patient had any medication with him, he 
didn’t and didn’t know what he was taking. The doctor copied the medication from the GP 
summary into the case notes and then from the GP summary onto the drug chart; researcher 
advised that Prograf brand should be prescribed rather than tacrolimus as the different 
products available have differing bioavailabilities 
 
VTE RA – Paper available – removed and discarded 
 
Outcome 
LMWH not prescribed. Pt had low Hb and possibly bleeding so it wasn’t indicated. 1 error out 
of 12 items prescribed; ferrous sulphate 200mg od missed off. Length of stay 8 days. 
 
 
Patient B46 (48F) 
Admission time: 11.30 (Monday) 
Clerking time: 12.55 – 13.50 (55 minutes) 
Staff: ST1 
Information provided: GP letter – no information re medicines 
Interruptions:  None 
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Summary 
GP referred patient as he is concerned that patient still has cough and SOB despite 3 courses 
of antibiotics. Renal transplant patient; acute rejection Aug 2009, started on steroids. Doctor 
didn’t ask the patient about medicines, no information provided by GP, I checked EMIS – 
patient not on EMIS.  I went back to ask the patient – he had his own medication with him. 
Alfacalcidol wasn’t labelled – he said 0.25 micrograms on Mon, Wed and Fridays, he had a 
loose strip of tacroliomus 1mg he indicated 1mg BD, his dose of sodium bicarbonate (5grams 
BD) and cinacalcit also had to be confirmed. The drug history was written in the case notes 
and then copied onto the drug chart. The doctor went back to ask which antibiotics the patient 
has had, he said flucloxacillin but also said he was allergic to penicillin, he had also had 
ciprofloxacin. The doctor wrote the history and examination from memory; no notes were 
taken during the examination. 
 
VTE RA – Paper available – removed and discarded 
 
Outcome 
LMWH not prescribed – no results back so clinically unclear. Calcichew prescribed instead of 
cinacalcit. PPI written in plan in notes but not prescribed. Length of stay 5 days. 
 
 
Patient B48 (81F) 
Admission time: 14.21 (Monday) 
Clerking time: 15.50 – 17.00 (70 minutes) 
Staff: ST1 
Information provided: GP summary 
Interruptions:  15.50 Results received for previous patient – went to tell her that she can go 
home 
 
Summary 
Known DVT – on dalteparin; now has back pain, painkillers don’t work, GP now suspects PE. 
Doctor asked “which painkillers” – morphine given in ED on Saturday caused vomiting. Patient 
was also given trmethoprim on Saturday for ?UTI but hasn’t taken today due to vomiting.  
Medication copied from GP summary into case notes, Calcichew D3 forte written as Calcichew 
 
VTE RA – Paper available not completed 
 
Outcome 
Patient is already prescribed therapeutic dalteparin for DVT. Patient is prescribed dalteparin 
25,000 units / ml 0.6ml od. The doctor first prescribed 2,500 units od, when asked to check 
this dose she prescribed 25,000 units od (Maximum recommended daily dose 18,000 units). 
She had difficulty in calculating the correct dose of 15,000 units od from the information 
provided. Length of stay 4 days. 
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Patient B86 (68F) 
Admission time: 13.14 (Tuesday) 
Clerking time: 13.45 – 14.35 (50 minutes) 
Staff: ST1 
Information provided: GP hand written letter 
Interruptions:  None 
 
Summary 
GP handwritten letter provided – no past medical history or medication listed. Patient has 
presented SOB, and was prescribed immediate nebules and prednisolone. The doctor took no 
notes during the examination; the history and examination were written from memory. The 
patient had her own medication with her although I had to ask her the doses of her inhalers as 
these were not labelled (as a diversion while the doctor took arterial blood gases) 
 
VTE RA – Paper available but not completed 
 
Outcome 
The doctor asked the researcher about the VTE risk assessment – the patient has 2 risk 
factors – age and CPOD, she was prescribed dalteparin 2,500 units od as prophylaxis (no 
apparent reason for dose reduction). There was no attempt by the doctor to prescribe the 
regular medication until prompted to do so. No medication chart available from Nov 2009 so 
unable to assess accuracy. 
 
 
Patient B161 (36F) 
Admission time: 12.10 (Thursday) 
Clerking time: 13.20 – 15.00 (100 minutes) 
Staff: ST1 
Information provided: GP hand written letter 
Interruptions: 14.10 by F1 re patient clerking 
  14.10 by nurse needing a doctor to speak to a patients family re DNAR order 
 
Summary 
Handwritten letter from GP has no details of patient’s medication. Patient has had stomach 
pain for the past 5 days, has been off her food for 3 days, has a swollen abdomen and is 
jaundiced. She has brought her some of her own medication with her: fluoxetine 20mg od, 
omeprazole 20mg od, Cerazette 1 od (the doctor had to ask what this was – OCP), the patient 
states that she also usually takes vitamin B compound strong 2 od, multivitamins and thiamine.  
 
VTE RA – paper available but not completed 
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Outcome 
The doctor stated that she would not prescribed Fragmin due to the likelihood of deranged 
clotting; this was not documented in the case notes. Blood samples had not been taken as 
there was no HCA available; the doctor took the samples at the end of the clerking process. 3 
errors out of 3 items which should have been prescribed – fluoxetine and vitamin B compound 
strong omitted, omeprazole prescribed 20mg od, patient takes 20mg BD. Length of stay 3 
days. 
 
 
Patient B119 (72M) 
Admission time: 13.16 (Wednesday) 
Clerking time: 13.35 – 14.50 (75 minutes) 
Staff: F1 
Information provided: None 
Interruptions:  None 
 
Summary 
Patient has a pain behind their eye – went to GP who said go to the opticians. Has had 
spectacles from the optician but there is no improvement in the pain so sent to hospital; 
unclear who sent the patient. Patient can’t concentrate for more than 10 minutes without pain, 
suffers many episodes a day – whenever reading or writing, the top of his head is sore to the 
touch. Patient was asked if they take regular medication from the GP – had ‘diarrhoea tablets’ 
1 week ago – now finished. The doctor wrote a detailed history during history and examination 
and then used to write case notes, various potential diagnosis were looked up on the internet.   
 
VTE RA – Paper available – removed and discarded 
 
Outcome 
Dalteparin not prescribed. Patient on no regular medication – medication chart written and 
aspirin 300mg started – diagnosis embolus of retinal artery. Length of stay 14 days. 
 
Timeline 
13.35: start – nowhere to review case notes; doctors’ office full 
14.25: forgot to test cerebellar function – hand clap – had to go back 
14.35: handed patient over to registrar 
14.35: Ordered investigations on ICE: cholesterol, carotid Doppler, cardiac echo, and 
documented in notes 
14.50: drug chart and clerking complete 
 
 
Patient B120 (75M) 
Admission time: 14.00 (Wednesday) 
Clerking time: 14.55 – 16.10 (75 minutes) 
Staff: F1 
Information provided: GP letter and summary - faxed 
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Interruptions:  None 
 
Summary 
Patient confused. Has UTI resistant to ciprofloxacain and has had recent course of both 
trimethoprim and nitrofurantoin. Admitted on Fragmin 18,000 units od for PE diagnosed 
4/4/2009; this should actually have been stopped by the GP after 3 months but had been 
continued. Difficult history as patient was both deaf and confused. Microscopy report shows 
sensitivity to Tazocin and gentamicin – patient is allergic to penicillin so the only suitable 
option seems to be gentamicin. As this will probably require inpatient treatment I suggested 
contacting medical microbiology to see if an alternative oral antibiotic can be found. The doctor 
tried telephoning at 15.25 – med micro engaged twice. He got through at 15.55 and was told 
to ring back in 20 minutes! I rang ward 3y (infectious diseases) and spoke to an ID SpR for 
some advice – I suggested IV ertapenem as this is more likely to be accepted by the home IV 
team than gentamicin, the ID registrar agreed but suggested confirming with medical 
microbiology.  
 
VTE RA – Paper available – not completed 
 
Outcome 
Medication copied from GP summary onto medication chart – patient confused but no attempt 
made to confirm medication with patient. 14 items prescribed – no errors. Dalteparin dose 
reduced from 18,000 units od to 5,000 units od as prophylaxis ( age, previous PE, infection) 
Length of stay 7 days. 
 
Timeline 
14.55: start 
15.25: tried to contact Med Micro – engaged x 2 
15.55: spoke to med micro – asked to ring back in 20 minutes 
16.00: I spoke to an ID registrar re appropriate IV antibiotics 
16.00 drug chart written 
16.10 clerking complete 
 
 
Patient B122 (77F) 
Admission time: 18.30 (Wednesday) 
Clerking time: 18.30 – 19.27 (60 minutes) 
Staff: F1 
Information provided: GP hand written letter, listed medications but no doses or frequencies 
Interruptions:  None 
 
Summary 
Doctor checked blood results on ICE first before speaking to patient. Patient has 3 day history 
of diarrhoea; no blood passed, was vomiting 3 days ago, hasn’t eaten for a week and has 
cramping stomach pain. Has COPD – cough – greenish sputum. During the history and 
examination I chaperoned for the PR examination.  No medication was obviously available but 
when asked the patient had their own inhalers x 3 with them. The inhalers were not labelled so 
I asked the patient how she used them. 
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VTE RA – Paper available but not completed 
 
Outcome 
Dalteparin prophylaxis not prescribed; patient has at least 4 risk factors – age, COPD, 
dehydrated, immobile. Regular medication prescribed 1 error out of 4 items Calcichew should 
be BD not OD. Length of stay 6 days. 
 
 
Patient B162 (64M) 
Admission time: 14.34 (Thursday) 
Clerking time: 16.00 – 17.20 (80 minutes) 
Staff: F1 
Information provided: None 
Interruptions:  16.15: Had to do blood test requests for another patient 
  16.40 ECG technician arrived – doctor in the middle of clinical examination 
 
Summary 
Patient admitted from K clinic – clerking and plan already in case notes. Yesterday was 
sweaty and shaky around lunchtime; felt worse as the night went on – had to turn heating off, 
fine now. Doctor talked very quickly and used medical terminology so the patient didn’t always 
follow. The patient said that the doctor in the clinic wanted ‘tests’. The doctor explained that he 
probably had an infection, he had been on cyclophosphamide since October 2009, and we 
needed to find the source hence chest X-Ray, urine sample. When asked about current 
medication the patient said there was a “list in the file”. The list was a printout from Proton, the 
renal patient management system; unfortunately this is not always updated with medication 
changes. Doctor took notes during history and examination and used to write history in case 
notes.  
 
VTE RA – Paper available – discarded 
 
Outcome 
Regular medication prescribed; the doctor attempted to check the days of the week for the co-
trimoxazole taken three times a week and the alendronate. Dalteparin was not prescribed. 
Case notes from January 2010 missing; unable to confirm accuracy of medication history.  
Length of stay 2 days. 
 
Timeline 
16.00: start 
16.05: asked Registrar about the need for blood cultures 
16.25: Asked Registrar what was needed for ‘cardiology work up’ – Troponin T, ECG, echo 
16.40: ECG technician arrived in the middle of the clinical examination 
16.58: Ordered investigations on ICE – echo 
17.15: Drug chart written 
17.20: Clerking complete 
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Patient B163 (50F) 
Admission time: 15.42 (Thursday) 
Clerking time: 17.25 – 19.00 (95 minutes) 
Staff: F1 
Information provided: GP letter 
Interruptions:  18.10: went to BC to take blood cultures for sick patient 
  18.40: nurse asked to write drug chart for patient clerked earlier 
 
Summary 
Patient presented with left sided facial pain and collapse; has already been seen by the stroke 
nurse. Woke on Saturday with pain in forehead which moved to eye then ear. Monday still had 
pain – relieved by hot flannels. Wednesday at work felt dizzy had chest pains and collapsed. 
Afterwards was confused, didn’t know where she was, the room was spinning, her speech was 
funny and she felt disorientated. She was speaking half in English and half in Spanish – lasted 
for the rest of the morning. The doctor asked if she was on any medication, patient said “No”; 
however list form GP states zopiclone and lansoprazole. The patient says that she doesn’t 
take these regularly. CNS examination showed leg weakness, she had migraine as a child. 
Woking diagnosis ?migraine – needs MRI scan 
 
VTE RA – paper available with drug chart but drug chart not written 
 
Outcome 
Dalteparin not prescribed – no risk factors identified. Medication chart had no errors out of a 
total of one item. Length of stay 5 days. 
 
 
Patient B197 (37M) 
Admission time: 14.17 (Friday) 
Clerking time: 14.45 – 15.20 (35 minutes) 
Staff: ST2 
Information provided: Walk in centre proforma 
Interruptions:  None 
 
Summary 
Presenting complaint – burning / sharp pain in chest. Coughing or laughing makes him SOB; 
pain is worse when lying down. Patient says he is asthmatic but when asked if he takes any 
medicine she stated “none”. The doctor asked about inhalers; the patient says he last used an 
inhaler about 10 years ago; he says a wheeze is normal for him. The doctor took his own 
blood samples; he used a glove as a tourniquet as a tourniquet wasn’t available. Patient was 
asked to do a peak flow but was unable to comply due to pain.  
 
VTE RA – Paper available but drug chart not written. Need blood results and X-Ray to decide 
on treatment indicated 
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Outcome 
Dalteparin not prescribed, drug chart written later, prescriber not known. Risk factors asthma 
and infection. Medication history not checked by pharmacist; length of stay 1 day. 
 
 
Patient B198 (75F) 
Admission time: 14.22 (Friday) 
Clerking time: 16.30 – 17.30 (60 minutes) 
Staff: ST2 
Information provided: None – sent by GP  
Interruptions:  
16.35: called to radiology to discuss another patient 
16.51: interrupted by stroke nurse re patient seen earlier 
 
Summary 
No information provided so doctor consulted old notes, 3 volumes, for past medical history; 
arthritis, mitral valve replacement 2007 – on warfarin. Patient says he had “bleeding into his 
brain” prior to MVR.  Patient says he came to hospital because his blood level was too high 
yesterday – INR 19.4. He denied taking any new tablets or changing his diet.  He had his 
medication with him in a blister pack but had been told not to take “the yellow one or the white 
one” – bumetanide and spironolactone; the doctor was unable to identify these from the 
information on the blister pack. He didn’t know why he had been told to stop them. I used 
EMIS to see if he had been prescribed any acute medication; he had a diagnosis of cellulitis 
on 20/01/10 but denied being prescribed antibiotics. The EMIS printout was used to transcribe 
the patient’s current medication into the case notes. The patient was advised that he will have 
to stay in hospital until his INR is <5.  
 
Outcome 
The medication chart was not written during the clerking despite the patient being told that he 
will have to stay in hospital; the chart was written later 0 errors out of a total of 5 items. 
Therapeutic dalteparin was prescribed on 01/02/10 to be continued as the patient has a MVR 
and is no longer considered suitable for warfarin. Length of stay 5 days. 
 
Timeline 
16.30: start 
16.35: called to radiology to discuss another patient 
16.50: returned from X-Ray 
16.51: interrupted by Stroke Nurse re patient seen earlier 
17.30: clerking complete 
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Patient B199 (84F) 
Admission time: 16.18 (Friday) 
Clerking time: 18.50 – 20.20 (90 minutes) 
Staff: ST2 
Information provided: GP hand written letter and printed summary, MAR chart from care 
home 
Interruptions:  18.52 went to start clerking – nurse doing ECG (no ECG technician) 
  19.30 doctor bleeped by biochemistry 
 
Summary 
History provided by member of staff from care home. Until recently patient was quite mobile, 
for the past 2 days unable to talk, walk, feed herself and is now incontinent.  Patient responds 
to pain but no communication was possible.  
 
VTE RA – paper available but drug chart not written 
 
Outcome 
Dalteparin not prescribed on admission but CT scan ordered to exclude an intracranial bleed 
as the cause of the symptoms. When the chart was written, prescriber unknown, there were 0 
errors out of 8 items prescribed. Dalteparin prophylaxis was prescribed on ward 7a on the day 
following admission; length of stay 7 days. 
 
Timeline 
18.50: start 
18.52: nurse doing patients ECG 
19.40: doctor rang X-Ray re need for urgent CT scan 
20.00: started writing in case notes 
20.20; rang biochemistry re results 
20.20: clerking complete 
 
 
Patient C1 (77F) 
Admission time: 15.32 (Wednesday) 
Clerking time: 18.20 – 20.02 (100 minutes) 
Staff: Locum SHO (?F2) 
Information provided: GP letter and printed GP summary with current medication 
Interruptions:  19.00: Discussed complicated patient seen earlier with senior doctor 
  19.24: asked to put cannula in – patient need IV antibiotics 
  19.24: asked to request R leg Doppler for complicated patient 
 
Summary 
Patient had an episode of unresponsiveness; head went back, became vacant, eyes open. 
The relative said it lasted about 4 minutes and the patient was confused for about 20 minutes 
afterwards. Patient doesn’t remember the episode. When asked about other health problems 
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the patient indicated that she is on warfarin and says she has her INR checked regularly. She 
had her own medicines with her which the doctor looked at briefly – warfarin, digoxin, 
atorvastatin. The patient also had her yellow warfarin booklet with her. The doctor copied the 
information from the patient’s own medicines into the case notes and then returned them to 
the patient. 
 
VTE RA – Available on ICE – not completed 
 
Outcome 
Dalteparin not indicated as the patient is on warfarin. Regular medication was prescribed 0 
errors out of 3 items; however warfarin was not prescribed in the regular medication section of 
the chart. No dose of warfarin was prescribed as the doctor was unable to find current INR on 
ICE. Length of stay 10 days. 
 
Timeline 
18.20: start 
18.25: nurse brought in patients own medicines 
19.00: discussed complicated patient seen earlier with Registrar 
19.20: discussed problem with blood taken earlier – incorrect information on form, will have to 
take another sample 
19.24: asked to put in a cannula for patient who needs IV antibiotics 
19.24: asked to request Doppler of leg for complicated patient seen earlier 
19.30: ordered X-Ray on ICE and blood tests – printed forms 
19.40: finished writing up case notes 
19.40 wrote drug chart 
19.45: went to take blood samples 
19.50: ordered more blood tests on ICE and printed forms 
20.02: clerking complete 
 
 
Patient C2 (80M) 
Admission time: 16.48 (Thursday) 
Clerking time: 18.50 – 19.47 (60 minutes) 
Staff: ST5 
Information provided: Hand written GP letter, GP repeat form (provided by patient) 
Interruptions:  19.33: To review chest X-Ray and discharge patient 
   
Summary 
Presenting complaint SOB, possibly due to anaemia, Hb 7.9 from GP.  Patient drinks 
significant amount of alcohol, 2 whiskies and 2 bottles of Becks per night – possible upper GI 
bleed. When asked about medication the patient produced a GP repeat form (date unknown) 
which the doctor copied into the case notes and then returned to the patient. He also had foil 
strips of medication with him. 
 
VTE RA – Available on ICE – not completed 
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Outcome 
Dalteparin not indicated – HB 7.9. Regular medication prescribed, one error out of 12 items, 
isoosrbide mononitrate SR 60mg om prescribed; should be 120mg om. Length of stay 2 days. 
 
Timeline 
18.50: start 
19.22: investigations ordered on ICE 
19.30: drug chart started 
19.33: interrupted to review chest X-Ray and discharge patient 
19.35: Drug chart completed 
19.35 OGD ordered on ICE 
19.47: clerking complete 
 
 
Patient C3 (98F) 
Admission time: 16.25 (Friday) 
Clerking time: 18.20 – 20.20 (120 minutes) 
Staff: F1 
Information provided: Hand written GP letter, on a patient record card, patient had GP 
repeat form 
Interruptions:  19.55: To write TTO and book ETT for another patient 
   
Summary 
Patients son present during history taking. Fell over 2 weeks ago and banged head, now has a 
funny headache – different to usual, top of head is sensitive to touch. Also has had blurred 
vision over the last couple of weeks. When asked about medicines the patient said she took 
senna and Movelat (probably Movicol) now and again; GP repeat listed 12 items. 
The doctor took notes during the interview then examined the patient,  
19.30 ordered necessary tests blood tests, X-Ray, ECG, VTE RA on ICE 
19.40 wrote drug chart – I was asked to clarify dose of digoxin as 125 microgram and 62.5 
microgram tablets on GP repeat. The medicines were copied from the GP repeat into the case 
notes and then initially from the case notes onto the medication chart. Half way through the 
process the doctor started copying the medicines directly from the GP repeat onto the 
medication chart. There was no frequency stated for the Celluvisc eye drops so I asked the 
patient 
19.50 doctor went to take blood samples but patient in X-Ray 
20.10 patient returned from X-Ray but no suitable location to take blood samples; another 
doctor using the interview room; samples were taken at 20.20 
 
VTE RA – Completed on ICE while ordering blood tests etc 
 
Outcome 
VTE – patient aged over 60 but BP 200 / 92, and to have CT head. Dalteparin not prescribed. 
Medication prescribed 0 errors out of 12 items but digoxin and Celluvisc clarified at point of 
prescribing. Length of stay 3 days. 
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Timeline 
18.20 start – read case notes 
18.55: clinical examination 
19.30: investigations ordered on ICE, blood tests, X-Ray, ECG, VTE RS 
19.40: drug chart written 
19.50: went to take blood sample – patient in X-Ray 
19.55: asked to write TTO and book exercise tolerance test for a different patient 
20.03: discussed patient with consultant 
20.10: ordered CT brain on ICE 
20.10: patient returned from X-Ray but interview room occupied 
20. 20: clerking complete but blood samples not taken 
 
Patient C68 (58F) 
Admission time: 10.25 (Monday) 
Clerking time: 12.40 – 14.15 (95 minutes) 
Staff: F2 
Information provided: Very brief hand written GP letter; medicines listed no doses or type of 
inhalers 
Interruptions:  13.31: To prescribe antiemetic for a different patient 
  13.41: Pyrexial patient need paracetamol prescribing 
  
Summary 
Patient presented with back pain, made worse by breathing ?PE. GP letter stated medication 
as salbutamol, tiotropium, mucodyne, seretide. When asked about medication the patient said 
she also took co-codamol 30/500 for arthritis. The doctor asked for clarification of the doses of 
inhalers. This doctor said that they usually write notes during history taking but on this 
occasion forgot to take some paper with them. 
 
VTE RA – Doctor found a green form (they were all supposed to have been removed); the 
doctor was advised that the RA should be completed on ICE – an ICE RA was completed 
 
Outcome 
Dalteparin not prescribed; has 2 VTE risk factors – age and COPD but BP 193/91. 5,000 units 
od prescribed later.  Medication history not confirmed by pharmacist, doctor asked about 
appropriate NSAID for back pain – ibuprofen not diclofenac, and asked how to prescribe 
tiotropium inhaler 18 micrograms od. Length of stay 2 days. 
 
Timeline 
12.40: start – read notes – confusion – nursing documentation for a different patient 
13.15: ECG shows ? pace maker not working. Started writing up case notes 
13.30: went to take arterial blood sample – patient in X-Ray 
13.31: interrupted to prescribe anti-emetic for different patient 
13.37: drug chart started 
13.41: interrupted – pyrexial patient needs paracetamol prescribing 
13.41: VTE RA completed on ICE 
13.50: Drug chart completed; went to take arterial blood sample 
14.05: cannula inserted and venous blood samples taken 
14.15: clerking complete – consultant came to discuss patient 
238 
 
Patient C69 (91M) 
Admission time: 15.55 (Monday) 
Clerking time: 17.10 – 19.00 (110 minutes) 
Staff: F1 
Information provided: GP summary 
Interruptions:   
Summary: 
When the doctor initially went to clerk the patient he was having a blood sample taken; 
however the EPA was unsuccessful so the doctor had to take the samples after the history 
and examination. The history was given by the patients niece as the patient had early 
dementia. Presenting complaint, falls, not eating, ?dehydration, ?CVA. the patient has been 
getting worse over the past 6 months but has not carers as he won’t allow anyone into the 
home to help. The patients 2 sons then arrived and conformed that the patient has refused 
help / hospital admission in the past. The doctor asked water tablets, the patient’s niece said 
he was not currently taking any medicines. 
 
VTE RA – Available on ICE – not completed 
 
Outcome 
Patient has 2 VTE risks, age, dehydration and possibly an infection. Bleeding risk – creatinine 
158. Dalteparin not prescribed; later entry in notes states “hold dalteparin pending CT scan”. 
Unable to locate medication chart to assess accuracy of prescribing. Length of stay 33 days. 
 
Timeline 
17.10: start 
17.14: went to see patient; EPA trying to take blood sample but unsuccessful 
17.50: started writing case history (from memory no notes taken) 
18.05: went back to complete clinical examination – needed assistance from nurse 
18.20: successfully inserted butterfly to obtain blood samples 
18.50: ordered ECG, X-Rays on ICE 
19.00: clerking complete 
 
 
Patient C104 (63F) 
Admission time: 13.17 (Tuesday) 
Clerking time: 14.00 – 15.20 (80 minutes) 
Staff: ST1 
Information provided: GP home visit report 
Interruptions:  13.44: Bleeped 
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Summary 
Patient suddenly became confused 3 days ago; also complained of diarrhoea and vomiting. 
Husband said she kept leaving taps running. Diagnosed with lung cancer November 2009. 
The patient had her own medication with her; the doctor checked that these were the same as 
listed in the GP summary. The patient said that she doesn’t use inhalers anymore, she has 
home oxygen instead; she doesn’t take the sleeping tablets (zopiclone) anymore – she last 
had them in February. 
 
VTE RA – Available and completed on ICE 
 
Outcome 
Patient has VTE risks, age and cancer, no bleeding risks identified; dalteparin not prescribed. 
Medication prescribed 0 errors out of 3 items. Length of stay 3 days. 
 
Timeline 
14.00: start – read case notes and checked ICE for results 
14.15: ECG technician came to do ECG 
14.23: ECG complete 
14.44: bleeped 
14.45: reviewed previous scans on ICE – CT, X-Ray, PET 
14.55: wrote up clerking 
15.10: wrote drug chart 
15.15: ordered investigations on ICE 
15.20: clerking complete 
 
 
Patient C105 (37F) 
Admission time: 15.09 (Tuesday) 
Clerking time: 15.45 – 17.00 (75 minutes) 
Staff: ST1 
Information provided: GP referral proforma 
Interruptions:  15.50: bleeped 
  16.07: bleeped 
  16.46: bleeped – number unobtainable 
  
Summary 
Presenting complaint cough and SOB; patient known to be IVDU and drink excess alcohol. 
The doctors asked the patient about medication; she said that she doesn’t take any medicines. 
Working diagnosis ?PE, patient has had previous DVT. Patient indicated that she has an 
allergy to LMWH so a therapeutic dose of fondaparinux was prescribed. 
 
VTE RA – Available on ICE – not completed 
 
Outcome 
Therapeutic fondaparinux prescribed for ?PE, patient has had previous DVT and high risk as 
IVDU. Clotting studies requested as patient drinks 40+ units of alcohol per week. Medication 
history 0 errors out of 0 items, length of stay 4 days. 
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Timeline 
15.45: start – read case notes 
15.50: bleeped 
15.52: consultant for 15.00 post take ward round has not arrived – tried to contact via 
secretary 
15.55: went to see patient – having ECG 
16.07: bleeped 
16.10: returned from answering bleep 
16.15: took blood samples difficult access – butterfly used, 2 sites tried 
16.35: ordered investigations on ICE 
16.45: started writing up case notes 
16.46: bleeped – number unobtainable 
16.55: drug chart written 
17.00: clerking complete 
 
 
Patient C134 (71F)  
Admission time: 12.45 (Tuesday) 
Clerking time: 13.45 – 15.15 (90 minutes) 
Staff: ST1 
Information provided: None 
Interruptions:  14.30: nurse came to discuss patient from morning ward round re ENT clinic 
appt 
14.33: nurse practitioner asked doctor to request ultrasound – doctor gave 
nurse ICE access 
  14.40: spoke to ENT re above patient – needs Cantonese interpreter 
  
Summary 
Doctor wrote brief notes on the back of addressograph label sheet during interview. Patient 
says she was sent in by her GP as her sugar levels were very high; no letter received from GP. 
Patient was complaining of tiredness over the past 2 weeks, decreased appetite, drinking lots 
of fluid. When asked which medicines she usually takes she gave the nurse a list which she 
had written. The patient was advised that she will probably need treatment with insulin. 
 
VTE RA – Available on ICE – not completed 
 
Outcome 
Dalteparin was indicated – 2 VTE risk factors, diabetes and dehydrated, but was not 
prescribed. Medication was copied from patients own list onto the medication chart. Length of 
stay 4 days. 
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Timeline 
14.43: start 
14.05: went to take blood gases; no syringes on trolley had to get from treatment room 
14.07: went to take blood for blood gas analysis 
14.15: blood silt on blood gas machine – had to clean – infection risk 
14.20: checked insulin regimen in Trust formulary 
14.30: nurse came to discuss patient from the morning post take round – needs to go to ENT 
clinic 
14.33: nurse practitioner asked doctor to request ultrasound for patient she was seeing; doctor 
gave nurse appropriate access to ICE to make request 
14.35: drug chart written 
14.40: had to speak to ENT re above patient; need Cantonese interpreter and ultrasound  
14.53: returned to writing up case notes 
14.55: supposed to be on 3pm post take ward round; went to look for consultant 
15.04: ordered chest X-Ray on ICE 
15.08: went to cannulate patient – 2 staff unsuccessful 
15.15 clerking complete and patient cannulated 
 
 
Patient C135 (82F) 
Admission time: 15.09 (Wednesday) 
Clerking time: 15.15 – 16.25 (70 minutes) 
Staff: ST1 
Information provided: Case notes – patient referred from G clinic, entry from haematology 
SpR 
Interruptions:  16.05: F1 – to discuss another patient 
  
Summary 
Doctor took no notes during the interview. Presenting complaint, collapse in toilet on G clinic, 
patient was seen with her daughter. Patient was in haematology clinic, has NHL and is due to 
start chemotherapy. When asked about medication her daughter said she takes: blood 
pressure tablets, metformin, bendrofluazide, allopurinol and a new tablet for diabetes 
beginning with S – sitagliptin. 
 
VTE RA – Available on ICE – not completed 
 
Outcome 
Patient has 2 VTE risk factors, age and cancer. Enoxaparin was prescribed as ACS is a 
possible diagnosis. Regular medication was confirmed using recent TTO and EMIS and 
prescribed; 0 errors out of 6 items prescribed. Length of stay 2 days. 
 
Timeline 
15.15: start – read case notes and reviewed ECG 
15.43: history taking and examination complete – asked nurse to start telemetry 
15.50: drug chart written 
16.00: results on ICE reviewed; X-Ray ordered 
16.05: discussed another patient with F1 
16.23: clerking complete 
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Patient C167 (62F) 
Admission time: 11.43 (Thursday) 
Clerking time: 12.12 – 12.52 (40 minutes) 
Staff: ST1 
Information provided: GP letter – very brief 
Interruptions:  None 
  
Summary 
No notes taken during interview. Presenting complaint, patient has recently returned from 
Tenerife – had diarrhoea. Visited GP who diagnosed UTI and prescribed trimethoprim which 
caused nausea so was changed to cefalexin. Now she has a headache. The doctor asked 
what she had taken for the headache, the patient said ‘paracetamol and Brufen’. The doctor 
asked the patient if the GP had said why they wanted her to go to hospital; the patient said 
that the GP was worried about a ‘brain bleed’. 
 
VTE RA – Available on ICE – not completed 
 
Outcome 
2 VTE risks – age and UTI; dalteparin not prescribed. No regular medication taken; drug chart 
not written, no medicines reconciliation by pharmacist. Length of stay 1 day. 
 
Timeline 
12.12 Start 
12.34 Asked HCA to take blood 
12.40 Prescribed co-dydramol for headache 
12.52 clerking complete 
 
 
Patient C168 (51F) 
Admission time: 12.10 (Thursday) 
Clerking time: 14.45 – 15.35 (50 minutes) 
Staff: ST1 
Information provided: Hand written GP letter listing medication 
Interruptions:  None 
  
Summary 
Presenting complaint, back pain and possible reaction to doxycycline – swollen tongue. Has 
been wheezing and having night sweats, SOB Has been taking Solpadeine for back pain. 
When asked about regular medicines she said that she takes ‘lots’ and the GP has sent a list. 
Possible PE, d dimer ordered. 
 
VTE RA – Available on ICE – not completed 
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Outcome 
No VTE risk factors; dalteparin not prescribed. Drug chart written, oxybutynin patch prescribed 
but no strength, no medicines reconciliation by pharmacist so accuracy unknown. Length of 
stay 1 day. 
 
Timeline 
14.45: start 
15.10: history taking and examination complete 
15.25: wrote drug chart 
15.35: reviewed results; blood tests, chest X-Ray, WTU, ordered d-dimer 
15.35: complete 
 
 
Patient C136 (76M) 
Admission time: 17.16 (Wednesday) 
Clerking time: 18.10 – 19.35 (85 minutes) 
Staff: F1 
Information provided: Handwritten GP letter with details of medication on reverse 
Interruptions:  18.47: bleeped – letter needed for patient – asked nurse to bring the case 
notes 
  18.55: bleeped – electronic TTO for wd 7b won’t print, needs completing 
  19.05: bleeped – took nurse from 7b back to lift 
  
Summary 
Presenting complaint, pain in shoulder and anaemia. Pain only occurs when walking, not at 
rest, has to stop every 10 minutes or so. When asked if he takes any medication the patient 
said ‘a statin, felodipine, bendroflumethiazide and has just started iron tablets’, patient hasn’t 
brought his medicines with him. 
 
VTE RA – Available on ICE not completed, green form completed later. Hb 6.5 on admission, 
dalteparin not indicated.  
 
Outcome 
Dalteparin not prescribed. Medicines confirmed with EMIS; no drug chart written. Usual 
medication prescribed later and VTE RA completed ? by whom,  0 errors out of 3 items. 
Length of stay 3 days. 
 
Timeline 
18.10: start 
18.47: bleeped – discharge letter needed for patient – nurse asked to bring case notes 
18.48: started writing up clerking 
18.55: nurse arrived electronic TTO for 7b required won’t print, doctor completed 
19.05: took nurse back to lifts 
19.12: registrar came to discuss patient 
19.20: reviewed results on ICE and ordered more investigations 
19.30: patient needs PR examination 
19.35: patient has gone to X-Ray – clerking complete 
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Patient C169 (96F)  
Admission time: 15.28 (Thursday) 
Clerking time: 18.10 – 19.30 (80 minutes) 
Staff: ST1 
Information provided: Handwritten list of medicines from patients daughter 
Interruptions:  18.57: nurse from HEC came to ask dose of Premarin prescribed earlier 
 
Summary 
Patient referred by GP; history from daughter, patient has vascular dementia. Patient lives 
alone but has carers three times a day. Presenting complaint cellulitis, needs IV antibiotics. 
 
VTE RA - available on ICE and completed; doctor forgot to ask about personal and family 
history of VTE and asked me to go and ask the patients daughter. RA was not correctly 
completed on ICE as it entry could not be verified later (Dec 2010). 
 
Outcome 
Three VTE risk factors, age, immobile , cellulitis. Dalteparin prescribed. Regular medicines 
prescribed using patients own hand written list and TTO from December 2009 (4 months ago). 
0 errors out of 4 items prescribed. Length of stay 36 days. 
 
Timeline 
18.10: start 
18.35: had to remove dressings from legs to assess 
18.45: reviewed results on ICE 
18.55: went to ask patient for list of medication but patient had gone to X-Ray 
18.57: nurse from HEC came to clarify dose of Premarin prescribed earlier 
19.10: antibiotics and dalteparin prescribed 
19.15: reviewed chest X-Ray 
19.20: went to insert cannula for IV antibiotics 
19.30: clerking complete 
 
 
Patient C205 (81M)  
Admission time: 14.03 (Friday) 
Clerking time: 16.15 – 17.30 (75 minutes) 
Staff: F1 
Information provided: GP summary 
Interruptions:  16.55: doctor came to say that patient seen earlier needs DNAR 
  
Summary 
Presenting complaint – swollen leg for past 2 weeks. Fell this morning. Also has pain in hip 
and no analgesia seems to work.  Provisional diagnosis ?DVT 
 
VTE RA – available on ICE  - not completed 
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Outcome 
Therapeutic dalteparin prescribed, had to confirm dose with me, estimated patient’s weight. 
Regular medication prescribed using GP summary. Case notes from April 2010 missing; 
unable to confirm accuracy of medication history. Length of stay 54 days. 
 
Timeline 
16.15: start – read case notes 
16.20: went to interview patient 
16.25: doctor came to say post take ward round starting 
16.40: completed writing history (started during patient interview) 
16.42: went back to check allergies with patient 
16.55: interrupted by F1 re patient seen earlier – needs DNAR 
17.10: ordered investigations on ICE – blood tests, Doppler, drug chart written 
17.15: went to check patients weight to dose Fragmin 
17.18: reviewed ECG 
17.25: printed out blood test forms; ICE was down earlier 
17.30 clerking complete 
 
 
Patient D35 (76M)  
Admission time: 10.22 (Monday) 
Clerking time: 11.45 – 12.45 (60 minutes) 
Staff: ST1 
Information provided: GP summary 
Interruptions:  12.20: porter came to take patient for CT scan 
  
Summary 
Sudden headache and blurred vision 3 days ago - can’t focus, can’t read. Previous stroke – 
lost some vision as a result.  Used list of medicines written by Stroke nurse and asked if had 
taken any more – had telephoned GP who had advised paracetamol for headache.  Asked re 
OTC ? herbal medicines ‘ Holland & Barrett’. Ophthalmoscope beside bed not working – 
couldn’t find a mobile one. CT scan showed new stroke. 
 
VTE RA – completed on ICE – paper just bleeding risks ticked – no VTE RFs ticked 
 
Outcome 
Dalteparin contra indicated – new stroke – not prescribed. MH accurate – 0 errors out of 4 
items prescribed. Length of stay 3 days 
 
Timeline 
Patient seen b y stroke nurse first 
11.50: Went to start clerking – patient in toilet 
11.55: start clerking 
12.20: Porter came to take patient for CT scan 
12.27: started writing up clerking 
12.45: clerking complete 
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Patient D36 (66F)  
Admission time: 11.45 (Monday) 
Clerking time: 13.30 – 15.25 (115 minutes) 
Staff: ST1 
Information provided: GP referral proforma 
Interruptions:  13.52: Bleeped re referral made at weekend by SHO on call – bleep passed 
on 
  15.20: Bleeped – didn’t answer it 
 
Summary 
Presenting complaint – chest pain. Went shopping, suddenly felt terrible hot and cold, felt 
confused. Pain was crushing and lasted a couple of hours, GTN spray didn’t work. Kept going 
hot and cold, nauseated, had palpitations. Patient says she takes esomeprazole – not on GP 
summary. Checked on EMIS – also on atorvastatin, montelukast, ezetimibe, bezafibrate; none 
in GP summary! Doctor confused with buprenorphine patches – from summary thought patient 
was applying four patches at a time not one each week. Diagnosis PE. 
 
VTE RA – Completed on ICE and paper; ICE the day after the paper 
 
Outcome 
Dalteparin not prescribed initially as surgical review requested. Therapeutic dalteparin 
prescribed 13.04.11 once PE diagnosed. Regular medication prescribed but not confirmed 
with patient. O errors out of 17 items prescribed. Length of stay 16 days. 
 
Timeline 
13.31: No computer to review bloods 
13.52: Bleeped re referral made at weekend by SHO on call – bleep passed on 
14.10: Stared writing up clerking 
14.40: Bleeped surgical SHO 
14.42: Surgical SHO answered – will review when results available 
14.55: Rang biochemistry to add amylase and LFTs to blood tests 
15.15: PR examination 
15.20: Bleeped – didn’t answer it 
 
 
Patient D37 (86F)  
Admission time: 14.57 (Monday) 
Clerking time: 16.15 – 17.35 (80 minutes) 
Staff: ST1 
Information provided: GP handwritten letter – partly illegible; medication list incomplete 
Interruptions:  16.20: Interrupted about another patient 
  17.32: Bleeped – didn’t answer it 
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Summary 
Patient was very deaf and seen with niece: niece ‘talked over’ the patient throughout the 
interview. 
Presenting complaint – leg swelling over last 2 weeks. Bendroflumethiazide changed to 
furosemide 5 days ago by GP.  Also taking amoxicillin for ? cellulitis – has all her own 
medication with her. Differential diannoses – DVT or cardiac cause, not cellulitis.  
  
VTE RA – Completed on ICE and paper 
 
Outcome 
Dalteparin 5,000 units daily prescribed.  Regular medication prescribed but not confirmed with 
patient. O errors out of 3 items prescribed. Length of stay 25 days. 
 
Timeline 
16.20: Interrupted about another patient 
17.22: Ordered tests on ICE 
17.32: Bleeped – didn’t answer it 
 
 
Patient D61 (77F)  
Admission time: 10.29 (Tuesday) 
Clerking time: 11.35 – 12.45 (70 minutes) 
Staff: ST5 
Information provided: Kent Lodge notes and copy of medication chart 
Interruptions:  None 
  
Summary 
Son present during interview but didn’t interrupt. Presenting complaint SOB, cough and legs 
have swollen over last 2 weeks. Doctor checked list of medication provided by Kent Lodge 
with patient; explained that omeprazole was to be stopped as it has little benefit and causes 
problems with infections. Diagnosis infective exacerbation of COPD – doxycycline prescribed. 
 
VTE RA – VTE RA available in office and ICE – neither completed. Both completed next day. 
 
Outcome 
Dalteparin prescribed 2,500 units od pt wt 45kg approximately   - same dose as Kent Lodge. 
Doctor asked about dose reduction in elderly – no evidence for reduction in elderly. Doctor 
checked list of medication provided by Kent Lodge with patient before prescribing. 1 error out 
of 5 items Length of stay 31 days. 
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Timeline 
11.50: Took arterial blood for blood gas (difficult – had to try twice) 
 Inserted cannula for IV antibiotics and took venous blood and blood for cultures 
12.17: AMU blood gas machine not working – had to go to ED 
12.19: Went back to check allergies as will need antibiotics 
12.20: Ordered tests on ICE; blood cultures, chest X-Ray 
12.27: Blood samples podded to labs – no pods – had to go to ED. None in ED left blood in 
ED to be sent when pods available 
12.30: Started writing up clerking 
12.40: Started writing up drug chart 
 
 
Patient D62 (60F)  
Admission time: 13.10 (Tuesday) 
Clerking time: 14.30 – 15.45 (75 minutes) 
Staff: ST1 
Information provided: GP summary 
Interruptions:  15.05: Had to chaperone registrar 
  
Summary 
Presenting complaint – SOB, cough, chest pain. Seen by GP last week for chest infection, 
went to GP for a sick note and GP sent to hospital as has been unwell for 9 days; has had 
several chest infections Paracetamol makes the chest pain better also takes ‘ blood pressure’ 
tablets. Doctor asked for a list of medication; patient doesn’t have one but says she takes 
bendroflumethiazide. Doctor prescribed clarithromycin, pharmacist intervened – patient has 
had erythromycin recently from GP, penicillin allergic – anaphylaxis, levofloxacin 500mg od 
suggested and prescribed. 
. Diagnosis ?PE ? pneumonia 
 
VTE RA – Completed on ICE and paper 
 
Outcome 
Dalteparin 5,000 units daily prescribed. Regular medication prescribed but not confirmed with 
patient. O errors out of 2 items prescribed. Length of stay 1 day. 
 
Timeline 
14.45: Ordered chest X-Ray and did VTE on ICE 
14.50: Went back to examine patient 
15.00: Stared writing up clerking 
15.05: Went to chaperone registrar 
15.15: Returned 
15.19: Wrote drug chart 
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Patient D63 (84F)  
Admission time: 13.453 (Tuesday) 
Clerking time: 15.45 – 17.25 (100 minutes) 
Staff: F1 
Information provided: GP summary 
Interruptions:  16.00: Technician came to do ECG 
  
Summary 
Presenting complaint – SOB, lack of energy. Been away for a few days and felt unwell since 
coming home – shivering and sweating. Patient has neuralgia – takes carbamazepine and is 
allergic to cefaclor – face swells. Doctor asked for list of medication; patient has her GP repeat 
with her. Diagnosis PE. 
 
VTE RA – Completed on ICE and paper. 
 
Outcome 
Dalteparin 10,000 units stat prescribed for ?PE. No regular medicines prescribed just nebules 
and dalteparin, prescription not discussed with patient; no medicines reconciliation by 
pharmacist. Length of stay 2 days. 
 
Timeline 
15.50: Blood gases – may need oxygen 
16.00: Technician came to do ECG; took blood gas to analyser 
16.10: Went to see patient – HCA taking blood 
16.40: Discussed oxygen concentration with senior doctor 28% asked nurse to give 
16.45: Ordered chest X-Ray – started writing up clerking 
17.05: Discussed with registrar – to have steroids and nebules 
17.15: Patient in X-Ray – doctor needs to ask social history 
17.25: handed over to registrar 
 
 
Patient D97 (71M)  
Admission time: 15.49 (Wednesday) 
Clerking time: 16.01 – 17.31 (90 minutes) 
Staff: F2 
Information provided: GP summary 
Interruptions:  None 
  
Summary 
Presenting complaint – very breathless for past 2 weeks. Doctor asked the patient if he had 
his medicines with him – he had; the doctor said that they would look at them later. Asked if 
the patient used nebules at home –he does – salbutamol and Atrovent. Information from the 
labels on the patient’s own medicines was used to prescribe, the prescription was not 
confirmed with the patient. The Seretide inhaled had no label but was prescribed as 2 puffs 
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BD – the dose was not confirmed with the patient. The drugs on the medication chart were 
copied into the DH in the case notes. 
Diagnosis infective exacerbation COPD. 
 
VTE RA – Completed on ICE only – no paper RA 
 
Outcome 
Dalteparin not prescribed by clerking doctor; 5,000 units od prescribed later the same day. 
Regular medication was prescribed but was not confirmed with the patient. O errors out of 8 
items prescribed. Length of stay 8 days. 
 
Timeline 
16.01: Nurses have admission notes; checked old results on ICE 
16.28: Ordered tests on ICE then went to interview patient 
16.37: Arterial blood gas 
16.40: Blood gas taken – ECG technician arrived 
16.43: Went to get patients own medicines – asked about ITU admissions and BIPAP 
16.56: Went to take venous blood – technician still doing ECG 
17.01: Took blood 
17.08: Started writing up clerking 
 
 
Patient D254 (85F)  
Admission time: 11.37 (Tuesday) 
Clerking time: 14.05 – 15.37 (90 minutes) 
Staff: F2 
Information provided: GP handwritten letter – legible; current repeat prescription faxed 
Interruptions:  15.12: By another doctor asking how to make a spinal team referral on ICE 
  
Summary 
Presenting complaint – legs give way so unable to walk. Been putting on weight over last 6 
months; previously walked with a trolley. Patient said that she has her medication in her 
handbag; the doctor said that her GP has sent a list. The doctor copied the GP repeat into the 
case notes; doses but no frequencies were recorded. The doctor checked BNF on line to find 
out the indications for levetiracetam.. Diagnosis heart failure. 
 
VTE RA – Completed on ICE and paper 
 
Outcome 
Dalteparin 5,000 units prescribed . Therapeutic dalteparin prescribed 13.04.11 once PE 
diagnosed. Regular medication prescribed but the prescription was not checked with either the 
patient or her own medicines. O errors out of 8 items prescribed. Length of stay 4 days. 
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Timeline 
14.05: Reviewed notes – no GP letter; I retrieved from fax machine 
14.11: Rang cardio respiratory regarding ECHO which GP letter says patient had 2 weeks ago 
14.55: Doctor finished seeing patient – booked chest X-Ray on ICE 
14.57: Rang clinical chemistry to add LFTs to blood tests 
14.59: Rang LHCH for copy of ECHO report to be faxed 
15.01: Started writing up 
15.12: Interrupted by another doctor re making a referral to the spinal team on ICE 
15.20: Wrote drug chart 
15.22: VTE done on ICE 
15.33: Rang LHCH back to see if they have found the ECHO report 
15.37: Consultant came to discuss 
 
 
Patient D138 (46F)  
Admission time: 13.07 (Thursday) 
Clerking time: 14.06 – 15.57 (110 minutes) 
Staff: F2 
Information provided: GP handwritten letter and summary 
Interruptions:  None 
 
Summary 
Presenting complaint – low haemoglobin. Hb 9.3g/dl on ferrous sulphate now feels short of 
breath when going up and down stairs. Has had 2 periods in the last month.  When asked 
about medication the patient was able to list her medication with doses: domperidone 10mg 
TDS, omeprazole 40mg BD, ferrous sulphate 200mg TDS, fluoxetine – but she hasn’t taken 
this for the last few days. The doctor correctly documented this information in the case notes 
and discussed with me whether or not to prescribe fluoxetine. I suggested that she ask the 
patient why she stopped taking it; the doctor did not discuss this with the patient. Diagnosis 
anaemia ? cause. 
 
VTE RA – Completed on ICE and paper. 
 
Outcome 
Dalteparin not prescribed – no risk factors and ?PV bleed. Regular medication prescribed but 
not confirmed with patient. No medicines reconciliation by pharmacist. Length of stay 1 day. 
 
Timeline 
14.06: Read GP letter and nurse triage notes 
14.35: Started writing up clerking – had to stand up – no seats in doctors office 
14.40: Checked old blood results on ICE 
15.07: Finished writing up clerking 
15.17: Discussed plan with consultant 
15.33: Completed clerking – plan agreed with consultant 
15.45: Took blood – first attempt unsuccessful 
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Patient D139 (80M)  
Admission time: 15.59 (Thursday) 
Clerking time: 17.31 – 20.10 (160 minutes) 
Staff: F2 
Information provided: GP summary 
Interruptions:  18.30: Nurse from Obs ward asking about a patient with ?DVT 
  
Summary 
Presenting complaint – has chest infection; has stopped drinking fluids and now can’t stand up. 
Has cough, SOB and sweats. The patient has his own medication with him, the doctor used to 
write drug chart and DH in notes. There was no label on the Seretide inhaler; advised to check 
GP summary for dose. Asked about the need to write doses in the DH in the case notes – 
explained problems in the drug chart goes missing.  Patient came in on flucloxacillin; showed 
how to prescribe the remaining 8 doses.. Diagnosis pneumonia. 
 
VTE RA – Completed on ICE and paper. No paper RA forms in doctors’ office – doctor asked 
where supplies were kept and went to get more from ED with nurse practitioner. 
 
Outcome 
Dalteparin 5,000 units od prescribed. Regular medication prescribed but not confirmed with 
patient .1 error out of 7 items prescribed – ferrous sulphate missed off. Length of stay 8 days. 
 
Timeline 
17.31: Reviewed notes and previous results on ICE, X-Rays on PACS 
17.45: Went to see patient 
18.15: Stared writing up clerking – had to get VTE forms and drug charts from ED 
18.41: Went to get patients own medicines to write DH 
18.55: Ordered ECG on ICE 
19.17: Chest X-Ray ordered on ICE 
19.25: Went to take blood and put in venflon; 3
rd
 attempt successful, couldn’t get blood sample 
from it 
19.50: Went to take venous blood as unable to get via venflon – unsuccessful – I suggested 
that someone else should try 
20.00: F2 successfully took blood 
 
 
Patient D256 (82F)  
Admission time: 12.59 (Wednesday) 
Clerking time: 14.35 – 16.45 (130 minutes) 
Staff: F2 
Information provided: GP summary and GP repeat 
Interruptions:  16.27: F2 came to hand over a patient with pneumonia who needs monitoring 
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Summary 
Initially no GP letter – I found beside the fax machine after the patient interview. Presenting 
complaint – GP telephoned patient at home as she has a low Hb 6.1g/dl. Feels light headed, 
has to sit down regularly and gets very SOB. Symptoms have developed over last 2 – 3 
months; previously able to go out to hairdresser etc. now has to sit down on the way from 
lounge to kitchen. Patient takes ‘water tablets’ and laxatives, has raised cholesterol and takes 
‘takes two little tablets’ ; doctor didn’t pursue. She has been told not to take aspirin as ‘it will 
make her bleed inside’ Doctor asked ‘how often do you use your GTN?’ Doctor asked if patient 
has her own medicines – she has but they are in an unlabelled Dosette box but she also has 
her GP repeat; initially she only gave the doctor page 2 which was discovered when she was 
writing the DH in the clerking – she had to back and ask for page 1. However the patient is 
only taking half of one of the tablets – GP repeat has the old dose listed. The patient is also 
prescribed inhalers but wasn’t aware that she had either asthma or COPD. She also takes co-
codamol for ‘bones / cramp’ Doctor asked ‘have you ever had clots in your legs or lungs?’ 
Diagnosis iron deficiency anaemia 
 
VTE RA – Completed on ICE and paper.  
 
Outcome 
Dalteparin 5,000 units od prescribed. Regular medicines prescribed but not confirmed with 
patient, clopidogrel and dipyridamole withheld. 0 errors out of 7 items prescribed. Length of 
stay 4 days. 
 
Timeline 
15.09: Started writing up clerking – I found GP fax beside fax machine 
15.55: Finished writing clerking and went to discuss patient with registrar 
15.57: Ordered blood tests on ICE 
16.05: Wrote drug chart 
16.10: Went to insert cannula and take blood 
16.27: F2 came to hand over a patient with pneumonia who needs monitoring 
16.40: Ordered blood for transfusion – had to go and ask patient about transfusion history to 
complete the form. Blood samples podded  
 
 
Patient D180 (62F)  
Admission time: 13.12 (Friday) 
Clerking time: 14.22 – 15.23 (60 minutes) 
Staff: F2 
Information provided: GP summary 
Interruptions:  None 
  
Summary 
Presenting complaint – very SOB – talking, walking and eating make it worse. When asked 
about medication the patient says she has a Seretide inhaler and uses home nebules, 
Ventolin TDS when her chest is bad. She has taken ciprofloxacin for the last 10 days and also 
steroids when she tried to stop these her chest became worse. Patient also says that she 
takes bendroflumethiazide 2.5mg od and ‘vitamins’. The doctor asked if she has a list; she 
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hasn’t but has her own medicines with her. Medicines from GP summary copied into case 
notes – Seretide inhaler without form and strength. 
Diagnosis non infective exacerbation COPD. 
 
VTE RA – Completed on ICE and paper.  
 
Outcome 
Dalteparin not prescribed; no contra indications identified.  Regular medication prescribed but 
not confirmed with patient .Doctor asked whether it’s better to prescribe fluticasone / 
salmeterol or Seretide inhaler (better to use brand) and how to prescribe calcium carbonate 
1.5g / cholecalciferol – Adcal D3. Doctor had to ask patient which days she took her twice 
weekly alfacalicdol – Tues and Sat – days correctly crossed out on drug chart. No medicines 
reconciliation by pharmacist. Length of stay 1 day. 
 
Timeline 
14.38: Ordered tests and chest X-Ray on ICE 
14.46: Asked consultant difference between broochiectasis and COPD 
14.50: Stared writing up clerking 
15.11: Wrote drug chart 
15.22: went back to speak to patient to complete history 
 
 
Patient D181 (64M)  
Admission time: 15.59 (Friday) 
Clerking time: 16.45 – 18.12 (85 minutes) 
Staff: F1 
Information provided: GP short typed letter re current problem – no information re medicines 
Interruptions:  18.03: Nurse – to write up IV fluids for another patient 
 
Summary 
Presenting complaint –severe vomiting – GP has prescribed cyclizine and buccal 
prochlorperazine – patient has run out of tablets today but were not effective. OK lying down 
but standing or sitting up causes vomiting. Had a similar episode about 3 years ago – 
gastroparesis diagnosed – discharged on erythromycin. Doctor asked about medication – 
patient has his own with him; doctor asked for a list – patient doesn’t have a list. Doctor asked 
if anything missing – just antiemetics as he has run out.  Patients own medicines used to write 
DH in case notes. Patient had an old bottle with illegible label ? vitamins. Diagnosis 
gastroparesis 
 
VTE RA – Completed on ICE and paper.. 
 
Outcome 
Dalteparin 5,000 units od prescribed. Regular medication prescribed later; dose of Isotard XL 
confirmed with patient – no dose on label .0 errors out of 3 items prescribed. Length of stay 14 
days. 
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Timeline 
17.15: Reviewed chest X-Ray on PACS; ordered X-Rays chest & abdo and ECG 
17.25: PR examination 
17.30: Stared writing drug chart – PRN cyclizine prescribed and given 
17.52: Went back to ask pt about weight loss 
17.55: Prescribed regular medicines 
17.57: Went back to confirm dose of Isotard XL 
18.03: Interrupted by nurse to prescribe IV fluids for another patient 
 
 
Patient D182 (79F)  
Admission time: 14.12 (Friday) 
Clerking time: 18.29 – 20.30 (120 minutes) 
Staff: F1 
Information provided: GP proforma – not used 
Interruptions:  18.29: Asked by patients relative for incontinence pad 
  19.45: By nurse to prescribe co-codamol for a different patient 
19.48: By nurse to review ECG – asked another F2 to look at it as writing up 
drug chart 
20.00: Nurse asked doctor to take blood so they can move the patient as they 
have no space to see any more patients. Went to take blood 
20.18: Bleeped by HEC 
20.25: Nurse came from HEC with query about Digami regimen 
20.30: Asked to prescribe PRN nebuliser for a different patient 
 
Summary 
Presenting complaint – sharp pain in leg from buttocks to ankle when moving; OK sitting or 
lying down. Nothing makes it better has tried: Voltarol, paracetamol, amitriptylline – all no 
effect. Recently stopped taking atorvastatin – been on it for about a year but wondered if it 
was causing the pain. Doctor asked if there was any history of clots in the legs or lung. Patient 
had a large bag of medication with him which the doctor used to write the drug chart. The drug 
chart was not checked with the GP summary. 
Diagnosis ?Sciatica 
 
VTE RA – Completed on ICE and paper. 
 
Outcome 
Dalteparin 5,000 units od prescribed. Regular medication prescribe but not confirmed with 
patient.0 Medication chart misplaced. Length of stay 7 days. 
 
Timeline 
18.29: Asked by a relative for incontinence pad while retrieving notes from trolley 
18.30: Read GP letter and nurse triage information 
18.33: Went to see patient 
18.55: Needed help to lower trolley to examine patient – Stroke nurse assisted 
19.20: PR examination 
19.23: Examination finished 
19.27: Ordered blood test on ICE 
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19.28: Discussed patient with SpR 
19.35: Went back to ask patient re bowel / bladder problems 
19.36: Ordered X-Ray spine 
19.45: Interrupted to prescribe co-codamol for a different patient 
19.47: Wrote drug chart 
19.48: Asked by nurse to review ECG – asked another F2 to look at it as busy writing drug 
chart 
19.50: Started writing up clerking 
20.00: Nurse came to ask doctor to take this patient’s blood as no space for other patients to 
be seen – went to take blood 
21.10: Continued writing history 
20.18: Bleeped by HEC 
20.25: Nurse from HEC with query about Digami regimen 
20.27: Rang X-Ray re lumbar spine X-Ray 
20.30: Asked to prescribe nebuliser for different patient 
 
 
Patient D251 (73M)  
Admission time: 15.37 (Monday) 
Clerking time: 16.20 – 16.49 (30 minutes) 
Staff: Consultant 
Information provided: GP proforma 
Interruptions:  16.40: Another patient waiting to see the doctor in the interview room 
  
Summary 
Presenting complaint – ascites and swelling of legs and feet. Patient known to have cirrhosis – 
needs ascetic tap. Doctor asked patient’ Do you take any tablets?’ – Patient said ‘water tablets 
– but I haven’t had any for a while’ Doctor asked why the patient was taking pyridostigmine – 
for myasthenia gravis. Doctor explained the need to take medication regularly to stop 
abdomen swelling.  
Diagnosis ascites 
 
VTE RA – Not completed on ICE or paper. 
 
Outcome 
Dalteparin not prescribed probably has abnormal clotting and for paracentesis Regular 
medication prescribed using GP proforma – not confirmed with patient as all items ‘no issue’ 
other than pyridostigmine .1 error out of 5 items prescribed; spironolactone prescribed 50mg 
BD should be 100mg BD. Proforma badly formatted – 2 daily at the bottom of 1 page and 
100mg at top of next page.  Confirmed calcium carbonate 1.25g / cholecalciferol 10mcg with 
me – Calcichew D3 Forte Length of stay 4 days. 
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Timeline 
16.20: Technician doing ECG so read notes 
16.25: Ordered chest X-Ray 
16.33: Examination finished 
16.36: Went back to ask pt about allergies 
16.37: Stared writing up history 
16.40: Nurse to say there is another patient to see the doctor in the interview room 
16.46: Drug chart written 
 
 
Patient D252 (86M)  
Admission time: 16.58 (Monday) 
Clerking time: 18.05 – 19.40 (95 minutes) 
Staff: F1 
Information provided: GP summary 
Interruptions:  None 
  
Summary 
Presenting complaint – Fall – not dizzy, no palpitations, didn’t lose consciousness. Had PR 
bleeding for past 3 weeks – happened a few years ago and needed blood transfusion. Doctor 
asked ‘Do you take any regular medicines’ Patient responded ‘about ten a day’  
Diagnosis PR bleed, CCF Hb 8.8g/dl 
 
VTE RA – Completed on ICE and paper. – bleeding risks only filled in 
 
Outcome 
Dalteparin not prescribed – need discussed with F2 – Hb dropped from 12g/dl 6 months ago to 
8.8 now – decision to withhold. Regular medication prescribed; but not confirmed with patient. 
0 errors out of 12 items prescribed; clopidogrel not prescribed but should be withheld PR 
bleed Length of stay 14 days. 
 
Timeline 
18.05: Read GP letter 
18.12: Went to find patients wife to clarify sequence of events 
18.35: PR examination 
18.40: Started writing up history 
18.55: Ordered X-Rays on ICE 
19.00: Went to insert cannula and take blood – 2
nd
 attempt but not sufficient for all tests 
19.35: Drug chart 
19.40: VTE on ICE 
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Patient D257 (16M)  
Admission time: 15.26  (Wednesday) 
Clerking time: 17.15 – 18.10 (55 minutes) 
Staff: F1 
Information provided: None - GP summary promised but not received.  
Interruptions:  None 
  
Summary 
Presenting complaint –  nausea, weakness and cramps. Recent admission with Addisonian 
crisis – diagnosed 3 weeks ago. Pt has polyendocrinopathy type 1. Blood test at GP – Na 
129mmol /l – accepted by endocrine registrar. Patients own medicines available and used to 
write DH in clerking and then copied onto drug chart – two strengths of olanzapine 5mg 
labelled 2 nocte and 2.5mg labelled 1 nocte. Doctor checked dose with patient’s mother – 
12.5mg nocte. Doctor unsure re diagnosis and management and unwilling to ask AMU 
consultant for help so I asked him. 
Diagnosis – worsening of polyendocrine syndrome 
 
VTE RA – Completed on ICE and paper. – bleeding risks only filled in 
 
Outcome 
Dalteparin 5,000 units od prescribed. Regular medication prescribed. 0 errors out of 5 items 
prescribed.  Length of stay 2 days. 
 
Timeline 
17.40: Documented DH in clerking using patient own medicines 
17.44: Ordered blood tests on ICE 
17.50: Insert cannula and take blood 
18.00: Discussed with F2 doctor 
18.02: Wrote drug chart 
18.05: Discussed with AMU consultant (I asked for help) 
 
Patient D258 (50M)  
Admission time: 13.52 (Thursday) 
Clerking time: 14.50 – 15.40 (50 minutes) 
Staff: ST5 
Information provided: GP summary 
Interruptions:  14.52 Bleeped 
  15.12 Bleeped 
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Summary 
Presenting complaint – series of blackouts, 5 episodes in last 2 weeks while reading, watching 
TV, no warnings. Doctor asked re medication – cream for eczema, doesn’t know the name 
(Fucibet cream according to GP summary); asked ‘what tablets do you take?’  Patient 
responded ‘none’. Asked about OTC medicines – only paracetamol for headache following 
blackout. The doctor asked ‘have you ever had clots in your legs or lungs?’  
Diagnosis recurrent collapse ?why. Needs 5 day ECG recording 
 
VTE RA – Completed on ICE and paper.  
 
Outcome 
Dalteparin not prescribed – no risk factors.  Regular medication prescribed; but not confirmed 
with patient – didn’t check is patient currently using Fucibet.  No medicines reconciliation by 
pharmacist Length of stay 1 day. 
 
Timeline 
14.52: Bleeped 
15.12: Bleeped 
15.15: Ordered ECG on ICE 
15.17: VTE and chest X-Ray on ICE 
15.26: Started writing up history 
15.34: Ordered chest X-Ray for patient seen earlier 
15.36: Drug chart 
 
 
Patient D259 (47M)  
Admission time: 13.20 (Thursday) 
Clerking time: 16.18 – 16.55 (35 minutes) 
Staff: ST5 
Information provided: GP summary 
Interruptions:  None 
  
Summary 
Presenting complaint – abdominal pain for last 2 days, coughing up blood. Clerking difficult as 
patient with a friend and both were drunk. The doctor asked ‘Are you taking any regular 
medication?’ Patient responded ‘ lansoprazole and vitamins’ Patient says he has asthma and 
takes blue, green and brown inhalers. The doctor asked me about the green inhaler – possibly 
Serevent. The doctor asked ‘have you had any problems with clots in your legs?’ The patient 
responded ‘Yes, in my arm’  
Diagnosis LRTI 
 
VTE RA – Completed on ICE and paper.  
 
Outcome 
Dalteparin not prescribed – no risk factors.  Regular medication prescribed; but not confirmed 
with patient as patient had gone outside for cigarette. No medicines reconciliation by 
pharmacist. Length of stay 1 day. 
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Timeline 
15.41: Went to start clerking but patient not in waiting room 
15.55: EPA taking blood 
16.12: Technician doing ECG 
16.35: Started writing up history 
16.50: VTE RA and drug chart 
 
 
Patient D255 (17M) 
Admission time: 16.36 (Tuesday) 
Clerking time: 17.12 – 17.58 (45 minutes) 
Staff: ST3 (Only been in Trust 2 weeks) 
Information provided: GP letter 
Interruptions:  17.16: By SHO to discuss another patient with low sats 
  17.55: Hand over from day registrar 
18.00: To assist the other registrar 
  
Summary 
Presenting complaint – From gastro clinic – patient has ulcerative colitis and needs IV steroids. 
The doctor asked the patient if he takes any medicines, patient responded ‘Pentasa 2g BD, 
prednisolone 40mg od for the last 10 days’. Doctor used ‘Up to date’ to find the dose of 
steroids 
Diagnosis PR bleed, CCF Hb 8.8g/dl 
 
VTE RA – VTE RA available on paper and ICE; neither completed on admission. Both 
completed next day 
 
Outcome 
Dalteparin not prescribed – no apparent contra indications.  Regular medication prescribed; 
Adcal D3 prescribed  as 1 od, should be 2 od; not confirmed with patient. 1 error out of 5 items 
prescribed.  Length of stay 4 days. 
 
Timeline 
17.12: Read notes from clinic 
17.16: Interrupted by SHO about another patient with low sats 
17.34: Interview and examination finished 
17.50: Drug chart 
17.55 Handover from day registrar 
17.55: Computer locked – doctor has no password – I unlocked 
18.00: Interrupted to assist the other registrar 
 
Patient still needs cannula 
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Appendix 17:  Case Summaries for patients in whom LMWH was 
contraindicated but prescribed (33 patients) 
Dalteparin Contra indicated but prescribed (Consultants consensus 
decision 22.03.12) 
 
Patient A82 (76 M) 
Medical problems: Glioblastoma – newly diagnosed 
VTE risk factors: 2 
Age, active cancer 
Bleeding risk factors: 1 
PT 14.9 (9 – 13 seconds) 
Benefit outweighs risk: Yes  
 
Patient A95 (34 F) 
Medical problems: Overdose Syndol (paracetamol, codeine, caffeine) 
VTE risk factors: 0 
Bleeding risk factors: 1 
PT 15.7 
Benefit outweighs risk:   No 
 
Patient A231 (68 M) 
Medical problems: cellulitis, cardiomyopathy 
VTE risk factors: 2 
Age, acute infection - cellulitis 
Bleeding risk factors: 1 
Platelets 79 
Benefit outweighs risk: Yes  
 
 
262 
 
Patient B3 (76 F) 
Medical problems: Pain ? due to fracture as a result of myeloma. CVA possible on CT scan 
VTE risk factors: 2 
Age, active cancer 
Bleeding risk factors: 1 
CVA possible on CT scan 
Benefit outweighs risk:   No 
 
Patient B43 (75 M) 
Medical problems: Pr bleed, known thrombus right arm came in on dalteparin 7,500 units od 
VTE risk factors: 1  
Age 
Bleeding risk factors: 1 
PR bleed 
Benefit outweighs risk:   No 
 
Patient B76 (68 F) 
Medical problems: Decompensated alcoholic liver disease 
VTE risk factors: 1 
Age 
Bleeding risk factors: 2 
PT 21 on admission, ?PR bleed 
Benefit outweighs risk:  No 
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Patient B109 (79 F) 
Medical problems: Social – not coping at home 
VTE risk factors: 2 
Age, COPD 
Bleeding risk factors: 1 
On warfarin INR 2.3 on day 5; no earlier result on ICE 
Benefit outweighs risk:   No 
 
Patient B123 (74 M) 
Medical problems: Known pancreatic Ca, acute renal failure requiring haemofiltration 
VTE risk factors: 2 
Age, active cancer 
Bleeding risk factors: 1 
Admission creatinine 1056, creatinine day 4 392 
Benefit outweighs risk: Yes  
 
Patient B164 (85 M) 
Medical problems: Collapse, ?PUD, ?Bleed. Transfused 3 units 28.1.10, 2 units 5.2.10, 
9.2.10 and 16.2.10 
VTE risk factors: 1 
Age 
Bleeding risk factors: 2 
?bleed Hb 7.5, PT 15.2 
Benefit outweighs risk:   No 
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Patient B178 (45 M) 
Medical problems: Upper GI bleed 
VTE risk factors: 0 
Bleeding risk factors: 3 
GI bleed, platelets 73, PT 17.9 
Benefit outweighs risk:   No 
 
Patient B184 (62 F) 
Medical problems: Infective exacerbation COPD 
VTE risk factors: 3 
Age, chronic lung disease, infection 
Bleeding risk factors: 1 
PT 25.1  
Benefit outweighs risk:   No 
 
Patient B198 (75 F) 
Medical problems: Increased INR 19 
VTE risk factors: 1 
Age 
Bleeding risk factors: 1 - On warfarin for MVR -  INR 19 on admission 
Day 1  INR 19.0 
Day 2 INR 10.0 
Day 3 INR  1.7 
Day 4 INR  1.2 
Day 5 INR  1.3 
 
Benefit outweighs risk:   No 
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Patient B204 (90 F) 
Medical problems: From Kent Lodge; ?upper GI bleed, haematuria, sepsis, new AF, pelvic 
abscess, developed DCT diarrhoea 
VTE risk factors: 6 
Age, chronic lung disease, chronic heart failure, infection – HAP, immobile, obesity 
Bleeding risk factors: 1 
Haematuria ? GI bleed 
Benefit outweighs risk:   No 
 
Patient C44 (84 F) 
Medical problems: Back pain – referred to physio 
VTE risk factors: 1 
Age 
Bleeding risk factors: 1 
Severe renal disease creatinine 523 - chronic 
Benefit outweighs risk: Yes   
 
Patient C57 (76 F) 
Medical problems: AKI secondary to dehydration – K 6.6mmol/l 
VTE risk factors: 1 
Age 
Bleeding risk factors: 1 
Warfarin INR 10.3 on day 3; 1.3 on day 10 
Benefit outweighs risk:   No 
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Patient C84 (90 F) 
Medical problems: Confusion and aggression; AF, acute stroke 
VTE risk factors: 1 
Age 
Bleeding risk factors: 1 
Acute CVA on CT scan 
Benefit outweighs risk:   No 
 
Patient C92 (83 F) 
Medical problems: SOB, anaemia - transfused 
VTE risk factors: 1 
Age 
Bleeding risk factors: 1 
Bleeding risk Hb 6.3g/dl 
Benefit outweighs risk:   No 
 
Patient C200 (81 M) 
Medical problems: Collapse, sepsis secondary to leg ulcer, AKI 
VTE risk factors: 2 
Age, infection 
Bleeding risk factors: 1 
PT 18.2 
. Day 2 – creatinine 220 and PT 16.0; day 6 creatinine 175 and PT 14.6; day 9 creatinine 91 
Benefit outweighs risk: Yes  
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Patient D21 (52 M) 
Medical problems: Collapse, seizure ? due to alcohol withdrawal, ? vasovagal, ? 
haematemesis, ear infection 
VTE risk factors: 1 
Infection 
Bleeding risk factors: 1 
?haematemesis Hb 14.6 on admission; Hb 15.2 on day 3 
Benefit outweighs risk:   No 
 
Patient D29 (47 M) 
Medical problems: Alcohol related seizure 
VTE risk factors: 0 
Bleeding risk factors: 1 
Platelets 30 on day1; 58 on day 11 
Day 11 platelets 58 
Day 18  72 
Day 22  63 
Day 27  59 
 
Benefit outweighs risk:   No 
 
Patient D44 (72 M) 
Medical problems: Known lung Ca. SOB ?PE, ? infection. Neutropenic sepsis 
VTE risk factors: 4 
Age, infection, lung cancer, thrombophilia 
Bleeding risk factors: 1: Platelets 50 
Benefit outweighs risk:   No 
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Patient D64 (80 F) 
Medical problems: Diarrhoea & vomiting 
VTE risk factors: 1 
Age 
Bleeding risk factors: 1 
On warfarin INR 3.3 on day 1 
Benefit outweighs risk:   No 
 
Patient D66 (59 M) 
Medical problems: Haematemesis, malaena 
VTE risk factors: 0 
Bleeding risk factors: 1 
?bleeding Hb 9.2 
Benefit outweighs risk:   No 
 
Patient D71 (83 F) 
Medical problems: Seizure following a fall ? sub dural haematoma 
VTE risk factors: 1 
Age 
Bleeding risk factors: 1 
? sub dural haematoma 
Benefit outweighs risk:   No 
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Patient D75 (44 F) 
Medical problems: SOB, known COPD - ?DVT / PE 
VTE risk factors: 4 
COPD, immobility, personal / family history DVT / PE, obesity 
Bleeding risk factors: 1 
Platelets 94 
Benefit outweighs risk: Yes   
 
Patient D113 (38 M) 
Medical problems: ?Gi bleed, alcoholic hepatitis 
VTE risk factors: 0 
Bleeding risk factors: 1 
?GI bleed Hb 16.4 day 1 and 4.3 day 3 
Day 1 Hb 16.4 
Day 3        4.3 
Day 6      13.9 
Day 12      15.3 
 
Benefit outweighs risk:   No 
 
Patient D116 (49 F) 
Medical problems: SOB ?PE 
VTE risk factors: 1 
leukaemia 
Bleeding risk factors: 2 
Hb 6.4; platelets 69 
Benefit outweighs risk:   No 
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Patient D183 (56 F) 
Medical problems: Self neglect, secondary to alcohol excess, fall, peripheral neuropathy 
VTE risk factors: 0 
Bleeding risk factors: 1 
Platelets 50; day 6 platelets 107 
Benefit outweighs risk:  No 
 
Patient D226 (76 F) 
Medical problems: Ascites ? cause 
VTE risk factors: 1 
Age 
Bleeding risk factors: 3 
Drain needed for ascites, platelets 35, PT 17.4; platelets 43 on day 27 
Benefit outweighs risk:  No 
 
Patient D229 (75 F) 
Medical problems: Increasing SOB on exercise, oedema, fluid overload 
VTE risk factors: 2 
Age, obesity 
Bleeding risk factors: 1 
Warfarin for AF 
Day 4 INR 2.7  Day 11  2.5  
Day 5  3.1  Day 13  2.8 
Day 8  3.1  Day 14  3.3 
 
Benefit outweighs risk:   No 
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Patient D230 (39 M) 
Medical problems: Jaundice, ascites, encephalopathic, due to alcohol excess. Sub-acute 
bacterial peritonitis 
VTE risk factors: 1 
Infection 
Bleeding risk factors: 2 
Platelets 82, PT 24.5 
Benefit outweighs risk:   No 
 
Patient D253 (74 M) 
Medical problems: SOB LVF secondary to pneumonia 
VTE risk factors: 3 
Age, chronic heart failure, infection 
Bleeding risk factors: 1 
Warfarin  
INR 2,9 on day 2, 2.4 on day 3, 1.8 on day 4. INR in range on day 1 
Benefit outweighs risk:  No 
 
Patient D256 (82 F) 
Medical problems: Hb 6.1 ? bleeding ? iron deficiency anaemia 
VTE risk factors: 1 
Age 
Bleeding risk factors: 1 
Hb 6.1 ? bleeding  Hb 6.8 day 2, no evidence of bleeding 
Benefit outweighs risk:   No 
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Appendix 18:  Validation Summary – Bleeding risks and prescribed 
LMWH (33 patients) 
Validation of Patients with bleeding risks who were prescribed 
LMWH (13.02.12) 
 
Patient 
No 
Observed Cons 1 Cons 2 Cons 3 Cons 4 Lack of 
initial 
consensus 
Consensus 
Decision 
22/03/12 
A82  N Y N N ** Yes 
A95  N Y?? N N ** No 
A231  Y Y Y Y  Yes 
B3  N N N Y ** No 
B43  N N Y Y ** No 
B76  N N N N  No 
B109  N N N N  No 
B123  Y Y Y Y  Yes 
B164  N N N N  No 
B178  N N N N  No 
B184  N N N Y ** No 
B198  N N N N  No 
B204  N N N N  No 
C44  Y Y Y Y  Yes 
C57  N N N N  No 
C84  N N N ?? ** No 
C92  N N N N  No 
C200  Y Y Y Y  Yes 
D21  N N N ?? ** No 
D29  N N N N  No 
D44  N N N Y ** No 
D64  N N N N  No 
D66  N N N N  No 
D71  N N N N  No 
D75  Y Y Y Y  Yes 
D113  N N N N  No 
D116  N N N ?? ** No 
D183  N N N N  No 
D226  N N N N  No 
D229  N N N N  No 
D230  N N N N  No 
D253  N N N N  No 
D256  N N N N  No 
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Appendix 19  No initial consultant consensus – bleeding risks and 
prescribed LMWH (9 patients) 
Dalteparin Contra indicated but prescribed (no consensus) – 
Consultant decision 22.03.12 
 
Patient A82 (76 M) 
Medical problems: Glioblastoma – newly diagnosed 
VTE risk factors: 2 
Age, active cancer 
Bleeding risk factors: 1 
PT 14.9 (9 – 13 seconds) 
Benefit outweighs risk: Yes   
 
Patient A95 (34 F) 
Medical problems: Overdose Syndol (paracetamol, codeine, caffeine) 
VTE risk factors: 0 
Bleeding risk factors: 1 
PT 15.7 
Benefit outweighs risk: No 
 
Patient B3 (76 F) 
Medical problems: Pain ? due to fracture as a result of myeloma. CVA possible on CT scan 
VTE risk factors: 2 
Age, active cancer 
Bleeding risk factors: 1 
CVA possible on CT scan 
Benefit outweighs risk: No 
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Patient B43 (75 M) 
Medical problems: Pr bleed, known thrombus right arm came in on dalteparin 7,500 units od 
VTE risk factors: 1  
Age 
Bleeding risk factors: 1 
PR bleed 
Benefit outweighs risk:  No 
 
Patient B184 (62 F) 
Medical problems: Infective exacerbation COPD 
VTE risk factors: 3 
Age, chronic lung disease, infection 
Bleeding risk factors: 1 
PT 25.1  
Benefit outweighs risk:   No 
 
Patient C84 (90 F) 
Medical problems: Confusion and aggression; AF, acute stroke 
VTE risk factors: 1 
Age 
Bleeding risk factors: 1 
Acute CVA on CT scan 
Benefit outweighs risk:   No 
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Patient D21 (52 M) 
Medical problems: Collapse, seizure ? due to alcohol withdrawal, ? vasovagal, ? 
haematemesis, ear infection 
VTE risk factors: 1 
Infection 
Bleeding risk factors: 1 
?haematemesis Hb 14.6 on admission; Hb 15.2 on day 3 
Benefit outweighs risk:   No 
 
Patient D44 (72 M) 
Medical problems: Known lung Ca. SOB ?PE, ? infection. Neutropenic sepsis 
VTE risk factors: 4 
Age, infection, lung cancer, thrombophilia 
Bleeding risk factors: 1: Platelets 50 
Benefit outweighs risk:  No 
 
Patient D116 (49 F) 
Medical problems: SOB ?PE 
VTE risk factors: 1 
leukaemia 
Bleeding risk factors: 2 
Hb 6.4; platelets 69 
Benefit outweighs risk:  No 
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Appendix 20:  RLUBHT VTE Risk Assessment form – April 2010 
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Appendix 21:  Abstract for oral presentation – HSRPP conference 2010 
 
 
278 
 
Appendix 22: Abstract for oral presentation – PRIMM conference 2011 
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Appendix 23:  Abstract for poster - PRIMM conference 2012 
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Appendix 24:  Abstract for oral presentation – RPS conference 2011 
Title: 
From admission to prescription: medicines reconciliation or the lack of it 
 
Abstract: 
Focal points 
This study explored the processes used by doctors and nurses when taking a medication 
history and prescribing on admission to hospital, using direct observation of patients admitted 
to an Acute Medical Unit over 3 one-week periods.  
Only 39 (76%) of 51 patients observed were asked any medication-related questions; in 25 
(49%) no attempt was made to confirm the medication history with the patient before 
documenting in case notes or prescribing.  
Despite medicines reconciliation guidance, there are still failures in the processes, which may 
require greater effort to educate those involved.  
Introduction An accurate, comprehensive current medication history is essential for safe and 
appropriate management of patients on admission to hospital. NICE defines medicines 
reconciliation on admission to hospital as: the process of collecting information to prepare the 
patient’s current medication history, verifying this list against the current hospital medication 
chart, identifying any discrepancies and taking appropriate action.
1
 Errors in medicines 
reconciliation have an adverse impact on clinical care and financial resources.
2
 Several studies 
have shown doctors’ medication histories are inaccurate and a large study in North West 
England found prescribing errors were mostly made at the time of hospital admission.
3
 
However no studies have investigated the actual processes doctors and nurses use to obtain a 
medication history and prescribe on admission to hospital; this study explored these  
processes. 
Methods Approval was granted by the National Research Ethics Service and NHS Trust. The 
admission process was directly observed for patients admitted to the Acute Medical Unit 
(AMU) at a large teaching hospital over three one-week periods. Consent was obtained from 
the staff involved; however to prevent behaviour change, they were advised only that the 
research covered the admission process and staff roles. Patients could refuse permission for 
observation at any time. 
Results A total of 23 doctors and one nurse practitioner (non-prescribing) were observed as 
they clerked 51 medical patients on admission to AMU. The most common source used for the 
medication history was information provided by the GP, either a hand written letter or a 
printed patient summary (33 admissions; 65%); however in 8 (15%) admissions this 
information was available but not used. 
Only 39 of the 51 patients (76%) were asked any medication-related questions. Of the 
remaining 12, three had complete medication records (two from nursing homes, one from 
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another hospital) and communication with one was via an interpreter. Only 19 patients (37%) 
could provide verbal information regarding their medication, which was incomplete in eight 
cases. 14 patients (26%) had some/all their medication with them; however the clerking 
doctor/nurse did not realise this in two cases. In 25 (49%) cases no attempt was made to 
confirm the medication history with the patient prior to documentation in the case notes and / 
or on the medication chart.  
Of the 37 patients for whom a medication chart was written on admission, the medication 
history was confirmed with only nine (29%) of a possible 31 patients; five were too ill for 
discussion and one patient was taking no medication prior to admission. For 14 patients no 
medication chart was written; two already had a chart, two were discharged the same day; for 
the remaining 10 the reasons were unclear. 
Discussion Despite guidance on the importance of medicines reconciliation, doctors and 
nurses often fail to ask patients about medicines on admission to hospital or confirm the 
accuracy of medications prescribed with patients. While pharmacy staff subsequently identify 
most errors within 24 hours, according to guidance, increased educational initiatives for 
admitting staff, covering the importance of medicines reconciliation and medication history 
taking, may reduce patient risk.  
References 
1. Technical patient safety solutions for medicines reconciliation on admission of adults to hospital. National 
Institute for Health and Clinical Excellence; National Patient Safety Agency; 2007. 
2. Campbell F, Kamon J, Czoski-Murray C, Jones R. A systematic review of the effectiveness and cost-
effectiveness of interventions aimed at preventing medication error (medicines reconciliation) at hospital 
admisison: University of Sheffield. 2007. 
3. Dornan T, Ashcroft D, Heathfield H et al. Final Report - An in depth investigation into causes of prescribing 
errors by foundation trainees in relation to their medical education. EQUIP study. General Medical Council 
2009. 
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Appendix 25:  Abstract for poster - SAM conference 2011 
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 Appendix 26:  Abstract for poster - SAM conference 2012 
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Appendix 27:  VTE paper published in BMJ Open 2012 
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Appendix 28:  Medicines Reconciliation paper published in BMJ 
Quality and Safety 2013 
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